<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">98152</article-id><article-id pub-id-type="doi">10.7554/eLife.98152</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.98152.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>SERBP1 interacts with PARP1 and is present in PARylation-dependent protein complexes regulating splicing, cell division, and ribosome biogenesis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Breunig</surname><given-names>Kira</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lei</surname><given-names>Xuifen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0000-1071-6190</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Montalbano</surname><given-names>Mauro</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0456-452X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Guardia</surname><given-names>Gabriela DA</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1789-2768</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ostadrahimi</surname><given-names>Shiva</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Alers</surname><given-names>Victoria</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kosti</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chiou</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Klein</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Vinarov</surname><given-names>Corina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lily</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Mujia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Weidan</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kraus</surname><given-names>W Lee</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8786-2986</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Libich</surname><given-names>David S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6492-2803</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tiziani</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Weintraub</surname><given-names>Susan T</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8328-7814</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Galante</surname><given-names>Pedro AF</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4820-4155</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Penalva</surname><given-names>Luiz O</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4491-6769</contrib-id><email>penalva@uthscsa.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Children’s Cancer Research Institute, UT Health San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/016tfm930</institution-id><institution>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch</institution></institution-wrap><addr-line><named-content content-type="city">Galveston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/016tfm930</institution-id><institution>Department of Neurology, University of Texas Medical Branch</institution></institution-wrap><addr-line><named-content content-type="city">Galveston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r5mk904</institution-id><institution>Centro de Oncologia Molecular, Hospital Sírio-Libanês</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff5"><label>5</label><institution>Department of Cell Systems and Anatomy, UT Health San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Biochemistry and Structural Biology, UT Health San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hj54h04</institution-id><institution>Department of Nutritional Sciences, College of Natural Sciences, University of Texas at Austin</institution></institution-wrap><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences,The University of Texas Southwestern Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hj54h04</institution-id><institution>Department of Pediatrics, Dell Medical School, University of Texas at Austin</institution></institution-wrap><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hj54h04</institution-id><institution>Department of Oncology, Dell Medical School, University of Texas at Austin</institution></institution-wrap><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Donlin-Asp</surname><given-names>Paul</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>University of Edinburgh</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Sussel</surname><given-names>Lori</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wmf1y16</institution-id><institution>University of Colorado Anschutz Medical Campus</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>12</day><month>02</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP98152</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-04-16"><day>16</day><month>04</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-03-25"><day>25</day><month>03</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.03.22.586270"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-07-02"><day>02</day><month>07</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.98152.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-01-06"><day>06</day><month>01</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.98152.2"/></event></pub-history><permissions><copyright-statement>© 2024, Breunig, Lei, Montalbano et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Breunig, Lei, Montalbano et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-98152-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-98152-figures-v1.pdf"/><abstract><p>RNA binding proteins (RBPs) containing intrinsically disordered regions (IDRs) are present in diverse molecular complexes where they function as dynamic regulators. Their characteristics promote liquid-liquid phase separation (LLPS) and the formation of membraneless organelles such as stress granules and nucleoli. IDR-RBPs are particularly relevant in the nervous system and their dysfunction is associated with neurodegenerative diseases and brain tumor development. Serpine1 mRNA-binding protein 1 (SERBP1) is a unique member of this group, being mostly disordered and lacking canonical RNA-binding domains. We defined SERBP1’s interactome, uncovered novel roles in splicing, cell division and ribosomal biogenesis, and showed its participation in pathological stress granules and Tau aggregates in Alzheimer’s brains. SERBP1 preferentially interacts with other G-quadruplex (G4) binders, implicated in different stages of gene expression, suggesting that G4 binding is a critical component of SERBP1 function in different settings. Similarly, we identified important associations between SERBP1 and PARP1/polyADP-ribosylation (PARylation). SERBP1 interacts with PARP1 and its associated factors and influences PARylation. Moreover, protein complexes in which SERBP1 participates contain mostly PARylated proteins and PAR binders. Based on these results, we propose a feedback regulatory model in which SERBP1 influences PARP1 function and PARylation, while PARylation modulates SERBP1 functions and participation in regulatory complexes.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SERBP1</kwd><kwd>PARP1</kwd><kwd>RNA binding protein</kwd><kwd>glioblastoma</kwd><kwd>proteomics</kwd><kwd>alzheimer's</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004917</institution-id><institution>Cancer Prevention and Research Institute of Texas</institution></institution-wrap></funding-source><award-id>RP200595</award-id><principal-award-recipient><name><surname>Penalva</surname><given-names>Luiz O</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000957</institution-id><institution>Alzheimer's Association</institution></institution-wrap></funding-source><award-id>AARGD-NTF-22-968603</award-id><principal-award-recipient><name><surname>Penalva</surname><given-names>Luiz O</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Mays Cancer Center</institution></institution-wrap></funding-source><award-id>Pilot Grant</award-id><principal-award-recipient><name><surname>Penalva</surname><given-names>Luiz O</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Serrapilheira Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Galante</surname><given-names>Pedro AF</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>2018/15579-8</award-id><principal-award-recipient><name><surname>Galante</surname><given-names>Pedro AF</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000957</institution-id><institution>Alzheimer's Association</institution></institution-wrap></funding-source><award-id>AARF-21-720991</award-id><principal-award-recipient><name><surname>Montalbano</surname><given-names>Mauro</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>2017/19541-2</award-id><principal-award-recipient><name><surname>Guardia</surname><given-names>Gabriela DA</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Hospital Sírio-Libanês</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Guardia</surname><given-names>Gabriela DA</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001655</institution-id><institution>Deutscher Akademischer Austauschdienst</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Breunig</surname><given-names>Kira</given-names></name><name><surname>Li</surname><given-names>Mujia</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>2R01 HG006015</award-id><principal-award-recipient><name><surname>Kosti</surname><given-names>Adam</given-names></name><name><surname>Penalva</surname><given-names>Luiz O</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution>Greehey Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kosti</surname><given-names>Adam</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution>Voelker Fund</institution></institution-wrap></funding-source><award-id>Young Investigator Grant</award-id><principal-award-recipient><name><surname>Libich</surname><given-names>David S</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA54174-23</award-id><principal-award-recipient><name><surname>Kosti</surname><given-names>Adam</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>SERBP1 is associate with protein complexes regulating splicing, cell division, and ribosomal biogenesis that likely depend on G quadruplex (G4) binding and polyADP-ribosylation (PARylation) for their assembly and function.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>RNA binding proteins (RBPs) are a diverse group of regulators with 1500 members cataloged in the human genome (<xref ref-type="bibr" rid="bib50">Gerstberger et al., 2014</xref>; <xref ref-type="bibr" rid="bib28">Corley et al., 2020</xref>). They display a variety of RNA binding domains (RRMs, zinc-fingers, KH domains, dsRBD, etc.) and control multiple stages of gene expression, including RNA processing (splicing, capping, 3’ end processing, and polyadenylation), modification, transport, decay, localization, and translation (<xref ref-type="bibr" rid="bib28">Corley et al., 2020</xref>; <xref ref-type="bibr" rid="bib71">Kelaini et al., 2021</xref>). RBPs are particularly relevant in the nervous system, where they regulate critical aspects of neurogenesis, neuronal function, and nervous system development (<xref ref-type="bibr" rid="bib23">Chan et al., 2022</xref>; <xref ref-type="bibr" rid="bib20">Bryant and Yazdani, 2016</xref>). Alterations in RBP expression and function are linked to neurological disorders, neurodegenerative diseases, and brain tumor development (<xref ref-type="bibr" rid="bib112">Prashad and Gopal, 2021</xref>; <xref ref-type="bibr" rid="bib93">Marcelino Meliso et al., 2017</xref>; <xref ref-type="bibr" rid="bib119">Sanya et al., 2023</xref>; <xref ref-type="bibr" rid="bib69">Kavanagh et al., 2022</xref>; <xref ref-type="bibr" rid="bib143">Velasco et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">Gebauer et al., 2021</xref>; <xref ref-type="bibr" rid="bib107">Nussbacher et al., 2015</xref>).</p><p>RBPs assemble in complexes to regulate gene expression. RBP interactions can take place in the context of macromolecular complexes associated with liquid-liquid phase separation (LLPS). This process supports important regulatory environments and is the foundation for membraneless organelles such as stress granules, Cajal bodies, nucleoli, and P-bodies (<xref ref-type="bibr" rid="bib3">An et al., 2021</xref>; <xref ref-type="bibr" rid="bib37">Drino and Schaefer, 2018</xref>; <xref ref-type="bibr" rid="bib54">Gomes and Shorter, 2019</xref>). RBPs in LLPS tend to share characteristics that include intrinsically disordered regions (IDRs) and RGG boxes. IDR-RBPs can interact with RNA without the presence of specific folded RNA-binding domains (<xref ref-type="bibr" rid="bib152">Zeke et al., 2022</xref>). These features provide unique structural and biophysical characteristics to dynamically regulate translation, stress response, RNA processing, and neuronal function (<xref ref-type="bibr" rid="bib117">Roden and Gladfelter, 2021</xref>).</p><p>Many RBPs in LLPS share a binding preference for G-quadruplexes (G4s). G4s are complex DNA or RNA structures that display stacked tetrads of guanosines stabilized by Hoogsteen base pairing. They function as regulatory elements in different stages of gene expression, promote LLPS, and are implicated in cancer, viral replication, neurodegenerative diseases, neurological disorders, and prion diseases (<xref ref-type="bibr" rid="bib22">Cave and Willis, 2022</xref>; <xref ref-type="bibr" rid="bib96">Masai and Tanaka, 2020</xref>; <xref ref-type="bibr" rid="bib105">Nakanishi and Seimiya, 2020</xref>; <xref ref-type="bibr" rid="bib77">Kosiol et al., 2021</xref>).</p><p>RBPs containing IDRs and RGG motifs are particularly relevant in the nervous system. Their misfolding contributes to the formation of pathological protein aggregates in Alzheimer’s disease (AD), Frontotemporal Lobar Degeneration (FTLD), Amyotrophic Lateral Sclerosis (ALS), and Parkinson’s disease (PD) while their aberrant expression has been linked to glioblastoma development (<xref ref-type="bibr" rid="bib29">Darling and Shorter, 2021</xref>; <xref ref-type="bibr" rid="bib146">Webber et al., 2020</xref>; <xref ref-type="bibr" rid="bib138">Uversky, 2017</xref>). SERBP1 (Serpine1 mRNA-binding protein 1) is a unique member of this group of RBPs for being mostly disordered and lacking typical RNA binding domains other than two short RG/RGG motifs (<xref ref-type="bibr" rid="bib9">Baudin et al., 2021</xref>). SERBP1 is a highly conserved protein with homologs identified in yeast, plants, invertebrates, and vertebrates. SERBP1 is highly expressed in neuronal and glioma stem cells and a decrease in its levels is required for neuronal differentiation (<xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>). In glioblastoma, SERBP1 functions as a central regulator of metabolic pathways, coordinating the expression of related enzymes and associated factors implicated in serine biosynthesis, one-carbon, and 5'-methylthioadenosine (MTA) cycles. Ultimately, SERBP1 impacts methionine production and, consequently histone methylation and the expression of genes implicated in neuronal differentiation (<xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>).</p><p>In the present study, we investigated the SERBP1 interactome. Overall, our results established SERBP1 as a multi-regulatory protein, corroborating that RBPs containing IDRs are dynamic and can assemble different complexes. Despite its predominant cytoplasmic localization, SERBP1 is associated with proteins in specific nuclear complexes implicated in splicing regulation, cell division, and ribosome biogenesis. Approximately a third of SERBP1-associated proteins bind to G4s. These proteins are implicated in various stages of gene expression, indicating that G4s function as SERBP1 regulatory motifs in different scenarios. Finally, our study has identified important associations between SERBP1 and PARP1 that suggest a regulatory loop, in which SERBP1 influences PARylation, and PARP activity. At the same time, PARylation of SERBP1 and its partner proteins modulate their association and function.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>SERBP1 interactome reveals its associations with diverse regulatory complexes</title><p>To identify SERBP1-associated proteins and molecular complexes in which it is involved, we conducted pull down experiments in 293T cells followed by proteomics analysis. Cells were transfected with pSBP-SERBP1 or pUltra-SERBP1(control). The SBP tag is a short peptide with high affinity for streptavidin. Protein complexes are then isolated via pulldown using streptavidin beads. Analysis by mass spectrometry yielded a high-confidence list of 570 SERBP1-associated proteins. Peptides for these proteins were only present in the pSBP-SERBP1 pull-down samples or displayed a minimum of threefold enrichment in comparison to control – <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. Gene Ontology (GO) analyses (<xref ref-type="bibr" rid="bib48">Ge et al., 2020</xref>; <xref ref-type="bibr" rid="bib154">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib127">Supek et al., 2011</xref>) of identified partners indicated that SERBP1 participates in diverse regulatory complexes in the cytoplasm and nucleus – <xref ref-type="fig" rid="fig1">Figure 1A and B</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. We compared our data to the results of two large-scale studies that used proximity-dependent biotinylation (Bio ID; <xref ref-type="bibr" rid="bib53">Go et al., 2021</xref>; <xref ref-type="bibr" rid="bib150">Youn et al., 2018</xref>) to identify protein-protein interactions and checked the datasets in BioGRID (<xref ref-type="bibr" rid="bib124">Stark et al., 2006</xref>). 146 SERBP1 interactors identified in our analysis were also identified in other high-throughput studies – <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Gene ontology (GO) analysis and characterization of SERBP1-interacting proteins.</title><p>(<bold>A</bold>) SERBP1-interacting factors were identified via pull-down analysis in 293T cells. GO enrichment analysis (Biological Processes, Molecular Function, and Cellular Component) was performed with ShinyGO (<xref ref-type="bibr" rid="bib48">Ge et al., 2020</xref>). A selection of the most relevant GO terms is represented. FE = fold enrichment; FDR = false discovery rate. (<bold>B</bold>) Visualization of associated GO-enriched terms in three main regulatory branches: translation, ribosome biogenesis, and RNA processing. Sum and circle size represent the count of SERBP1 interactors assigned to each GO term. (<bold>C</bold>) Representation of top enriched protein domains according to PFAM (<xref ref-type="bibr" rid="bib123">Sonnhammer et al., 1997</xref>) among SERBP1 interactors. Only PFAM domains with counts of 5 or more and significant fold enrichment (FE) and false discovery rate (FDR) were included. The occurrence of each domain within the total human proteome (ALL) is listed as a reference. (<bold>D</bold>) Occurrence of intrinsically disordered proteins (IDPs; <xref ref-type="bibr" rid="bib111">Piovesan et al., 2023</xref>) among SERBP1 interactors according to PFAM (‘derived’=automatic entries from databases; ‘curated’=manually checked). (<bold>E</bold>) Distribution of identified SERBP1-interacting proteins in reference to the presence of RGG boxes (<xref ref-type="bibr" rid="bib132">Thandapani et al., 2013</xref>) and binding to G-quadruplexes (G4s) (<xref ref-type="bibr" rid="bib126">Su et al., 2021b</xref>; <xref ref-type="bibr" rid="bib63">Herviou et al., 2020</xref>). Data used to generate the figures are in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>SERBP1-associated proteins isolated via pulldown experiments in 293T cells.</title><p>293T cells were transfected with plasmids expressing SBP-SERBP1 or pUltra-SERBP1(control). SERBP1-associated proteins were isolated via pull-down with streptavidin beads. Images show the aspect of protein gels used in the mass spectrometry analysis. Three control and three experimental samples were obtained using two different cell lysis procedures. Figure shows uncropped gel.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>PDF file containing original protein gels for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98152-fig1-figsupp1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Original protein gels for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98152-fig1-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>SERBP1 in translation and ribosome biogenesis.</title><p>(<bold>A</bold>) SERBP1 knockdown in U251 and U343 cells decreased translation as determined by puromycin incorporation assay. Control (C) and siSERBP1 knockdown (KD). (<bold>B</bold>) Localization of SERBP1 in nucleoli of HeLa cells as indicated by transfected mGreen-SERBP1 corroborates its participation in ribosome biogenesis. (<bold>C</bold>) mGreen-SERBP1 co-localizes with endogenous FBL (red) in the nucleoli of HeLa cells.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98152-fig1-figsupp2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1s2sdata2"><label>Figure 1—figure supplement 2—source data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98152-fig1-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>SERBP1-associated helicases and their respective domains.</title><p>Listed are all helicases found among identified SERBP1 interactors and their respective helicase domains (27, 42, 71), information on binding to DNA, RNA (71) or G4s (46, 47) and expression correlation with SERBP1 in different datasets (141–143). Green label indicates the presence of respective characteristics; ND = no data; ns = not significant. Datasets used to prepare the figure, and detailed analyses are in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig1-figsupp3-v1.tif"/></fig></fig-group><p>Although SERBP1’s partners indicate its participation in different stages of translation as well as in its regulation, the many associations with translation initiation factors suggest that SERBP1’s primary function is in initiation – <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. As expected, based on previous studies (<xref ref-type="bibr" rid="bib18">Brown et al., 2018</xref>; <xref ref-type="bibr" rid="bib104">Muto et al., 2018</xref>; <xref ref-type="bibr" rid="bib2">Ahn et al., 2015</xref>; <xref ref-type="bibr" rid="bib95">Martini et al., 2021</xref>), we identified several ribosomal proteins associated with SERBP1 – <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. SERBP1 knockdown in U251 and U343 cells resulted in a decrease of overall translation as shown by puromycin incorporation assays – <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</p><p>SERBP1 is mostly localized in the cytoplasm. SERBP1 nuclear localization increases in response to stress and is regulated by arginine methyltransferases (<xref ref-type="bibr" rid="bib82">Lee et al., 2014</xref>; <xref ref-type="bibr" rid="bib81">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="bib109">Passos et al., 2006</xref>). SERBP1-associated proteins suggest it participates in nuclear functions; out of 570 associated proteins, 344 display cytoplasmic/nuclear localization, while 100 are exclusively found in the nucleus – <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. GO analyses of this group identified specific nuclear complexes. The functions of SERBP1-associated proteins suggest that SERBP1 is involved in different stages of ribosome biogenesis – <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. SERBP1 participation in ribosome biogenesis is corroborated by its presence in nucleoli – <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B, C</xref>. Results of our previous RIP-Seq analysis (<xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>) and a CLIP-seq study (<xref ref-type="bibr" rid="bib95">Martini et al., 2021</xref>) showed that SERBP1 binds preferentially to multiple snoRNAs (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) and at specific sites in 18 S and 28 S rRNA. These results, aligned with the fact that SERBP1 associates with FBL and DKC1, two critical snoRNP components, strongly indicate SERBP1 involvement in rRNA modification. Besides ribosome biogenesis, SERBP1 is also likely involved in different stages of RNA processing, in particular splicing, and telomere maintenance – <xref ref-type="fig" rid="fig1">Figure 1A and B</xref>.</p><p>SERBP1 is a highly conserved protein. In <italic>S. cerevisiae</italic>, SERBP1 homolog is STM1 (<xref ref-type="bibr" rid="bib27">Coppolecchia et al., 1993</xref>). According to BioGRID (<xref ref-type="bibr" rid="bib124">Stark et al., 2006</xref>), 183 proteins were identified as STM1 interactors. Of the 144 identified human homologs, we found that 53 were SERBP1 interactors – <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>. GO analyses of STM1 interactors indicated that STM1 is also a multi-functional protein. Comparisons of enriched GO terms from the SERBP1 and STM1 analyses suggest that several regulatory functions assigned to SERBP1 based on its associated proteins are evolutionarily conserved, including translation, ribosome biogenesis, RNA processing and telomere maintenance – <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>. SERBP1 also has homologs in plants. A recent study in <italic>A. thaliana</italic> established that AtRGG proteins (SERBP1 homologs) interact with ribosomal proteins and proteins involved in RNA processing and transport (<xref ref-type="bibr" rid="bib11">Bleckmann et al., 2023</xref>).</p></sec><sec id="s2-2"><title>SERBP1 preferentially associates with helicases and G-quadruplex binders</title><p>In order to define the characteristics of SERBP1-associated proteins, we cataloged them according to their protein domains using the Pfam database (<xref ref-type="bibr" rid="bib123">Sonnhammer et al., 1997</xref>) and performed an enrichment analysis. RNA binding and helicase are the two domain families that appeared most often – <xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref> and <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>. Based on the results of the proteomics analyses and gene expression correlation studies, DDX21, DHX9, and DHX15 are SERBP1’s top-associated helicases – <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>.</p><p>SERBP1 displays large intrinsically disordered regions (IDRs; <xref ref-type="bibr" rid="bib9">Baudin et al., 2021</xref>). IDRs are ubiquitous within biomolecular condensates in the cytoplasm and nucleus created via liquid-liquid phase separation (LLPS). They lead to the formation of membraneless organelles such as stress granules, P-bodies, and nucleoli (<xref ref-type="bibr" rid="bib45">Fonin et al., 2022</xref>; <xref ref-type="bibr" rid="bib125">Su et al., 2021a</xref>). Roughly 80% of SERBP1-associated proteins contain IDRs (<xref ref-type="bibr" rid="bib111">Piovesan et al., 2023</xref>) and are present in different membraneless organelles, as discussed below – <xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>.</p><p>SERBP1 is a G-quadruplex (G4) binder (<xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>; <xref ref-type="bibr" rid="bib126">Su et al., 2021b</xref>), as are 38% of its associated proteins (<xref ref-type="bibr" rid="bib126">Su et al., 2021b</xref>; <xref ref-type="bibr" rid="bib63">Herviou et al., 2020</xref>) – <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. RBPs, including SERBP1, often use RGG boxes to bind G4 motifs (<xref ref-type="bibr" rid="bib64">Huang et al., 2018</xref>; <xref ref-type="bibr" rid="bib110">Patra et al., 2021</xref>). We found that among 93 SERBP1-associated proteins containing RGG boxes (<xref ref-type="bibr" rid="bib132">Thandapani et al., 2013</xref>), 44 are G4 binders – <xref ref-type="fig" rid="fig1">Figure 1E</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. G4 binders associated with SERBP1 are mostly proteins implicated in translation, mRNA stability, and splicing, indicating that SERBP1 regulation via G4 binding takes place in different scenarios. Among G4 binders, we identified several RNA helicases (e.g. DDX5, DDX21, DDX3X, and DHX9) that enhance translation by unfolding G4s in 5’ UTRs (<xref ref-type="bibr" rid="bib61">Herdy et al., 2018</xref>; <xref ref-type="bibr" rid="bib98">McRae et al., 2020</xref>; <xref ref-type="bibr" rid="bib103">Murat et al., 2018</xref>; <xref ref-type="bibr" rid="bib142">Varshney et al., 2021</xref>) – <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. Since SERBP1 lacks helicase domains, interaction with these proteins could be critical for SERBP1 function in translation.</p><p>G4s regulate different aspects of the life cycles of RNA viruses (<xref ref-type="bibr" rid="bib118">Ruggiero and Richter, 2018</xref>; <xref ref-type="bibr" rid="bib149">Xu et al., 2021</xref>). GO terms related to viral translation are among those with the highest fold enrichment in our analyses – <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. In a study to define the SARS-CoV-2 RNA interactome, 168 human proteins were identified (after exclusion of ribosomal proteins and EI3F factors; <xref ref-type="bibr" rid="bib83">Lee et al., 2021</xref>), including SERBP1 and 92 of its associated proteins – <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. Of those 92 proteins, 52 are G4 binders – <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>.</p></sec><sec id="s2-3"><title>SERBP1 affects cell division</title><p>SERBP1 has been previously implicated in chromosome segregation and shown to localize in M bodies during mitosis (<xref ref-type="bibr" rid="bib95">Martini et al., 2021</xref>). In agreement, GO analyses of SERBP1-associated proteins revealed chromosome segregation as well as several related functions as enriched terms. Examination of proteins linked to these terms indicated that SERBP1 interacts with proteins in chromosomes as well as centrosomes and mitotic spindles – <xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. To evaluate SERBP1’s impact on cell division, U251 and U343 SERBP1 knockdown and control cells were exposed to 20 nM of paclitaxel for 24 hr and later stained with α-tubulin and DAPI. In both cases, SERBP1 knockdown cells had markedly increased numbers of polynucleated cells, reflecting mitotic catastrophe – <xref ref-type="fig" rid="fig2">Figure 2B–D</xref>. SERBP1 involvement in cell division appears to be conserved. STM1, the SERBP1 yeast homolog, is a suppressor of mutations in genes regulating mitosis (<xref ref-type="bibr" rid="bib26">Chung et al., 2007</xref>). Confirming that report, our GO analyses of STM1 genetic interactors showed enrichment for cell division – <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>SERBP1 is implicated in cell division.</title><p>(<bold>A</bold>) SERBP1-associated proteins and their presence in specific cellular structures relevant to mitosis. (<bold>B</bold>) Western blot showing SERBP1 knockdown in U251 and U343 cells. (<bold>C</bold>) Multinucleated cells in U251 and U343 control and SERBP1 knockdown (KD) cells after treatment with paclitaxel, an agent that causes cell cycle arrest. SERBP1 KD increased the number of multinucleated nuclei. Data are shown as means of counts of 1000 cells ± standard deviation (in triplicate) and statistical significance was determined by Student’s t-test. <italic>P</italic>&lt;0.001. (<bold>D</bold>) Aspect of cells exposed to paclitaxel. On the left staining with anti-α-Tubulin; in the middle staining with DAPI showing an increased number of multinucleated cells after siSERBP1 KD. ×100 magnification for detailed visualization of a single multinucleated cell. (<bold>E</bold>) Plot shows the results of a cell viability screening (291 drugs) performed in U343 control vs. U343 SERBP1 over-expressing (OE) cells. Red dots correspond to drugs whose impact on cell viability was significantly different between U343 control and U343 SERBP1 OE. (<bold>F</bold>) Highlights of the screening showing cell cycle/division and DNA damage/replication inhibitors whose impact on cell viability was smaller in U343 SERBP1 OE in comparison to control. Datasets used to prepare the figure and detailed analysis are in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> and <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98152-fig2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98152-fig2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig2-v1.tif"/></fig><p>We conducted a viability screening with 269 compounds in GBM U343 and U343 over-expressing (OE) SERBP1 (<xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>). Corroborating SERBP1 involvement in cell division, we determined that SERBP1 OE cells are less sensitive to drugs affecting cell division, cell cycle, and DNA replication. Interestingly, three of these drugs (Mitoxantrone, Flavopiridol, and Doxorubicin) are also known to affect rRNA transcription and processing – <xref ref-type="fig" rid="fig2">Figure 2E and F</xref> and <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>.</p></sec><sec id="s2-4"><title>SERBP1 interacts with splicing factors and influences splice site selection</title><p>Among identified SERBP1 partners, 134 proteins (23%) are implicated in mRNA processing, and from this group, 117 participate in mRNA splicing. They include many well-known alternative splicing regulators such as hnRNPU, KHDRBS1, PTBP1, SRSF6, TRA2B, SRSF2, and hnRNPA1 – <xref ref-type="fig" rid="fig3">Figure 3A</xref>. In particular, hnRNPU, TRA2B, and KHDRBS1 display high expression correlation with SERBP1 in multiple scenarios – <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>. To determine if SERBP1 expression levels influence splicing, we conducted an RNAseq study in U251 cells. SERBP1 knockdown altered the splicing of 1,625 events (PSI &gt;0.1, FRD &lt;0.05) with 70% of them being exon skipping events – <xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>. Next, we examined a SERBP1 CLIPseq dataset (<xref ref-type="bibr" rid="bib95">Martini et al., 2021</xref>) to search for evidence of SERBP1 direct participation in regulated splicing. From the 1625 splicing events altered in SERBP1 knockdown cells, CLIP sites were observed close to pertinent splice sites (&lt;100 nucleotides) of 443 (27%) of them – <xref ref-type="fig" rid="fig3">Figure 3C</xref> and <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>. SERBP1’s association with many known alternative splicing regulators suggests that its impact on regulated splicing requires interaction with other factors. Since hnRNPU was identified as one of SERBP1’s main partners and they display strong expression correlation in multiple instances (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), we decided to conduct additional RNAseq analysis in U251 cells to determine if the two proteins co-regulate splicing events. Circa 30% of the events identified in SERBP1 knockdown cells were also observed upon hnRNPU knockdown, with changes in the same direction – <xref ref-type="fig" rid="fig3">Figure 3E and F</xref> and <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>SERBP1 influences splicing.</title><p>(<bold>A</bold>) SERBP1-interacting factors are preferentially associated with splicing. Networks show connections between splicing factors identified as SERBP1 interactors. (<bold>B</bold>) SERBP1 knockdown in U251 cells produced major changes in splicing. Pie chart displays the distribution of splicing events affected by SERBP1 knockdown according to their type: SE, exon skipping; RI, intron retention; MXE, multiple exclusive exons; A5SS, alternative 5’ splice sites; A3SS, alternative 3’ splice site. (<bold>C</bold>) Bar graphs showing the percentage of splicing events affected by SERBP1 knockdown with evidence of SERBP1 binding sites close (&lt;100 nt) to regulated splice sites. (<bold>D</bold>) hnRNPU was identified as a potential partner of SERBP1 in splicing regulation. SERBP1 and hnRNPU display high expression correlation in normal and tumor tissues. (<bold>E</bold>) Venn diagram shows a strong overlap between the splicing events affected by SERBP1 and hnRNPU knockdowns in U251 cells. (<bold>F</bold>) Sashimi plots showing examples of splicing events affected by both SERBP1 and hnRNPU knockdowns in U251 cells. The red arrows indicate affected exons. Datasets used to prepare the figure, and detailed analyses are in <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig3-v1.tif"/></fig><p>The results of the splicing analysis also revealed another potential route by which SERBP1 could affect ribosome biogenesis. Most expressed snoRNAs are embedded in introns of protein-coding genes and lncRNAs. Our analysis indicates that SERBP1 knockdown affects splicing events that include introns containing snoRNAs in 13 host genes – <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>.</p></sec><sec id="s2-5"><title>SERBP1 has a two-way association with PARP1 and PARylation</title><p>We identified important associations between SERBP1 and PARP1, an enzyme that catalyzes the addition of poly(ADP-ribose) (PAR) on target proteins – <xref ref-type="fig" rid="fig4">Figure 4A</xref>. PARP1 is implicated in DNA repair and regulates multiple stages of gene expression, including transcription, splicing, ribosome biogenesis, and translation (<xref ref-type="bibr" rid="bib74">Kim et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Gupte et al., 2017</xref>; <xref ref-type="bibr" rid="bib66">Huang and Kraus, 2022</xref>). SERBP1 and PARP1 showed strong expression correlated in several scenarios and similar expression profiles during cortex development – <xref ref-type="fig" rid="fig4">Figure 4B and C</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>SERBP1 interacts with PARP1 and influences PARylation.</title><p>(<bold>A</bold>) Results of IP-western in U251 cells with control and anti-SERBP1 antibodies confirm SERBP1 interaction with PARP1, NCL, and SYNCRIP. SERBP1 and PARP1 strong association is corroborated by their high expression correlation in different studies (<bold>B</bold>) and similar expression profiles during cortex development according to Cortecon (<xref ref-type="bibr" rid="bib139">van de Leemput et al., 2014</xref>). (<bold>C</bold>). (<bold>D</bold>) PARylation sites observed in SERBP1 protein according to <xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>. (<bold>E</bold>) PARP1 ADP-ribosylates SERBP1 in vitro. Purified recombinant PARP1 (0.1 µM) and SERBP1 (0.6 µM) were combined in a reaction with or without sheared salmon sperm DNA (sssDNA) (100 ng/µL) and NAD+ (100 µM) as indicated. The reaction products were analyzed by SDS-PAGE with silver staining (left) and Western blotting for PAR (right). Uncropped gels are shown. (<bold>F</bold>) Venn diagram shows that majority of SERBP1-associated factors get PARylated and/or bind PAR (<xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Dasovich et al., 2021</xref>). (<bold>G</bold>) Increase of PARylation levels in 293T and U251 GBM cells after H<sub>2</sub>O<sub>2</sub> treatment. (<bold>H</bold>) SBP-SERBP1 and Flag-PARP1 were co-transfected into 293T cells. Cells were treated with H<sub>2</sub>O<sub>2</sub> to induce PARylation and a pull-down experiment with streptavidin beads was performed. Western analysis showed increased SERBP1 association with PARP1 in cells treated with H<sub>2</sub>O<sub>2</sub>. SBP-SERBP1-His detected by His antibody; Flag-PARP1 detected by Flag antibody. (<bold>I</bold>) SBP-SERBP1 was transfected into 293T cells. Cells were treated with DMSO or 10 μM PJ34 (PARP inhibitor) for two hours and a pull-down experiment with streptavidin beads was performed. Western analysis showed a decrease in SERBP1 association with PARP1 and GPBP1. (<bold>J</bold>) SERBP1 transgenic expression (mGreen-SERBP1) in 293T cells increased the levels of PARylated proteins as indicated by PAR-detecting agent. Datasets used to prepare the figure, and detailed analyses are in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98152-fig4-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig4">Figure 4E</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98152-fig4-data2-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig4">Figure 4G</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98152-fig4-data3-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig4">Figure 4H</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98152-fig4-data4-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><label>Figure 4—source data 5.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig4">Figure 4I</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98152-fig4-data5-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4sdata6"><label>Figure 4—source data 6.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig4">Figure 4J</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98152-fig4-data6-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4sdata7"><label>Figure 4—source data 7.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98152-fig4-data7-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>PARP, PARylation and SERBP1 function.</title><p>(<bold>A</bold>) SERBP1 shows increased nuclear localization and co-localization with PARP1 in U251 cells after treatment with H<sub>2</sub>O<sub>2</sub>. (<bold>B</bold>) Effect of PARylation/PAR binding on SERBP1 protein interactions. 293T cells were transfected with SBP-SERBP1. The experimental group was treated with PJ34 10 mM for 2 hr. SERBP1-associated proteins were recovered via pulldown with streptavidin beads. Western blot shows PARylated proteins detected in input and pulldown using a poly-ADP-ribose binding reagent. (<bold>C</bold>) Effects of combined siSERBP1 knockdown and PARP inhibitor treatment on GBM cell viability. Reduction in proliferation displayed by U251 and U343 cells treated with only PJ34 (PARP inhibitor) or SERBP1 siRNA (partial SERBP1 KD) and combination. The combination treatment showed a synergistic effect as judged by the Combination Index (CI; <xref ref-type="bibr" rid="bib25">Chou, 2010</xref>). Data are shown as means ± standard deviation. Each group has 6 replicates. Statistical significance was evaluated by Student’s t-test.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>PDF file containing western blots for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98152-fig4-figsupp1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98152-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Results of high throughput studies established that SERBP1 gets PARylated and binds to PAR (<xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Dasovich et al., 2021</xref>) – <xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. SERBP1 PARylation by PARP1 was confirmed in an in vitro assay – <xref ref-type="fig" rid="fig4">Figure 4E</xref>. Moreover, we determined that circa 56% of all identified SERBP1 interactors get PARylated and/or bind PAR (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>), suggesting that PARylation is an important component in the assembly of protein complexes in which SERBP1 participates. We further investigated SERBP1-PARP1 interaction in 293T and U251 cells in the context of PARP activation. Cell exposure to H<sub>2</sub>O<sub>2</sub> enhances PARP1 activity and protein PARylation as shown by Western blots probed with an anti-poly-ADP-ribose binding reagent – <xref ref-type="fig" rid="fig4">Figure 4G</xref>. In U251 cells, H<sub>2</sub>O<sub>2</sub> treatment caused SERBP1 to shift to the nucleus, where it co-localized with PARP1 – <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>. Next, we co-transfected SBP-SERBP1-His and Flag-PARP1 in 293T cells and conducted pull-down experiments with streptavidin beads using extracts from cells treated with H<sub>2</sub>O<sub>2</sub> and control. An increase in SERBP1-PARP1 interaction was observed in cells treated with H<sub>2</sub>O<sub>2</sub> – <xref ref-type="fig" rid="fig4">Figure 4H</xref>. On the other hand, treatment with the PARP inhibitor PJ34 decreased SERBP1 interaction with PARP1 and G3BP1 as indicated by the results of the pulldown analysis with streptavidin beads – <xref ref-type="fig" rid="fig4">Figure 4I</xref>. Transgenic SERBP1 expression in 293T cells increased PARylation, as revealed by western blot probed with PAR detecting reagent – <xref ref-type="fig" rid="fig4">Figure 4J</xref>. To determine if PARylation/PAR binding affects SERBP1 interactions, we transfected 293T cells with an SBP-SERBP1 expressing vector. The experimental group was treated later with PJ34. SERBP1-associated proteins were isolated via pulldown with streptavidin beads and the presence of PARylated proteins was evaluated by Western blot. PARP inhibition decreased the amount of PARylated proteins associated with SERBP1 as shown in the pulldown lanes – <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</p><p>A recently published screening identified genes conferring sensitivity to PARP inhibitors, Olaparib, Rucaparib, and Talazoparib (<xref ref-type="bibr" rid="bib153">Zhang et al., 2023</xref>). From this study, we generated a list with top hitters for each drug and compiled the results to identify genes appearing in two or more analyses. The 424 identified genes include SERBP1 and 82 of its interactors – <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>. In agreement, using a proliferation assay, we determined that SERBP1 partial knockdown makes U251 and U343 GBM cells more sensitive to the PARP inhibitor PJ34 – <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</p><p>PARP1 and several of its characterized interactors were determined to be associated with SERBP1 – <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Our investigation has determined that the list of PARP1-SERBP1 shared factors is in fact more extensive. A comparison between SERBP1-associated factors and PARP1 interactors detected via proximity labeling (<xref ref-type="bibr" rid="bib102">Mosler et al., 2022</xref>) identified 199 common factors (including SERBP1 and PARP1), of which about 80% are also PARylated and/or bind PAR (<xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Dasovich et al., 2021</xref>) – <xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. These proteins are implicated in splicing regulation, ribosome biogenesis, and DNA repair – <xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. Among shared SERBP1-PARP1 interactors that get PARylated and/or bind to PAR are multiple key factors implicated in rRNA transcription, processing, and modification, including NOLC1, NOP16, NAT10, DKC1, DDX21, NCL, SMARCA4 and TCOF1 – <xref ref-type="fig" rid="fig5">Figure 5C</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. The binding of snoRNAs to PARP1 stimulates its catalytic activity in the nucleolus independent of DNA damage. Activated PARP1 PARylates the RNA helicase DDX21 to promote rDNA transcription (<xref ref-type="bibr" rid="bib73">Kim et al., 2019</xref>). DDX21 was identified as a top SERBP1-associated factor, and expression of the two proteins was highly correlated in several scenarios – <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> and <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>. Moreover, we and others have determined that SERBP1 preferentially binds snoRNAs, including the ones implicated in PARP1 activation: snoRA37, snoRA74A, and snoRA18 (<xref ref-type="bibr" rid="bib73">Kim et al., 2019</xref>). Out of 58 snoRNAs bound by PARP1 (<xref ref-type="bibr" rid="bib99">Mekishvili et al., 2017</xref>), 32 of them are also targeted by SERBP1 – <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Shared SERBP1 and PARP1 interactors.</title><p>(<bold>A</bold>) Venn diagram shows the overlap between PARP1 (<xref ref-type="bibr" rid="bib102">Mosler et al., 2022</xref>) and SERBP1 interactomes. Analysis of shared interactors indicated that the majority of them are PAR binding (<xref ref-type="bibr" rid="bib32">Dasovich et al., 2021</xref>) and/or get PARylated (<xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>). (<bold>B</bold>) Selection of enriched GO terms (biological processes) related to SERBP1-PARP1 shared interactors according to ShinyGO (<xref ref-type="bibr" rid="bib48">Ge et al., 2020</xref>). FE = fold enrichment; FDR = false discovery rate. (<bold>C</bold>) Network showing shared SERBP1 and PARP1 interactors implicated in ribosome biogenesis. (<bold>D</bold>) Proposed SERBP1-PARP1 feedback model; SERBP1 function and association with partner proteins is modulated by PARylation while SERBP1 influences PARP activity. Datasets used to prepare the figure, and detailed analyses are in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>SERBP1 interactors, PARylation, PAR- and G4-binding.</title><p>(<bold>A</bold>) Venn diagram showing that many SERBP1-associated proteins that get PARylated and/or bind PAR (<xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Dasovich et al., 2021</xref>) also bind to G4s (<xref ref-type="bibr" rid="bib126">Su et al., 2021b</xref>; <xref ref-type="bibr" rid="bib63">Herviou et al., 2020</xref>). (<bold>B</bold>) Prevalence of RRM (<xref ref-type="bibr" rid="bib8">Bateman et al., 2023</xref>) and RGG (<xref ref-type="bibr" rid="bib132">Thandapani et al., 2013</xref>) domains in those SERBP1 interactors that bind both PAR and G4s. Datasets used to prepare the figure, and detailed analyses are in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Adding up to SERBP1-PARP1 strong functional association, we determined that about 50% of SERBP1 interactors known to bind PAR, are also G4 binders – <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>, <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. Different types of protein domains bind to PAR, including RGG boxes and RRMs (<xref ref-type="bibr" rid="bib147">Wei and Yu, 2016</xref>; <xref ref-type="bibr" rid="bib151">Zaja et al., 2012</xref>). These two types of domains are also among the ones that bind G4s. About half of SERBP1-associated proteins that were identified as both PAR and G4 binders contain RGG boxes and/or RRMs (<xref ref-type="bibr" rid="bib132">Thandapani et al., 2013</xref>; <xref ref-type="bibr" rid="bib8">Bateman et al., 2023</xref>) – <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>. Based on our findings, we propose the existence of a feedback regulatory model in which SERBP1 influences PARP1 function and PARylation, while PARylation modulates SERBP1 functions and association with its protein partners – <xref ref-type="fig" rid="fig5">Figure 5D</xref>.</p></sec><sec id="s2-6"><title>SERBP1 is in association with proteins present in membraneless organelles and Tau aggregates</title><p>GO analysis of SERBP1-associated proteins based on cellular compartment (<xref ref-type="bibr" rid="bib133">Thomas et al., 2022</xref>) determined that SERBP1 interacts with factors often present in membraneless organelles, including stress granules, P bodies, Cajal bodies, nuclear speckles, paraspeckles, and nucleoli, which suggests SERBP1’s likely participation in protein complexes present in these organelles – <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref> and <xref ref-type="fig" rid="fig6">Figure 6</xref>. SERBP1 binding to snoRNAs and scaRNAs further supports its presence in Cajal bodies and nucleolus – <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. Liquid-liquid phase separation (LLPS) is a main contributor to the formation of membraneless organelles or granules (<xref ref-type="bibr" rid="bib87">Li et al., 2021</xref>). We have previously established that SERBP1 forms biomolecular condensates in vitro that are modulated by RNA (<xref ref-type="bibr" rid="bib9">Baudin et al., 2021</xref>). A characteristic of proteins in LLPS is the presence of IDRs (<xref ref-type="bibr" rid="bib68">Kastano et al., 2022</xref>; <xref ref-type="bibr" rid="bib44">Feng et al., 2021</xref>). Of all SERBP1-associated proteins present in membraneless organelles, 77% of them contain IDRs – <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>SERBP1-associated proteins are present in membraneless organelles.</title><p>(<bold>A</bold>) Different types of membraneless organelles in a cell and examples of SERBP1-associated proteins present in each structure. (<bold>B</bold>) Membraneless organelles identified in the GO enrichment analysis (cellular component) of SERBP1 interactors (<xref ref-type="bibr" rid="bib133">Thomas et al., 2022</xref>). FE = fold enrichment; FDR = false discovery rate. (<bold>C</bold>) Bar graph showing the distribution of SERBP1-associated proteins in different membraneless organelles. (<bold>D</bold>) Venn diagram representing the distribution of SERBP1-associated proteins present in membraneless organelles in respect to G4 binding (<xref ref-type="bibr" rid="bib126">Su et al., 2021b</xref>; <xref ref-type="bibr" rid="bib63">Herviou et al., 2020</xref>), PAR binding (<xref ref-type="bibr" rid="bib32">Dasovich et al., 2021</xref>), and PARylation (<xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>). Datasets used to prepare the figure, and detailed analyses are in <xref ref-type="supplementary-material" rid="supp1 supp6 supp9">Supplementary files 1, 6 and 9</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig6-v1.tif"/></fig><p>SERBP1 has been observed in Tau aggregates in Alzheimer’s disease (AD) brains and is part of a group of 261 proteins detected in several studies that examined the composition of Tau aggregates (<xref ref-type="bibr" rid="bib69">Kavanagh et al., 2022</xref>). We further investigated SERBP1’s association with pathological Tau by co-staining SERBP1 in AD tissues with phospho-tau (Thr231), which is associated with large inclusion and paired helical filaments (PHF) (<xref ref-type="bibr" rid="bib75">Kimura et al., 2018</xref>). We found a signal overlap between large hyperphosphorylated Tau inclusions and SERBP1 puncta (<xref ref-type="fig" rid="fig7">Figure 7A</xref>), confirming their close interaction in AD tissue. The interaction between SERBP1 and pTau was confirmed using an in situ proximity ligation assay – <xref ref-type="fig" rid="fig7">Figure 7B</xref>. Quantification of the PLA signal showed increased SERBP1-pTau interaction in AD compared to Ctr – <xref ref-type="fig" rid="fig7">Figure 7C</xref>. Western blot analysis showed that SERBP1 displays increased expression in AD brains in comparison to normal controls. Interestingly, SERBP1 appears to be often present as a dimer – <xref ref-type="fig" rid="fig7">Figure 7D and E</xref>. Overall, our data suggest that SERBP1 shows increased accumulation in AD brains and condenses in hyperphosphorylated Tau aggregates.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>SERBP1 is present in Tau aggregates.</title><p>(<bold>A</bold>) Representative co-immunofluorescence of SERBP1 and Phospho-Tau (Thr231) in AD brain tissues. Merged channel is represented. DAPI was used to stain nuclei. Magnification 20 x and white scale bar: 50 µm. Three different Insets selected from merged channels are represented in zoomed images as merged, SERBP1 (green) and Phospho-Tau (red). (<bold>B</bold>) Representative PLA of SERBP1 vs. pTau in AD and aged-matched control brains (magnification 40 x and white scale bar: 50 µm). (<bold>C</bold>) Percentage of positive area to PLA fluorescence in region of interests in AD and control brains (Ctr vs AD, *** p<italic>&lt;0.001</italic>, paired t-test). (<bold>D</bold>) Western blot showing SERBP1 expression in normal and AD brains and presence of oligomers. GAPDH and Tau oligomers immunoblot are shown. (<bold>E</bold>) SERBP1 relative density in Ctr and AD brains, quantified as function of GAPDH (from immunoblot in D). (Ctr vs. AD, * p<italic>&lt;0.05</italic>, paired t-test). (<bold>F</bold>) Venn diagram shows overlap between proteins often identified in Tau aggregates and SERBP1 associated proteins identified in this study (top). Gene Ontology (GO) enrichment analysis (Biological Processes) using ShinyGO (<xref ref-type="bibr" rid="bib48">Ge et al., 2020</xref>) indicated that SERBP1-associated factors that are also present in Tau aggregates are implicated in ribosome biogenesis, translation, splicing and telome maintenance. FE = fold enrichment; FDR = false discovery rate. Datasets used to prepare the figure, and detailed analyses are in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> and <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig7">Figure 7D</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98152-fig7-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig7">Figure 7D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98152-fig7-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig7-v1.tif"/></fig><p>146 proteins present in Tau aggregates were also identified as SERBP1 interactors – <xref ref-type="fig" rid="fig7">Figure 7F</xref> and <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>. GO analysis indicated that this group is strongly associated with ribosome biogenesis, translation, and splicing – <xref ref-type="fig" rid="fig7">Figure 7F</xref>. snoRNAs are also aberrantly located in Tau aggregates (<xref ref-type="bibr" rid="bib85">Lester et al., 2021</xref>). Adding to SERBP1 participation in Tau aggregates, we determined that 66% of the snoRNAs enriched in Tau aggregates were bound by SERBP1 according to our study – <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>. Ribosome biogenesis and translation are impaired in AD (<xref ref-type="bibr" rid="bib62">Hernández-Ortega et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">Evans et al., 2021</xref>). SERBP1 may help trap snoRNAs and factors implicated in ribosome biogenesis and translation in Tau aggregates, but further investigation is required.</p><p>PARP1 activity is increased in AD brains. Immunostaining of PARP1 and PAR indicates that PARylation is hyperactivated in AD neurons. Ultimately, this hyperactivation can trigger proteins to condense into toxic aggregates that contribute to neurodegeneration (<xref ref-type="bibr" rid="bib92">Mao and Zhang, 2022</xref>). We investigated PARP1-SERBP1 association in normal vs. AD brains. PARP1 exhibited a stronger presence in AD cortices compared to controls. Furthermore, PARP1 appeared to co-localize with SERBP1 in the cytoplasmic fraction of AD samples (white arrowhead) – <xref ref-type="fig" rid="fig8">Figure 8A</xref>. In control samples, PARP1 and SERBP1 also co-localized, albeit to a lesser extent compared to AD samples (confirmed by PCC analysis) – <xref ref-type="fig" rid="fig8">Figure 8A and B</xref>. Fluorescence profiles corroborate their association – <xref ref-type="fig" rid="fig8">Figure 8C</xref>. We performed a PLA assay to measure physical interaction between SERBP1 and PARP1. PLA results showed an increased signal for SERBP1/PARP1 association in AD brains in comparison to control brains. This observation was confirmed by the quantification of positive PLA area covered by such association – <xref ref-type="fig" rid="fig8">Figure 8D</xref>.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>SERBP1 association with PARP1 in Alzheimer’s brains.</title><p>(<bold>A</bold>) Representative co-immunofluorescence of SERBP1 and PARP1 in AD and age-matched control brain tissues. PARP1 and SERBP1 are represented in gray while merged images represent PARP1 (red), SERBP1 (green). DAPI was used to stain nuclei (blue). Magnification ×20 and white scale bar: 100 µm. Each frame has a zoomed inset representing the detailed distribution of each target. (<bold>B</bold>) Pearson Coefficient (PCC) of co-localizing SERBP1 and PARP1 between cells of age-matched control and AD brains (CTR vs. AD, **** p&lt;0.001 paired t-test). (<bold>C</bold>) Fluorescence intensity profiles of PARP1 (red), SERBP1 (green), and DAPI (blue) in representative cells from age-matched control and AD brains. Distance is represented in pixels and fluorescence intensity as Grey value obtained using ImageJ FIJI software. (<bold>D</bold>) Representative PLA of SERBP1 vs. PARP1 in AD and aged-matched control brains (magnification 40 x and white scale bar: 50 µm). Percentage of positive area to PLA fluorescence in region of interests in AD and control brains (Ctr vs AD, ** p<italic>&lt;0.01</italic>, paired t-test).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>SERBP1 association with G3BP1 in pathological stress granules and glioblastoma cells.</title><p>(<bold>A</bold>) Representative co-immunofluorescence of G3BP1 and SERBP1 in control and AD brain tissues. Merged channel is represented. DAPI was used to stain nuclei. Magnification 20 x and white scale bar: 100 µm. Inset 1 (Ctr) and Inset 2 (AD) selected from merged channels are represented in zoomed images (white scale bar: 5 µm). (<bold>B</bold>) Quantification of SERBP1 puncta localized in stress granules (G3BP1 granules) in Ctr versus AD (unpaired t-test p&lt;0.001,****). Quantification of stress granule density (G3BP1-positive foci) Ctr versus AD (ordinary one-way ANOVA p=0.006,***) and total SERBP1 puncta comparing Ctr versus AD (ordinary one-way ANOVA p&lt;0.001,****). Quantification has been performed using BZ-X Analyzer software (Keyence) analyzing 3 frontal cortex sections (selected randomly) from 3 control and 3 AD cases. (<bold>C</bold>) SERBP1 co-localization with G3BP1 in U251 cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98152-fig8-figsupp1-v1.tif"/></fig></fig-group><p>G3BP1, a well-established regulator of stress granule assembly, has been identified here as a SERBP1-associated protein – <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. In AD brains, G3BP1 is present in pathological stress granules (<xref ref-type="bibr" rid="bib4">Ash et al., 2014</xref>; <xref ref-type="bibr" rid="bib141">Vanderweyde et al., 2012</xref>). Co-immunofluorescence (IF) experiments in control and AD brain sections revealed a stronger fluorescent signal for SERBP1 and G3BP1 in AD compared to controls, indicating higher levels of SERBP1 protein in stress granules in pathological condition – <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A</xref>. Moreover, SERBP1 IF showed a high density of puncta with some large aggregates in AD samples. To quantify the level of SERBP1 in stress granules in control and AD samples, we measured the number of positive SERBP1 puncta in G3BP1 stress granules, observing a significant increment of SERBP1 in stress granules in AD cases. The total number of G3BP1 and SERBP1 puncta indicated greater accumulation in AD tissues compared to control – <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1B</xref>. SERBP1 and G3BP1 also show strong co-localization in glioblastoma cells and highly correlated expression in different scenarios – <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1C</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>SERBP1’s name relates to its function as a regulator of the gene SERPINE1, which encodes the plasminogen activator inhibitor 1 (PAI-1) (<xref ref-type="bibr" rid="bib58">Heaton et al., 2001</xref>), a protein implicated in senescence and migration. SERBP1 is localized mostly in the cytoplasm, but it is also present in the nucleus. SERBP1 cytoplasmic/nuclear balance changes during the cell cycle, and its nuclear presence intensifies upon stress (<xref ref-type="bibr" rid="bib2">Ahn et al., 2015</xref>; <xref ref-type="bibr" rid="bib82">Lee et al., 2014</xref>; <xref ref-type="bibr" rid="bib109">Passos et al., 2006</xref>). We have identified SERBP1’s interactome and expanded its regulatory roles – particularly in the nucleus, where it is associated with specific complexes implicated in splicing, cell division, chromosome structure, and different aspects of ribosome biogenesis.</p><p>Most SERBP1-associated proteins are also RBPs. However, SERBP1 has unique characteristics; it is mostly disordered and does not display classic RNA binding domains other than RGG boxes (<xref ref-type="bibr" rid="bib9">Baudin et al., 2021</xref>). Two commonalities between SERBP1 and its associated proteins are their preference for G4 binding and the fact that they get PARylated and/or bind to PAR. These results indicate that complexes in which SERBP1 participates are assembled via G4 or PAR binding. Since SERBP1 does not display any apparent functional domains and is involved in very distinct regulatory complexes, we suggest that SERBP1 acts in the initial steps of their assembly via recognition of interacting sites in RNA, DNA, and proteins.</p><sec id="s3-1"><title>SERBP1 in translation regulation and ribosomal biogenesis</title><p>SERBP1 interacts with ribosomal proteins and regulates translation (<xref ref-type="bibr" rid="bib18">Brown et al., 2018</xref>; <xref ref-type="bibr" rid="bib104">Muto et al., 2018</xref>; <xref ref-type="bibr" rid="bib2">Ahn et al., 2015</xref>; <xref ref-type="bibr" rid="bib95">Martini et al., 2021</xref>), functioning as a repressor or activator depending on the context. For instance, SERBP1 binding to CtIP mRNA during the S phase increases its translation (<xref ref-type="bibr" rid="bib2">Ahn et al., 2015</xref>), while changes in binding to the 40 S ribosomal subunit during mitosis lead to PKCε pathway-mediated translation repression (<xref ref-type="bibr" rid="bib95">Martini et al., 2021</xref>). Additionally, the SERBP1 yeast homolog, STM1, is required for optimal translation under nutritional stress (<xref ref-type="bibr" rid="bib140">Van Dyke et al., 2006</xref>). SERBP1 migrates to stress granules under stress conditions (<xref ref-type="bibr" rid="bib82">Lee et al., 2014</xref>). Recent findings indicated that translation in these organelles is not uncommon (<xref ref-type="bibr" rid="bib97">Mateju et al., 2020</xref>), suggesting the possibility of a similar role for SERBP1 as a modulator of translation in stress conditions.</p><p>Our GO analyses revealed that SERBP1 interacts with proteins participating in all stages of translation – initiation, elongation, and termination – including both negative and positive regulators. We found that 17% of SERBP1-associated proteins are implicated in translation initiation, including several subunits of the eukaryotic initiation factor 3 (eIF3A-I, L, and M) and CSDE1, among others. These data suggest that SERBP1’s primary function in translation regulation lies in initiation. CSDE1 is a known regulator of both cap-dependent and cap-independent translation, functioning either as an enhancer (<xref ref-type="bibr" rid="bib115">Ray and Anderson, 2016</xref>; <xref ref-type="bibr" rid="bib101">Mitchell et al., 2001</xref>) or repressor (<xref ref-type="bibr" rid="bib36">Dormoy-Raclet et al., 2005</xref>; <xref ref-type="bibr" rid="bib1">Abaza et al., 2006</xref>). The expression of CSDE1 is highly correlated with SERBP1 in multiple instances. CSDE1 was proposed to function as a ‘protein-RNA connector’ enabling interactions between RNAs and regulators to control RNA’s translational fate (<xref ref-type="bibr" rid="bib55">Guo et al., 2020</xref>). A similar role could be ascribed to SERBP1, possibly explaining its different effects on translation.</p><p>Multiple SERBP1-associated proteins are involved in viral translation. For instance, the aforementioned interactors, components of the eIF3 complex and CSDE1, are both implicated in IRES-mediated viral translation in a variety of viruses (<xref ref-type="bibr" rid="bib144">Walsh and Mohr, 2011</xref>; <xref ref-type="bibr" rid="bib88">Locker et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">Boussadia et al., 2003</xref>). SERBP1 itself has also recently been shown to interact with dengue virus RNA and regulate its translation (<xref ref-type="bibr" rid="bib19">Brugier et al., 2022</xref>). Finally, we observed a significant overlap between SERBP1-associated proteins and the SARS-CoV-2 interactome, with 82 proteins out of 145 shared interactors being involved in translation.</p><p>SERBP1’s interactors and its presence in the nucleolus suggest its participation in ribosome biogenesis. Besides binding to mRNA, SERBP1 binds to rRNA and snoRNAs, which play a role in pre-rRNA processing and modification (<xref ref-type="bibr" rid="bib136">Tollervey and Kiss, 1997</xref>). SERBP1, and 98 of its associated proteins, were previously identified in a screening for factors affecting rRNA processing (<xref ref-type="bibr" rid="bib130">Tafforeau et al., 2013</xref>). SERBP1’s binding profile to rRNA and snoRNA is dynamic, as shown by differences in iCLIP sites in mitotic vs. asynchronous cells (<xref ref-type="bibr" rid="bib95">Martini et al., 2021</xref>), hinting that SERBP1’s participation in these processes is cell cycle-dependent as seen for translation. FBL, a SERBP1-associated protein, is involved in pre-rRNA processing, pre-rRNA methylation, and ribosome assembly (<xref ref-type="bibr" rid="bib135">Tollervey et al., 1993</xref>). Recently, it has been shown that FBL also modulates rDNA transcription during the cell cycle according to its acetylation status, leading to higher levels of rRNA synthesis in interphase and lower levels during mitosis (<xref ref-type="bibr" rid="bib67">Iyer-Bierhoff et al., 2018</xref>). SERBP1 also interacts with multiple proteins of the cohesin complex (SMC1, SMC3, and PDS5B) plus the associated factor, CTCF. Cohesin forms an enhancer boundary complex who’s binding upstream of the 47 S rDNA is as an early event in the activation of rDNA transcription (<xref ref-type="bibr" rid="bib60">Herdman et al., 2017</xref>). In accordance with this finding, mutations in cohesin components have been linked to defects in both rRNA production and processing in yeast and human cells (<xref ref-type="bibr" rid="bib14">Bose et al., 2012</xref>). Two of SERBP1’s top interactors, the RNA helicase DDX21 and NCL, also promote rDNA transcription (<xref ref-type="bibr" rid="bib21">Calo et al., 2015</xref>; <xref ref-type="bibr" rid="bib137">Ugrinova et al., 2018</xref>).</p><p>Overall, these findings indicate a rather fluid role for SERBP1 in translation regulation, promoting or repressing different translational steps and acting in rRNA processing/modification and ribosome biogenesis through diverse pathways.</p></sec><sec id="s3-2"><title>SERBP1 and PARylation</title><p>PARylation of SERBP1 was described in several different studies (<xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>; <xref ref-type="bibr" rid="bib59">Hendriks et al., 2019</xref>; <xref ref-type="bibr" rid="bib13">Bonfiglio et al., 2017</xref>; <xref ref-type="bibr" rid="bib10">Bilan et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Larsen et al., 2018</xref>). Moreover, the expression of human PARP1 in <italic>S. cerevisae,</italic> which does not naturally express PARP proteins, caused PARylation of many proteins implicated in ribosomal biogenesis, including STM1, SERBP1 homolog (<xref ref-type="bibr" rid="bib131">Tao et al., 2009</xref>). Our results suggest a two-way association between SERBP1 and PARP1. First, SERBP1 and 56% of its identified associated proteins either get PARylated and/or bind PAR (<xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Dasovich et al., 2021</xref>). This result suggests that SERBP1 participates in several regulatory complexes modulated via PARylation.</p><p>PARylation of RBPs ultimately influences RNA processing and expression (<xref ref-type="bibr" rid="bib74">Kim et al., 2020</xref>; <xref ref-type="bibr" rid="bib91">Manco et al., 2022</xref>). In particular, PARylation of splicing regulators is known to affect alternative splicing. For instance, PARylation of HRP38’s RNA binding domain decreases its binding activity and subsequently its ability to inhibit splicing (<xref ref-type="bibr" rid="bib74">Kim et al., 2020</xref>). PARylation also affects protein-protein interaction as observed in the case of hnRNPA1 (<xref ref-type="bibr" rid="bib38">Duan et al., 2019</xref>). Finally, PARP1 itself is involved in splicing. PARP1 binds RNA with a preference for intronic regions, while its knockdown affected many splicing events (<xref ref-type="bibr" rid="bib100">Melikishvili et al., 2017</xref>). Several splicing regulators known to get PARylated and/or bind to PAR were identified as SERBP1-associated proteins, including hnRNPs (A1, H1, A2B1, H3, K, I, and U) and SR proteins (SRSF2, SRSF3, and SRSF9). In particular, most splicing alterations observed in SERBP1 KD cells were also present upon hnRNPU KD, suggesting that they work as co-factors in splicing regulation. Altogether, the data suggest that SERBP1 is directly implicated in splicing regulation and is present in complexes modulated by PARylation.</p><p>PAR induces phase separation of proteins containing IDRs and the formation of molecular condensates or membraneless organelles such as stress granules, mitotic spindles, DNA repair foci, and nucleoli (<xref ref-type="bibr" rid="bib86">Leung, 2020</xref>). Similarly, ADP-ribose can be conjugated to polar and charged amino acids, which are often found in IDRs (<xref ref-type="bibr" rid="bib86">Leung, 2020</xref>). Ultimately, PAR serves as a scaffold to assemble protein complexes in different contexts where PAR length and structure influence their composition (<xref ref-type="bibr" rid="bib86">Leung, 2020</xref>). The large number of PARylated proteins and PAR binders found among SERBP1-associated proteins strongly indicates that PAR is a critical component of the regulatory complex in which SERBP1 participates, especially in membraneless organelles. As a protein that interacts with PARP1, promotes PARP activity, gets PARylated, and binds PAR, we suggest that SERBP1 acts as a critical factor in the assembly of PARylation-dependent complexes. Additional analyses are required to assess whether the formation of such complexes depends on SERBP1 and if inhibition of SERBP1 PAR binding activity could be explored as a therapeutic strategy.</p><p>SERBP1 exhibited a punctate distribution in normal brain, indicating its presence as functional singlet condensate. However, in AD brain tissues, SERBP1 appeared to accumulate in large cytoplasmic aggregates and to strongly co-localize with PARP1. This result suggests that PARP1 modulates liquid-liquid phase separation (LLPS) and a PARylation-mediated mechanism is likely involved in SERBP1’s pathological transition from condensate to aggregate. Several RBPs containing intrinsically disordered regions, like SERBP1, have been shown to display alterations in LLPS in neurodegenerative diseases (<xref ref-type="bibr" rid="bib108">Ottoz and Berchowitz, 2020</xref>; <xref ref-type="bibr" rid="bib106">Naskar et al., 2023</xref>).</p></sec><sec id="s3-3"><title>SERBP1 and G4 binders</title><p>SERBP1 belongs to a group of neuronal-related RBPs that share structural characteristics and preferentially bind to G quadruplexes (G4s). G4s are complex DNA or RNA structures that display stacked tetrads of guanosines stabilized by Hoogsteen base pairing. rG4s function as regulatory elements in different stages of gene expression, including splicing, mRNA decay, polyadenylation, and translation. G4s have been linked to cancer, viral replication, and in particular neurodegenerative diseases and neurological disorders (<xref ref-type="bibr" rid="bib90">Lyu et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Banco and Ferré-D’Amaré, 2021</xref>; <xref ref-type="bibr" rid="bib39">Dumas et al., 2021</xref>).</p><p>The SERBP1 interactome shows an interesting parallel between PAR and G4 binding. Almost half of the SERBP1-associated proteins that bind G4 also bind PAR. PAR and G4s occupy the same regulatory space that includes DNA repair and stress response, and both induce phase separation. However, not much is known regarding the association between G-quadruplex and PAR binding/PARylation, aside from the fact that PARP1 binds G4s, and this leads to the activation of its enzymatic activity (<xref ref-type="bibr" rid="bib41">Edwards et al., 2021</xref>). We envision two possible scenarios for SERBP1 and its associated proteins. Two types of domains have been implicated in both PAR and G4 binding, RGG boxes and RRMs. Among 105 SERBP1-associated factors that bind PAR and G4, 51 contain RGG and/or RRM domains. Proteins that employ the same domain to bind PAR and G4 could transit from G4 to PAR binding complexes, depending on the cellular state. In a different setting, binding to G4 motifs in DNA or RNA could serve as a starting point for the assembly of PAR binding/PARylated protein complexes. Further investigation on PAR- and G4-dependent interactions and identification of G4 and PAR binding domains in proteins present in these complexes are needed to elucidate the relationship between PAR and G4 binding.</p></sec><sec id="s3-4"><title>SERBP1 potential role in neurodegenerative diseases and neurological disorders</title><p>SERBP1 expression in the brain is lower than in other organs and is increased in glioblastoma (<xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>) and Alzheimer’s brains, as shown in this study. SERBP1 is present in Tau aggregates (<xref ref-type="bibr" rid="bib69">Kavanagh et al., 2022</xref>) and in pathological stress granules in connection with G3BP1. PAR levels regulate the dynamics of RNPs and aberrant PARP1 activity promotes aggregation (<xref ref-type="bibr" rid="bib38">Duan et al., 2019</xref>). Over 60% of SERBP1-associated proteins detected in Tau aggregates get PARylated and/or bind PAR (<xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Dasovich et al., 2021</xref>) and increased SERBP1-PARP1 interaction was observed in AD brains. Besides its potential role in aggregate formation, increased expression of SERBP1 in Alzheimer’s brains could lead to important changes in gene expression. SERBP1 is highly expressed in neuronal and glioma stem cells and its levels drop significantly during neurogenesis. SERBP1 transgenic expression disrupted neuronal differentiation while its knockdown increased the expression of genes implicated in nervous system development, synaptic signaling, organization, memory, learning, and behavior (<xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>).</p><p>SERBP1-associated proteins contain several factors involved in neurological disorders and neurodegenerative diseases, including FMR1, SMN1, and PABPN1. SERBP1 interaction with FMRP (FMR1) has been previously described (<xref ref-type="bibr" rid="bib95">Martini et al., 2021</xref>; <xref ref-type="bibr" rid="bib82">Lee et al., 2014</xref>). Not only was this interaction validated, but we also determined that SERBP1 associates with FMRP partner proteins FXR1 and FXR2. FMRP is the main driver of Fragile X mental retardation but has also been linked to Alzheimer’s disease and autism (<xref ref-type="bibr" rid="bib12">Bleuzé et al., 2021</xref>; <xref ref-type="bibr" rid="bib47">Fyke and Velinov, 2021</xref>). FMRP is a complex protein that binds different RNA motifs (including G4s) and regulates translation, splicing, RNA editing, and miRNA function, affecting synapse formation and plasticity, stress granule formation, channel signaling, and differentiation (<xref ref-type="bibr" rid="bib33">Davis and Broadie, 2017</xref>; <xref ref-type="bibr" rid="bib30">Darnell et al., 2004</xref>; <xref ref-type="bibr" rid="bib31">Darnell and Klann, 2013</xref>; <xref ref-type="bibr" rid="bib116">Richter and Zhao, 2021</xref>). Previous results indicate that SERBP1 and FMRP interact in different contexts (<xref ref-type="bibr" rid="bib95">Martini et al., 2021</xref>; <xref ref-type="bibr" rid="bib82">Lee et al., 2014</xref>), suggesting that they function together in diverse stages of gene expression.</p><p>Spinal Muscular Atrophy (SMA) is caused by mutations in the SMN1 gene. Patients show progressive lower motor neuron loss (<xref ref-type="bibr" rid="bib112">Prashad and Gopal, 2021</xref>). We observed associations between SERBP1, SMN1, and other members of the SMN complex, GEMIN4 and 5. SMN1 brings together the complex and is essential for spliceosome assembly. Since motor neurons are particularly sensitive to SMN1 mutations, additional roles for the SMN complex in these cells are proposed (<xref ref-type="bibr" rid="bib112">Prashad and Gopal, 2021</xref>).</p><p>SYNCRIP and hnRNPU were identified among the top proteins associated with SERBP1 based on our proteomics analyses and gene expression correlations. SYNCRIP plays multiple roles in neuronal cells, including dendritic translation, synaptic plasticity, axonogenesis, and morphology (<xref ref-type="bibr" rid="bib24">Chen et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Duning et al., 2008</xref>; <xref ref-type="bibr" rid="bib72">Khudayberdiev et al., 2021</xref>; <xref ref-type="bibr" rid="bib134">Titlow et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Halstead et al., 2014</xref>). hnRNPU has been implicated in cortex development (<xref ref-type="bibr" rid="bib120">Sapir et al., 2022</xref>). Mutations in both hnRNPU and SYNCRIP are linked to intellectual disability (<xref ref-type="bibr" rid="bib84">Lelieveld et al., 2016</xref>; <xref ref-type="bibr" rid="bib6">Balasubramanian, 2022</xref>; <xref ref-type="bibr" rid="bib16">Bramswig et al., 2017</xref>) and neurodevelopmental disorders (<xref ref-type="bibr" rid="bib52">Gillentine et al., 2021</xref>; <xref ref-type="bibr" rid="bib145">Wang et al., 2020</xref>), and were the two top candidates in an IBM Watson-based study to identify RBPs altered in amyotrophic lateral sclerosis (ALS) (<xref ref-type="bibr" rid="bib5">Bakkar et al., 2018</xref>).</p><p>SERBP1 has not been studied in the context of the nervous system, and its contribution to neurodegenerative diseases and neurological disorders remains to be investigated. Our results suggest that SERBP1 is ‘guilty by association’ as it interacts with several RBPs that function as key players in these scenarios. Moreover, SERBP1 regulates the expression of genes implicated in neuronal differentiation and synaptogenesis, processes often compromised in disease states. In the case of Alzheimer’s disease, increased expression of SERBP1 and its presence in pathological aggregates hint at a potential involvement. Additional studies are necessary to establish causal connections that link SERBP1 to AD phenotypes.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">SERBP1</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">HGNC:HGNC:17860</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">U251 (glioblastoma)</td><td align="left" valign="bottom">Uppsala University</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">U343 (glioblastoma)</td><td align="left" valign="bottom">Uppsala University</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">293T (normal)</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-3216</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">SERBP1 SMARTpool siRNA</td><td align="left" valign="bottom">Dharmacon</td><td align="left" valign="bottom">Cat#:L-020528-01-0005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Biological sample (human)</td><td align="left" valign="bottom">Control and Alzheimer’s Disease (AD) human brains</td><td align="left" valign="bottom">Institute for Brain Aging and Dementia at UC Irvine</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Braak Stage V-VI for AD brains</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-SERBP1 (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#:sc100800</td><td align="left" valign="bottom">WB (1:100 for human, 1:1000 for cell line samples), IF (1:50 for human, 1:200 for cell line samples), PLA (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-GAPDH (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat#:ab9485</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-G3BP1 (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#:17798 S</td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-PARP1 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#:9532 S</td><td align="left" valign="bottom">WB (1:1000), PLA (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-SYNCRIP (rabbit polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#:PA5-59501</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-hnRNPU (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#:34095</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Puromycin (mouse monoclonal)</td><td align="left" valign="bottom">Kerafast</td><td align="left" valign="bottom">Cat#:EQ0001</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-His (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#:sc-53073</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Flag (mouse monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#:MA1-91878</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-GAPDH (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#:SC32233</td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-β-Actin (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat#:ab8227</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-β-Tubulin (mouse monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#:T8328</td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-α-Tubulin (mouse monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#:236–10501</td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-FBL (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#:C13C3</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-NCL (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#:D4C70</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-G3BP1 (mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat#:ab56574</td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho-Tau (Thr231) (mouse monoclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat#:MN1040</td><td align="left" valign="bottom">IF(1:250), PLA(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP-conjugated anti-rabbit (goat polyconal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#:sc-2030</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP-conjugated anti-mouse (goat, polyclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#:sc-2005</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488-conjugated anti-rabbit (goat polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#:A11008</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 568-conjugated anti-mouse (goat polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#:A11004</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-poly-ADP-ribose binding reagent (with rabbit Fc-tag)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat#:MABE1031; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2665467">AB_2665467</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pEF1 (plasmid)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat#:V92120</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSBP-SERBP1 (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">SERBP1 ORF and SBP-tag cloned in frame in pEF1 backbone</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pUltra-SERBP1 lentiviral vector</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">control for pulldown experiments (no SBP-tag)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.1-mGreenLantern (plasmid)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_161912">Addgene_161912</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">mGreen-SERBP1 (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">SERBP1 ORF cloned in frame in pcDNA3.1-mGreenLantern backbone</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Flag-PARP1</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_111575">Addgene_111575</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">6xHis-tagged SERBP1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib9">Baudin et al., 2021</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Lipofectamine RNAiMAX</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#:13778150</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Streptavidin beads</td><td align="left" valign="bottom">GE Healthcare Life Sciences</td><td align="left" valign="bottom">Cat#:17-5113-01</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Cell Titer Glo 2.0</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat#:G9243</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Duolink PLA in Situ Red starter kit mouse/rabbit</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#:DUO92101</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cambridge Cancer Compound Library</td><td align="left" valign="bottom">Selleck Chem</td><td align="left" valign="bottom">Cat#:L2300</td><td align="left" valign="bottom">100 nM in 0.1% DMSO treatment concentration</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Puromycin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#:P7255</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Paclitaxel</td><td align="left" valign="bottom">Cayman Chem</td><td align="left" valign="bottom">Cat#:10461</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PARP inhibitor PJ34</td><td align="left" valign="bottom">Enzo</td><td align="left" valign="bottom">Cat#:ALX-270–289</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Mascot v2.7.0</td><td align="left" valign="bottom">Matrix Science</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_014322">SCR_014322</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Scaffold v4.9.0</td><td align="left" valign="bottom">Proteome Software</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_014321">SCR_014321</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ FIJI</td><td align="left" valign="bottom">NIH</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002285">SCR_002285</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">BioInfoRx</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://bioinforx.com/apps/venn.php">https://bioinforx.com/apps/venn.php</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Nematode genome comparison browser</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://nemates.org/MA/progs/overlap_stats.html">http://nemates.org/MA/progs/overlap_stats.html</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ShinyGO v0.67 &amp; v0.77</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib48">Ge et al., 2020</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Metascape v3.5</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib154">Zhou et al., 2019</xref><break/></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Panther v17.0</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib133">Thomas et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Revigo</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib127">Supek et al., 2011</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">STRING v11.5</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib129">Szklarczyk et al., 2023</xref><break/></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Cytoscape</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib35">Doncheva et al., 2023</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">R2</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://r2.amc.nl">http://r2.amc.nl</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">dcGO Enrichment mining service</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib43">Fang and Gough, 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">STAR v2.7.7.a</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib34">Dobin et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">rMATS v4.1.2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib121">Shen et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">rmats2sashimiplot tool</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/Xinglab/rmats2sashimiplot">https://github.com/Xinglab/rmats2sashimiplot</ext-link>; <xref ref-type="bibr" rid="bib148">Xinglab, 2024</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">BEDTools intersect software</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib114">Quinlan and Hall, 2010</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Kallisto v0.46.1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib17">Bray et al., 2016</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">R package tximport</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib122">Soneson et al., 2015</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DESeq2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib89">Love et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Fluor Save</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#:345789</td><td align="left" valign="bottom">Reagent, microscopy</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Prolong Gold Antifade with DAPI</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat#:P36931</td><td align="left" valign="bottom">Reagent, microscopy</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture, transfection, knockdown</title><p>U251 and U343 glioblastoma cell lines were obtained from Uppsala University (Uppsala, Sweden). 293T cells were obtained from the American Type Tissue Collection (ATCC). All cell lines were cultured in DMEM medium (HyClone, Cat# SH30243.01) supplemented with 10% FBS (Corning, Cat# 35015CV) and 1% penicillin/streptomycin (Gibco, Cat# 10378016). Cells were maintained at 37  °C in a 5% CO<sub>2</sub> atmosphere. Cell lines were confirmed to be correct using Short Tandem Repeat profiling. They were regularly tested for mycoplasma contamination.</p><p>Knockdown of SERBP1 (siSERBP1 KD) in U251 and U343 cells was performed by reverse transfection with 25  nM of control or SERBP1 SMARTpool siRNA (Dharmacon, Cat# L-020528-01-0005) using Lipofectamine RNAiMAX (Invitrogen, Cat# 13778150).</p></sec><sec id="s4-2"><title>Plasmid constructs</title><p>A vector containing the Streptavidin-Binding Peptide (SBP)-Tag was prepared in pEF1 (Thermo Fisher, Cat# V 92120), and SERBP1 ORF was cloned in frame with the His-Myc-tag present in the vector to create pSBP-SERBP1. The SBP-tag contains 38 amino acids and binds to streptavidin with an equilibrium dissociation constant of 2.5 nM (<xref ref-type="bibr" rid="bib70">Keefe et al., 2001</xref>). Ultra-SERBP1 lentiviral vector (<xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>) was used as a control in pulldown experiments. SERBP1 ORF was inserted into the pcDNA3.1-mGreenLantern plasmid (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_161912">Addgene_1619122</ext-link>) to make mGreen-SERBP1. Flag-PARP1 was obtained from Addgene (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_111575">Addgene_111575</ext-link>).</p><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Primer name</th><th align="left" valign="top">sequence</th></tr></thead><tbody><tr><td align="left" valign="top">SERBP1_for_ EcoRI</td><td align="left" valign="top">tatagaattcATGCCTGGGCACTTAATGCCTGGGCACTTA</td></tr><tr><td align="left" valign="top">SERBP1_rev_XbaI</td><td align="left" valign="top">tatatctagaAGCCAGAGCTGGGA</td></tr><tr><td align="left" valign="top">mGL_SERBP1_BsrGI</td><td align="left" valign="top">actgtacaagATGCCTGGGCACTTACAG</td></tr><tr><td align="left" valign="top">mGL_SERBP1_XbaI</td><td align="left" valign="top">atctagattaAGCCAGAGCTGGGAA</td></tr></tbody></table></table-wrap></sec><sec id="s4-3"><title>Identification of SERBP1 interactors</title><p>293T cells were seeded (triplicate) in 10 cm dishes the day before transfection. pSBP-SERBP1 or pUltra-SERBP1(control) plasmids were transfected using CaCl<sub>2</sub>. 48 hr later, cells were collected and washed twice in cold PBS. Total protein extract was prepared by using TNE buffer (Tris pH 7.4 10 mM, NP-40 1%, NaCl 150 mM, and phosphatase inhibitor cocktails, Thermo Fisher Scientific, Cat# 78430), incubating cells for 30 min on ice, and then sonicating five times for 3 s at 20% amplitude and 10 s intervals. A second batch of samples was prepared by using polysomal lysis buffer (KCl 100 mM, EDTA 25 mM, MgCl<sub>2</sub> 5 mM, HEPES pH 7.0 10 mM, NP-40 0.5%, DTT 2 mM, VRC 0.4 mM, glycerol 10%, and phosphatase inhibitor cocktails, Thermo Fisher Scientific). Cell lysates were centrifuged at 4 °C to eliminate debris and supernatants were collected and used later in pulldown assays.</p><p>50 µl of packed streptavidin beads (GE Healthcare Life Sciences, Cat# 17-5113-01) were washed two times in PBS and subsequently blocked in 1% BSA/PBS for 30 min at 4 °C. Beads were finally washed five times in TNE buffer and then combined with cell extracts. The solution was incubated at room temperature for 2 hr and beads were later recovered via centrifugation at 4 °C. The supernatant was discarded, and beads were washed five times with 1 ml of TNE buffer. To elute proteins, samples were resuspended in elution buffer (Tris pH 7.4 50 mM, NaCl 250 mM, NP-40 0.5%, deoxycholate 0.1%, 10 mM biotin), mixed, and incubated for 45 min at 37 °C in a thermo-shaker. The supernatant was collected after centrifugation for mass spectrometry analysis.</p></sec><sec id="s4-4"><title>Protein identification by mass spectrometry</title><sec id="s4-4-1"><title>Analysis of proteins associated with SERBP1</title><p>Proteins were separated by 1D SDS-PAGE using a Criterion XT 12% gel that was electrophoresed for ~1.5 cm and then stained with Coomassie blue (one experiment per gel). The protein-containing region of each gel lane was divided into six slices which were individually reduced in situ with TCEP [tris(2-carboxyethyl)phosphine] and alkylated in the dark with iodoacetamide prior to treatment with trypsin. Each digest was analyzed by capillary HPLC-electrospray ionization tandem mass spectrometry on a Thermo Scientific Orbitrap Fusion Lumos mass spectrometer. On-line HPLC separation was accomplished with an RSLC NANO HPLC system (Thermo Scientific/Dionex): column, PicoFrit (New Objective; 75 μm i.d.) packed to 15 cm with C18 adsorbent (Vydac; 218 MS 5 μm, 300 Å). Precursor ions were acquired in the Orbitrap mass spectrometer in centroid mode at 120,000 resolution (<italic>m/z</italic> 200); data-dependent higher-energy C-trap dissociation (HCD) spectra were acquired at the same time in the linear trap using the ‘top speed’ option (30% normalized collision energy). Mascot (v2.7.0; Matrix Science) was used to search the spectra against a combination of the human subset of the UniProt database plus a database of common contaminants [UniProt_Human 20181204 (95,936 sequences; 38,067,061 residues); contaminants 20120713 (247 sequences; 128,130 residues)]. Subset search of the identified proteins by X! Tandem, cross-correlation with the Mascot results, and determination of protein and peptide identity probabilities were accomplished by Scaffold (v4.9.0; Proteome Software). The thresholds for acceptance of peptide and protein assignments in Scaffold were set to yield &lt;1% protein FDR. Corresponding UniProt IDs for the proteins were obtained using the UniProt ID mapping service (<xref ref-type="bibr" rid="bib8">Bateman et al., 2023</xref>).</p></sec></sec><sec id="s4-5"><title>Western blots</title><sec id="s4-5-1"><title>Cells</title><p>Cells were harvested and lysed in Laemmli sample buffer (BioRad, Cat# 1610737). Cell extracts were separated on an SDS-PAGE gel, and transferred to PVDF membranes, previously activated with methanol. Membranes were blocked in 5% milk Tris-buffered saline with Tween 20 and probed with a collection of different antibodies listed below. Horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody (Santa Cruz Biotechnology, Cat# sc-2030) or HRP-conjugated goat anti-mouse (Santa Cruz Biotechnology, Cat# sc-2005) were used as secondary antibodies. Immobilon Western chemo-luminescence substrate (Millipore, Cat# WBKLS0500) was used to detect selected proteins.</p></sec><sec id="s4-5-2"><title>Human samples</title><p>Western blots were performed with proteins extracted from control and Alzheimer’s brains. Approximately 10 µg of protein were loaded into precast NuPAGE 4–12% Bis-Tris gels (Invitrogen) for analysis by sodium dodecyl sulfate–polyacrylamide gel electrophoresis. The separated proteins were subsequently transferred onto nitrocellulose membranes and blocked overnight at 4 °C with 10% nonfat dry milk. The membranes were then probed for 1 hr at room temperature with primary antibodies - anti-SERBP1 (1:100, sc100800) and anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:1000, ab9485, Abcam) - diluted in 5% nonfat dry milk. SERBP1 immunoreactivity was detected with a horseradish peroxidase–conjugated anti-mouse IgG (1:5000, GE Healthcare). GAPDH immunoreactivity was detected using an anti-mouse IgG (1:6000, GE Healthcare) diluted in 5% nonfat dry milk. An enhanced chemiluminescence reagent (ECL Plus, Amersham) was used to visualize the bands. The amount of protein was normalized and quantified using the loading control GAPDH.</p></sec></sec><sec id="s4-6"><title>Antibodies</title><p>anti-SERBP1 (Santa Cruz Biotechnology, Cat# SC100800), anti-G3BP1 (Cell Signaling, Cat# 17798 S), anti-PARP1 (Cell Signaling, Cat# 9532 S), anti-SYNCRIP (Invitrogen, Cat# PA5-59501), anti-hnRNPU (Cell Signaling, Cat# 34095), anti-Puromycin (Kerafast, Cat# EQ0001), anti-His (Santa Cruz Biotechnology, Cat# sc-53073), anti-Flag (Invitrogen, Cat# MA1-91878), anti-GAPDH (Santa Cruz Biotechnology, Cat# SC32233), anti-β-Actin (Abcam, Cat# ab8227), anti-β-Tubulin (Sigma-Aldrich, Cat# T8328), anti-α-Tubulin (Invitrogen, Cat# 236–10501), FBL (Cell Signaling, Cat# C13C3), NCL (Cell Signaling, Cat# D4C70).</p></sec><sec id="s4-7"><title>High-throughput drug screening</title><p>High-throughput screening was conducted with the Cambridge Cancer Compound Library (Selleck Chem, Cat# L2300) of 293 compounds of interest (<xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). All compounds dissolved in DMSO to a stock concentration of 10 mM and further diluted in PBS to achieve a final treatment concentration of 100 nM and a final DMSO concentration of 0.1%. Four replicates of both U343 OE and U343 Control cells were plated in 384 well white polystyrene microplates (Thermo Fisher Scientific) at a seeding density of 5.0x103 cells/well 12 hr before treatment. Cell seeding and treatment was conducted by an automated electronic pipetting system to increase pipetting accuracy and to minimize variability between replicates (Integra VIAFLO 384). After 24 hr of treatment, cells were incubated with Cell Titer Glo 2.0 (Promega, Cat# G9243) according to the manufacturer’s protocol. The addition of the reagent lyses cells and attaches a luminescent tag to ATP molecules in order to assess cell viability. Within 10 min of Cell Titer Glo 2.0 reagent addition, ATP measurements were then collected as luminescence intensities by a Tecan Spark microplate reader. Dixon’s Q test was used to eliminate outliers prior to statistical analysis. Experimental ATP intensities were normalized to respective vehicle controls to assess cell viability following drug treatment. Student’s Ttest was used to evaluate significant differences between reactions of U343 and U343 SERBP1 OE to each treatment.</p></sec><sec id="s4-8"><title>Puromycin assays</title><p>siSERBP1 KD in U251 and U343 cells was performed as described above. 72 hr after transfection, cells were incubated with 10 µg/ml Puromycin (Sigma-Aldrich, Cat# P7255) for 15 min at 37 °C and 5% CO<sub>2</sub>. Cells were then placed on ice and washed twice with cold PBS before being harvested in Laemmli sample buffer. Western blots were performed as described above with 15 µg protein extracts.</p></sec><sec id="s4-9"><title>Protein co-localization</title><p>U251 cells were cultured on glass coverslips until 80% confluent and fixed in 4% paraformaldehyde followed by permeabilization with 0.1% TritonX-100 for 2  min. Cells were then stained with primary antibody for 1 hr followed by the secondary antibody conjugated to Alexa Fluor 488 or 568 (Invitrogen, Invitrogen, Cat# A11004 and A11008). After washing with PBS, cells were stained with DAPI and mounted onto glass slides with FluorSave (Invitrogen, Cat# 345789) before being analyzed by fluorescence microscopy.</p></sec><sec id="s4-10"><title>Impact of SERBP1 on cell division</title><p>24 hr after siSERBP1 KD in U251 and U343, cells were exposed to 20 nM of Paclitaxel (Cayman Chem, Cat# 10461) for 24 hr. Cells were fixed in 4% PFA and stained with α-Tubulin and DAPI. The experiment was performed in triplicates and 1000 cells were counted per replicate. Statistical significance was evaluated by Student’s t-test.</p></sec><sec id="s4-11"><title>In vitro PARylation assay</title><p>Flag-tagged PARP1 was expressed in insect cells and purified as previously described (<xref ref-type="bibr" rid="bib65">Huang et al., 2020</xref>). 6xHis-tagged SERBP1 was purified as in <xref ref-type="bibr" rid="bib9">Baudin et al., 2021</xref>. Briefly, purified recombinant PARP1 (0.1 µM) and SERBP1 (0.6 µM) were combined in an ADP-ribosylation reaction (20 µL) with or without sheared salmon sperm DNA (sssDNA; 100 ng/µL) and NAD<sup>+</sup> (100 µM). The reactions were incubated at room temperature for 15 min. The reaction products were analyzed on 8% PAGE-SDS gels with silver staining or Western blotting for PAR using a recombinant anti-poly-ADP-ribose binding reagent (Millipore, Cat# MABE1031; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2665467">AB_2665467</ext-link>).</p></sec><sec id="s4-12"><title>SERBP1 impact on PARylation</title><p>pcDNA3.1-EF1a-mGreenLantern-SERBP1 or control plasmid pcDNA3.1-EF1a-mGreenLantern was transfected into 293T cells. 48 hr later, cells were collected and lysed in Laemmli sample buffer. 10 µg of extracted proteins were separated on SDS-PAGE gel and Western blot was performed as described. Poly-ADP-ribose binding reagent (Sigma-Aldrich, Cat# MABE1031) was used to detect oligo- and poly-ADP-ribosylated (PARylated) proteins.</p></sec><sec id="s4-13"><title>Sensitivity to PARP inhibitor</title><p>U251 and U343 siSERBP1 knockdown was performed as described above. 5 µM of PARP inhibitor PJ34 (Enzo, Cat# ALX-270–289) was used to treat the cells 24 hr later. The Essen Bioscience IncuCyte automated microscope system was used to follow the proliferation of U251 and U343 glioblastoma cells over 150 hr. Differences in proliferation between single and combined treatment at 100 or 150 hr were analyzed graphically. Statistical significance was calculated by Student’s t-test and the combination treatment was evaluated with the Combination Index (<xref ref-type="bibr" rid="bib25">Chou, 2010</xref>).</p></sec><sec id="s4-14"><title>Immunolabeling of fixed human brain sections</title><p>Frozen cortical sections were first fixed in chilled 20% methanol. To eliminate autofluorescence from lipofuscin, we incubated the sections with TrueBlack Lipofuscin Autofluorescence Quencher (#23007, Biotium) for 10 min at room temperature. After three washes with ethanol 70%, the sections were permeabilized in PBS/0.4% Triton-X100 for 5 min. After 1 hr of blocking in PBS/10% NGS/0.2% Triton at room temperature, the sections were incubated in primary antibodies diluted in PBS/10% NGS overnight at 4 °C. Immunolabeling for G3BP1 (5 μg/ml, 2F3, Abcam Cat# ab56574), Phospho-Tau (Thr231) (1:500, AT180, Thermo Fisher Scientific #MN1040) and SERBP1 (1:50, 1B9, Santa Cruz Bio Cat# sc-100800) was performed in all control (N=3) and AD (N=3, Braak Stage V-VI) human brains. The next day, sections were washed three times in PBS (5 min each), and secondary antibodies were applied for 45 min: Alexa Fluor 488 and 568 (1:200, Life Technologies). After further washing in PBS, slides were then mounted with Prolong Gold Antifade with DAPI (Thermo Fisher Scientific Cat# P36931) to stain the nuclei. Granule density of G3BP1 and SERBP1 were measured in 3 Ctr and 3 AD cases, and images in triplicate from each case were analyzed by ImageJ FIJI (NIH) software. SERBP1 associated with stress granules was measured as the ratio between colocalizing SERBP1/G3BP1 puncta and G3BP1 total granules in the cortical section using ImageJ FIJI (NIH) software.</p></sec><sec id="s4-15"><title>Human tissue harvesting</title><p>Frontal cortices of frozen brain tissues from age-matched control subjects (N=6), AD cases (N=6) were received as frozen blocks from the Institute for Brain Aging and Dementia at UC Irvine, approved by the Institutional Ethics Committee. Brain tissues were homogenized in 1 X PBS mixed with a protease inhibitor cocktail (Roche) and phosphatase inhibitor (Sigma) at 1:3 (w/v) dilution of brain: PBS. Samples were then centrifuged at 10,000 rpm for 20 min at 4 °C. The supernatants, PBS-soluble fractions were aliquoted, snap-frozen, and stored at −80 °C until use. The pellets were resuspended in the homogenization buffer (1 X PBS) and were considered as insoluble fractions. They were also aliquoted and frozen at –80 °C until use. Brain tissues analyzed in this study from diseased and age-matched non-demented control subjects are listed in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Brain tissues analyzed in this study from diseased and age-matched non-demented control subjects are summarized.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Clinical Diagnosis</th><th align="left" valign="bottom">Case Number</th><th align="left" valign="bottom">Age</th><th align="left" valign="bottom">Gender</th><th align="left" valign="bottom">PMI (Hours)</th><th align="left" valign="bottom">Braak Tangles (0–6)</th><th align="left" valign="bottom">Application</th></tr></thead><tbody><tr><td align="left" valign="bottom">AD</td><td align="left" valign="bottom">1154</td><td align="left" valign="bottom">86</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">3.25</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">IF/PLA</td></tr><tr><td align="left" valign="bottom">AD</td><td align="left" valign="bottom">1098</td><td align="left" valign="bottom">81</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">2.75</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">IF/PLA</td></tr><tr><td align="left" valign="bottom">AD</td><td align="left" valign="bottom">5773</td><td align="left" valign="bottom">74</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">IF/PLA</td></tr><tr><td align="left" valign="bottom">AD</td><td align="left" valign="bottom">5779</td><td align="left" valign="bottom">73</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">WB</td></tr><tr><td align="left" valign="bottom">AD</td><td align="left" valign="bottom">5781</td><td align="left" valign="bottom">88</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">WB</td></tr><tr><td align="left" valign="bottom">AD</td><td align="left" valign="bottom">5829</td><td align="left" valign="bottom">68</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">12</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">WB</td></tr><tr><td align="left" valign="bottom">Control</td><td align="left" valign="bottom">5263</td><td align="left" valign="bottom">88</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">12.17</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">IF/PLA</td></tr><tr><td align="left" valign="bottom">Control</td><td align="left" valign="bottom">1161</td><td align="left" valign="bottom">84</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">2.50</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">IF/PLA</td></tr><tr><td align="left" valign="bottom">Control</td><td align="left" valign="bottom">1106</td><td align="left" valign="bottom">79</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">1.75</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">IF/PLA</td></tr><tr><td align="left" valign="bottom">Control</td><td align="left" valign="bottom">1796</td><td align="left" valign="bottom">81</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">8</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">WB</td></tr><tr><td align="left" valign="bottom">Control</td><td align="left" valign="bottom">2–99</td><td align="left" valign="bottom">74</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">2.8</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">WB</td></tr><tr><td align="left" valign="bottom">Control</td><td align="left" valign="bottom">13–01</td><td align="left" valign="bottom">95</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">3.7</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">WB</td></tr></tbody></table><table-wrap-foot><fn><p>IF: Immunofluorescence; PLA: Proximity Ligation Assay; PMI:Postmortem Interval; WB:Western Blotting.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4-16"><title>Proximity ligation assay (PLA)</title><p>Detection of protein-protein interactions was conducted by an in-situ proximity ligation assay. The method depends on the recognition of target molecules in close proximity (&lt;40 nm) by pairs of affinity probes, giving rise to an amplifiable detection signal. Briefly, PLA in mouse brain tissue has been performed using Duolink PLA in Situ Red starter kit mouse/rabbit (Sigma-Aldrich, DUO92101). The staining was performed following each protocol passage without modifications. Time of incubation and concentration of antibodies is established from IF protocol. Primary antibodies used for in situ proximity assay were: SERBP1 (1:100), PARP1 (1:200), and pThr231-Tau (1:500). Amplified red signal has been detected using Keyence Microscope.</p></sec><sec id="s4-17"><title>Venn diagram statistics</title><p>Venn diagrams were created using online software (<ext-link ext-link-type="uri" xlink:href="https://bioinforx.com/apps/venn.php">https://bioinforx.com/apps/venn.php</ext-link>). P-values for overlaps between two groups were calculated with a separate online tool (<ext-link ext-link-type="uri" xlink:href="http://nemates.org/MA/progs/overlap_stats.html">http://nemates.org/MA/progs/overlap_stats.html</ext-link>).</p></sec><sec id="s4-18"><title>Gene ontology and network analyses</title><p>Gene Ontology (GO) enrichment analyses were performed using ShinyGO (versions 0.67 and 0.77), Metascape (version 3.5), and Panther (version 17.0; <xref ref-type="bibr" rid="bib48">Ge et al., 2020</xref>; <xref ref-type="bibr" rid="bib154">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib133">Thomas et al., 2022</xref>). Associations between GO terms were established using Revigo (<xref ref-type="bibr" rid="bib127">Supek et al., 2011</xref>). Network analyses were conducted using STRING (version 11.5) and Metascape (<xref ref-type="bibr" rid="bib154">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib129">Szklarczyk et al., 2023</xref>) and visualized using Cytoscape (version 3.9.1; <xref ref-type="bibr" rid="bib35">Doncheva et al., 2023</xref>).</p></sec><sec id="s4-19"><title>Expression correlation analyses</title><p>We performed expression correlation analyses using resources in R2 (<xref ref-type="bibr" rid="bib78">Koster, 2023</xref>) to identify genes with a strong positive correlation with SERBP1 (<italic>R</italic>≥0.3, p-value ≤0.05, Pearson correlation) in the TCGA glioblastoma set (RNA-Seq samples), sarcoma (TCGA), bladder urothelial carcinoma (TCGA), neuroblastoma (SEQC), pancreatic adenocarcinoma (TCGA), and normal brain (Hardy, <italic>R</italic>≥0.5 was selected in this case due to the high number of correlated genes). Additional analyses were conducted using the Ivy GAP glioblastoma dataset <xref ref-type="bibr" rid="bib113">Puchalski et al., 2018</xref> following their default parameters (<italic>R</italic>≥0.3).</p><p>The Cortecon resource (<xref ref-type="bibr" rid="bib139">van de Leemput et al., 2014</xref>) was used to identify genes that share similarity with SERBP1 regarding their expression profile during in vitro cortex development. SERBP1 is part of cluster 5 which is linked to pluripotency. Genes that were in clusters related to pluripotency and whose overall profile resembles cluster 5 were selected for further analyses.</p></sec><sec id="s4-20"><title>Identification of protein features and domain</title><p>Pfam accession numbers were obtained using the UniProt ID mapping service (<xref ref-type="bibr" rid="bib8">Bateman et al., 2023</xref>). R code was used to count the frequency of each accession number and create the consolidated data with fold enrichment and fdr-values. All accession numbers with a count above the average were analyzed with the dcGO Enrichment mining service (<xref ref-type="bibr" rid="bib43">Fang and Gough, 2013</xref>).</p></sec><sec id="s4-21"><title>Databases and datasets used for characterization of SERBP1-associated proteins</title><p>STM1 interactors were downloaded from BioGRID (version 4.4) <xref ref-type="bibr" rid="bib124">Stark et al., 2006</xref> and human orthologs were obtained using the WORMHOLE website (<xref ref-type="bibr" rid="bib128">Sutphin et al., 2016</xref>). Proximity-dependent biotinylation (Bio-ID) data for SERBP1 were taken from <xref ref-type="bibr" rid="bib53">Go et al., 2021</xref>; <xref ref-type="bibr" rid="bib150">Youn et al., 2018</xref>. Proteins of the SARS-CoV-RNA interactome were derived from <xref ref-type="bibr" rid="bib83">Lee et al., 2021</xref> and those of the PARP1 interactome from <xref ref-type="bibr" rid="bib102">Mosler et al., 2022</xref>. RGG box-containing proteins were obtained from <xref ref-type="bibr" rid="bib132">Thandapani et al., 2013</xref>, and RRM motif-containing proteins from UniProt (<xref ref-type="bibr" rid="bib8">Bateman et al., 2023</xref>). G4 binding proteins were extracted from <xref ref-type="bibr" rid="bib126">Su et al., 2021b</xref>; <xref ref-type="bibr" rid="bib63">Herviou et al., 2020</xref>, PAR binding proteins were obtained from <xref ref-type="bibr" rid="bib32">Dasovich et al., 2021</xref>, and PARylated proteins were identified by high-throughput studies described in <xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>. The MobiDB database (version 5.0; <xref ref-type="bibr" rid="bib111">Piovesan et al., 2023</xref>) was used for identifying IDR-containing proteins. Data on the Tau aggregate interactome were derived from different studies compiled by <xref ref-type="bibr" rid="bib69">Kavanagh et al., 2022</xref>.</p></sec><sec id="s4-22"><title>Splicing analyses</title><p>To identify splicing alterations induced by SERBP1 and hnRNPU knockdown, adapter sequences were first trimmed from raw RNA-Seq reads of control and knockdown samples (<xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>). RNA-Seq reads were then aligned against the human reference genome (version GRCh38; <xref ref-type="bibr" rid="bib76">Kitts et al., 2016</xref>) and matching GENCODE transcriptome (v29; <xref ref-type="bibr" rid="bib46">Frankish et al., 2021</xref>) using STAR (default parameters; version 2.7.7 .a; <xref ref-type="bibr" rid="bib34">Dobin et al., 2013</xref>). High-quality mapped reads (q&gt;20) from control and knockdown samples were processed using rMATS (default parameters; version v4.1.2; <xref ref-type="bibr" rid="bib121">Shen et al., 2014</xref>) to characterize splicing events. Events were classified into exon skipping (SE), mutually exclusive exons (MXE), intron retention (RI), alternative donor site (A5SS) or alternative acceptor site (A3SS). Splicing events were considered significant if their FDR-adjusted p-values were below 0.05 and absolute delta Percent Splice Inclusion (deltaPSI) above 0.1. Sashimi plots of splicing events were created using the rmats2sashimiplot tool <ext-link ext-link-type="uri" xlink:href="https://github.com/Xinglab/rmats2sashimiplot">https://github.com/Xinglab/rmats2sashimiplot</ext-link> (<xref ref-type="bibr" rid="bib148">Xinglab, 2024</xref>). To assess SERBP1 binding to the identified splicing alterations, we obtained processed iCLIP data from <xref ref-type="bibr" rid="bib95">Martini et al., 2021</xref>. The presence of iCLIP sites in the splicing alterations induced by SERBP1 knockdown was evaluated considering a window of 100 nt around splicing events using the bedtools intersect software (<xref ref-type="bibr" rid="bib114">Quinlan and Hall, 2010</xref>).</p></sec><sec id="s4-23"><title>Identification of snoRNAs and scaRNAs bound by SERBP1</title><p>RIP-sequencing results for SERBP1 were obtained from <xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>. Sequencing reads were processed using Kallisto (default parameters, version 0.46.1; <xref ref-type="bibr" rid="bib17">Bray et al., 2016</xref>) with an index of 31 k-mers and GENCODE (v28) as the reference for the human transcriptome (<xref ref-type="bibr" rid="bib46">Frankish et al., 2021</xref>). Transcript abundance estimates were then collapsed into gene-level counts using the R package tximport (<xref ref-type="bibr" rid="bib122">Soneson et al., 2015</xref>). Differential gene expression analyses were performed using DESeq2 (<xref ref-type="bibr" rid="bib89">Love et al., 2014</xref>). We compared SBP-SERBP1 versus SBP-GST samples and used log2 fold change ≥0.5 and adjusted (false discovery rate, FDR) p-value &lt;0.05 to identify snoRNAs and scaRNAs preferentially associated with SERBP1.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Supervision, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Validation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Investigation, Visualization</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Investigation, Visualization</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con12"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con13"><p>Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con14"><p>Data curation, Supervision, Investigation</p></fn><fn fn-type="con" id="con15"><p>Supervision, Investigation</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>SERBP1-associated proteins identified by pulldown in 293T cells.</title><p>Mass spectrometry results of pulled-down proteins with respective counts in SBP-SERBP1 and control cells in two different experimental conditions. The summary sheet displays gene names and UniProt IDs (<xref ref-type="bibr" rid="bib8">Bateman et al., 2023</xref>) of identified SERBP1 interactors. Additional sheets show SERBP1-associated proteins present in the nucleus and nucleolus. Also included are complete results of ShinyGO (<xref ref-type="bibr" rid="bib48">Ge et al., 2020</xref>) and Metascape (<xref ref-type="bibr" rid="bib154">Zhou et al., 2019</xref>) GO enrichment analyses of SERBP1 and all its identified associated proteins as well as comparisons of newly identified SERBP1 interactors with previous proximity-label (BIO-ID) studies (<xref ref-type="bibr" rid="bib53">Go et al., 2021</xref>; <xref ref-type="bibr" rid="bib150">Youn et al., 2018</xref>) and compilations from BioGRID (<xref ref-type="bibr" rid="bib124">Stark et al., 2006</xref>).</p></caption><media xlink:href="elife-98152-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>snoRNAs and scaRNAs bound by SERBP1 according to RIP-Seq analysis (<xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>) and comparisons to PARP1 bound snoRNAs identified CLIP-identified (<xref ref-type="bibr" rid="bib99">Mekishvili et al., 2017</xref>).</title></caption><media xlink:href="elife-98152-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>BioGRID data for STM1, SERBP1 yeast homolog.</title><p>STM1’s protein interactors as curated by BioGRID (<xref ref-type="bibr" rid="bib124">Stark et al., 2006</xref>) with their gene ontologies (<xref ref-type="bibr" rid="bib48">Ge et al., 2020</xref>), human homologs as derived from WORMHOLE (<xref ref-type="bibr" rid="bib128">Sutphin et al., 2016</xref>), and overlap with SERBP1-associated proteins.</p></caption><media xlink:href="elife-98152-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Protein domains and intrinsically disordered regions of SERBP1-associated proteins.</title><p>Analysis of protein domains present in SERBP1-associated proteins (<xref ref-type="bibr" rid="bib8">Bateman et al., 2023</xref>) with their respective counts in reference to the total human proteome (<xref ref-type="bibr" rid="bib123">Sonnhammer et al., 1997</xref>). Additional sheets display the results of gene ontology analyses for top-represented domains (<xref ref-type="bibr" rid="bib43">Fang and Gough, 2013</xref>). Also shown are derived and curated intrinsically disordered proteins associated with SERBP1 according to MobiDB (<xref ref-type="bibr" rid="bib111">Piovesan et al., 2023</xref>).</p></caption><media xlink:href="elife-98152-supp4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Gene expression correlation analysis.</title><p>Significant expression correlation values for SERBP1 and associated proteins in glioblastoma, neuroblastoma, pancreatic adenocarcinoma, bladder urothelial carcinoma, sarcoma, and normal brain datasets (<xref ref-type="bibr" rid="bib78">Koster, 2023</xref>; <xref ref-type="bibr" rid="bib113">Puchalski et al., 2018</xref>). Additionally, a list of SERBP1-associated proteins displaying a similar expression profile during cortex development according to Cortecon (<xref ref-type="bibr" rid="bib139">van de Leemput et al., 2014</xref>). The last sheet shows the top SERBP1 interactors with the highest number of high expression correlation instances and their respective proteomics counts from our pulldown experiment.</p></caption><media xlink:href="elife-98152-supp5-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Characteristics of SERBP1-associated proteins.</title><p>SERBP1-associated proteins are organized according to the presence of RGG boxes (<xref ref-type="bibr" rid="bib132">Thandapani et al., 2013</xref>), RRM motifs (<xref ref-type="bibr" rid="bib8">Bateman et al., 2023</xref>), G4 binding (<xref ref-type="bibr" rid="bib126">Su et al., 2021b</xref>; <xref ref-type="bibr" rid="bib63">Herviou et al., 2020</xref>), PAR binding (<xref ref-type="bibr" rid="bib32">Dasovich et al., 2021</xref>), PARylation (<xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>) and overlap with SARS-CoV-2 (<xref ref-type="bibr" rid="bib83">Lee et al., 2021</xref>) and PARP1 (<xref ref-type="bibr" rid="bib102">Mosler et al., 2022</xref>) interactomes. Additional sheets show gene ontology results (<xref ref-type="bibr" rid="bib48">Ge et al., 2020</xref>) of SERBP1-associated proteins that (1) get PARylated and/or bind to PAR, (2) overlap with SARS-CoV-2 interactors, or (3) overlap with PARP1 interactors. Mutual SERBP1- and PARP1-associated factors identified in an rRNA transcription and processing screening (<xref ref-type="bibr" rid="bib130">Tafforeau et al., 2013</xref>) are highlighted on the last sheet.</p></caption><media xlink:href="elife-98152-supp6-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>SERBP1 and drug sensitivity.</title><p>Results of cell viability screening in SERBP1-overexpressing vs. control U343 cells and information on the utilized drugs. Separate sheets list genes conferring high sensitivity to different PARP inhibitors (<xref ref-type="bibr" rid="bib153">Zhang et al., 2023</xref>) and SERBP1 interactors identified in this study.</p></caption><media xlink:href="elife-98152-supp7-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>Impact of SERBP1 and hnRNPU knockdown on the splicing of U251 cells.</title><p>List of splicing events and respective genes affected in siSERBP1 knockdown vs. control and sihnRNPU knockdown vs. control U251 cells. Additional files include splicing events affected by SERBP1 knockdown with evidence of SERBP1 binding sites (CLIP sites) (<xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>; <xref ref-type="bibr" rid="bib76">Kitts et al., 2016</xref>; <xref ref-type="bibr" rid="bib46">Frankish et al., 2021</xref>; <xref ref-type="bibr" rid="bib34">Dobin et al., 2013</xref>) in the proximity (&lt;100 nt) of regulated splice sites and splicing events affected by both SERBP1 and hnRNPU knockdown in the same direction.</p></caption><media xlink:href="elife-98152-supp8-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp9"><label>Supplementary file 9.</label><caption><title>Participation of SERBP1-associated proteins and snoRNAs in membraneless organelles.</title><p>Proteins associated with SERBP1 and their presence in stress granules, paraspeckles, Cajal bodies, nuclear specks, nucleoli, P-bodies (<xref ref-type="bibr" rid="bib133">Thomas et al., 2022</xref>) and Tau aggregates (<xref ref-type="bibr" rid="bib69">Kavanagh et al., 2022</xref>). UniProt ID mapping (<xref ref-type="bibr" rid="bib8">Bateman et al., 2023</xref>) was used to match gene names and UniProt IDs. SERBP1 interactors implicated in membraneless organelles were evaluated for prevalence of intrinsic disorder (<xref ref-type="bibr" rid="bib111">Piovesan et al., 2023</xref>), G4 binding (<xref ref-type="bibr" rid="bib126">Su et al., 2021b</xref>; <xref ref-type="bibr" rid="bib63">Herviou et al., 2020</xref>), PARylation (<xref ref-type="bibr" rid="bib51">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Martello et al., 2016</xref>), and PAR binding (<xref ref-type="bibr" rid="bib32">Dasovich et al., 2021</xref>). snoRNAs found in a previous study to be enriched in Tau aggregates (<xref ref-type="bibr" rid="bib85">Lester et al., 2021</xref>) that were also identified as SERBP1 targets according to RIP-Seq analysis (<xref ref-type="bibr" rid="bib79">Kosti et al., 2020</xref>).</p></caption><media xlink:href="elife-98152-supp9-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-98152-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The mass spectrometry datasets generated and analyzed during this study are available in the MassIVE repository as a partner with ProteomeXchange and can be accessed by: (1) MassIVE dataset identifier <ext-link ext-link-type="uri" xlink:href="https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?accession=MSV000091749">MSV000091749</ext-link>, ProteomeXchange dataset identifier PXD041664; (2) MassIVE dataset identifier <ext-link ext-link-type="uri" xlink:href="https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?accession=MSV000093355">MSV000093355</ext-link>, ProteomeXchange dataset identifier PXD046851. RNAseq datasets are available at the European Nucleotide Archive (ENA) with the accession number <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ena/browser/view/PRJEB69681">PRJEB69681</ext-link>. Code to perform the analysis of SERBP1 impact on splicing can be found in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17605/OSF.IO/4EHZS">Open Science Framework</ext-link>.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Penalva</surname><given-names>LO</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>SERBP1 interactome defines its novel regulatory roles in the cytoplasm and nucleus in conjunction with PARP1-, G-quadruplex- and PAR-binders</data-title><source>MassIVE</source><pub-id pub-id-type="accession" xlink:href="https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?accession=MSV000091749">MSV000091749</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Penalva</surname><given-names>LO</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>SERBP1 interactome defines its novel regulatory roles in the cytoplasm and nucleus in conjunction with PARP1-, G-quadruplex- and PAR-binders - DIA-MS data</data-title><source>MassIVE</source><pub-id pub-id-type="accession" xlink:href="https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?accession=MSV000093355">MSV000093355</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Penalva</surname><given-names>PO</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>SERBP1 interactome defines its novel regulatory roles in the cytoplasm and nucleus in conjunction with PARP1-, G-quadruplex- and PAR-binders</data-title><source>EBI European Nucleotide Archive</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ena/browser/view/PRJEB69681">PRJEB69681</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><name><surname>Gingras</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Youn_et_al_RNAbodies_SAINT3105_Set1</data-title><source>MassIVE</source><pub-id pub-id-type="accession" xlink:href="https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?accession=MSV000081411">MSV000081411</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset5"><person-group person-group-type="author"><name><surname>Gingras</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Youn_et_al_RNAbodies_SAINT3105_Set2</data-title><source>MassIVE</source><pub-id pub-id-type="accession" xlink:href="https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?accession=MSV000081412">MSV000081412</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset6"><person-group person-group-type="author"><name><surname>Gingras</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Youn_et_al_RNAbodies_SAINT3105_Set3</data-title><source>MassIVE</source><pub-id pub-id-type="accession" xlink:href="https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?accession=MSV000081413">MSV000081413</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset7"><person-group person-group-type="author"><name><surname>Gingras</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Go_BioID_humancellmap_HEK293_lowSDS_2019</data-title><source>MassIVE</source><pub-id pub-id-type="accession" xlink:href="https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?accession=MSV000084359">MSV000084359</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset8"><person-group person-group-type="author"><name><surname>Gingras</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Go_BioID_humancellmap_HEK293_highSDS_2019</data-title><source>MassIVE</source><pub-id pub-id-type="accession" xlink:href="https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?accession=MSV000084360">MSV000084360</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset9"><person-group person-group-type="author"><name><surname>Penalva</surname><given-names>LO</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>RNA sequencing of U251 SERBP1 knockdown cells and RIP sequencing for the identification of SERBP1 targets in 293T cells</data-title><source>EBI European Nucleotide Archive</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ena/browser/view/PRJEB35774">PRJEB35774</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset10"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>VN</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Profile of the SARS-CoV-2 RNA interactome</data-title><source>ProteomeXchange</source><pub-id pub-id-type="accession" xlink:href="https://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD024808">PXD024808</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset11"><person-group person-group-type="author"><name><surname>Beli</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>PARP1 proximity proteomics reveals interaction partners at stressed replication forks</data-title><source>ProteomeXchange</source><pub-id pub-id-type="accession" xlink:href="https://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD037154">PXD037154</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset12"><person-group person-group-type="author"><name><surname>Guillonneau</surname><given-names>F</given-names></name><name><surname>Millevoi</surname><given-names>S</given-names></name></person-group><source>PRIDE</source><year iso-8601-date="2020">2020</year><data-title>hnRNP 1 H/F drive RNA G-quadruplex-mediated translation linked to genomic instability and therapy resistance in glioblastoma</data-title><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD015609">PXD015609</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset13"><person-group person-group-type="author"><name><surname>Ule</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>SERBP1 iCLIP in mitotic and asynchronous cells with Blu577 treatment</data-title><source>ArrayExpress</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-10830">E-MTAB-10830</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>Mass spectrometry analyses were conducted at the Institutional Mass Spectrometry Laboratory, University of Texas Health Science Center, supported in part by NIH grant P30 CA54174-23 (S.T. Weintraub, Mays Cancer Center Mass Spectrometry Shared Resource) and the University of Texas System Proteomics Core Network for purchase of the Orbitrap Fusion Lumos mass spectrometer, with expert technical assistance of Sammy Pardo and Dana Molleur. We would like to thank Dr. Jernej Ule and Dr. Rupert Faraway for sharing the SERBP1 CLIP data and their valuable input. The authors would like to acknowledge Karen Klein for excellent editorial service. This work was supported by the Cancer Prevention and Research Institute of Texas [RP200595 to LP], Alzheimer’s Association [AARGD-NTF-22-968603 to LP] and a Mays Cancer Center Pilot Grant [to LP]. PAFG was supported by grants from Serrapilheira Foundation and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) [2018/15579-8]. MM was sponsored by the Alzheimer’s Association [AARF-21-720991]. GDAG was supported by a fellowship from FAPESP [2017/19541-2] and Young Scientist program, Hospital Sírio-Libanês. KB and ML were sponsored by the The German Academic Exchange Service (DAAD). AK was supported by NIH Supplement 2R01 HG006015 and the Greehey Foundation. DSL was partially supported by a Voelker Fund Young Investigator Grant.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abaza</surname><given-names>I</given-names></name><name><surname>Coll</surname><given-names>O</given-names></name><name><surname>Patalano</surname><given-names>S</given-names></name><name><surname>Gebauer</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title><italic>Drosophila</italic> UNR is required for translational repression of male-specific lethal 2 mRNA during regulation of X-chromosome dosage compensation</article-title><source>Genes &amp; Development</source><volume>20</volume><fpage>380</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1101/gad.371906</pub-id><pub-id pub-id-type="pmid">16452509</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>J-W</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Na</surname><given-names>W</given-names></name><name><surname>Baek</surname><given-names>S-J</given-names></name><name><surname>Kim</surname><given-names>J-H</given-names></name><name><surname>Min</surname><given-names>K</given-names></name><name><surname>Yeom</surname><given-names>J</given-names></name><name><surname>Kwak</surname><given-names>H</given-names></name><name><surname>Jeong</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>S-Y</given-names></name><name><surname>Choi</surname><given-names>CY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>SERBP1 affects homologous recombination-mediated DNA repair by regulation of CtIP translation during S phase</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>6321</fpage><lpage>6333</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv592</pub-id><pub-id pub-id-type="pmid">26068472</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>H</given-names></name><name><surname>de Meritens</surname><given-names>CR</given-names></name><name><surname>Shelkovnikova</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Connecting the “dots”: RNP granule network in health and disease</article-title><source>Biochimica et Biophysica Acta. Molecular Cell Research</source><volume>1868</volume><elocation-id>119058</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbamcr.2021.119058</pub-id><pub-id pub-id-type="pmid">33989700</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ash</surname><given-names>PEA</given-names></name><name><surname>Vanderweyde</surname><given-names>TE</given-names></name><name><surname>Youmans</surname><given-names>KL</given-names></name><name><surname>Apicco</surname><given-names>DJ</given-names></name><name><surname>Wolozin</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pathological stress granules in Alzheimer’s disease</article-title><source>Brain Research</source><volume>1584</volume><fpage>52</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2014.05.052</pub-id><pub-id pub-id-type="pmid">25108040</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakkar</surname><given-names>N</given-names></name><name><surname>Kovalik</surname><given-names>T</given-names></name><name><surname>Lorenzini</surname><given-names>I</given-names></name><name><surname>Spangler</surname><given-names>S</given-names></name><name><surname>Lacoste</surname><given-names>A</given-names></name><name><surname>Sponaugle</surname><given-names>K</given-names></name><name><surname>Ferrante</surname><given-names>P</given-names></name><name><surname>Argentinis</surname><given-names>E</given-names></name><name><surname>Sattler</surname><given-names>R</given-names></name><name><surname>Bowser</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis</article-title><source>Acta Neuropathologica</source><volume>135</volume><fpage>227</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1007/s00401-017-1785-8</pub-id><pub-id pub-id-type="pmid">29134320</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Balasubramanian</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><chapter-title>HNRNPU-related neurodevelopmental disorder</chapter-title><person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Feldman</surname><given-names>J</given-names></name><name><surname>Mirzaa</surname><given-names>GM</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name><name><surname>Amemiya</surname><given-names>A</given-names></name></person-group><source>GeneReviews</source><publisher-name>Seattle</publisher-name><fpage>1993</fpage><lpage>2025</lpage></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banco</surname><given-names>MT</given-names></name><name><surname>Ferré-D’Amaré</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The emerging structural complexity of G-quadruplex RNAs</article-title><source>RNA</source><volume>27</volume><fpage>390</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1261/rna.078238.120</pub-id><pub-id pub-id-type="pmid">33483368</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>MJ</given-names></name><name><surname>Orchard</surname><given-names>S</given-names></name><name><surname>Magrane</surname><given-names>M</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Alpi</surname><given-names>E</given-names></name><name><surname>Bowler-Barnett</surname><given-names>EH</given-names></name><name><surname>Britto</surname><given-names>R</given-names></name><name><surname>Bye-A-Jee</surname><given-names>H</given-names></name><name><surname>Cukura</surname><given-names>A</given-names></name><name><surname>Denny</surname><given-names>P</given-names></name><name><surname>Dogan</surname><given-names>T</given-names></name><name><surname>Ebenezer</surname><given-names>T</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Garmiri</surname><given-names>P</given-names></name><name><surname>da Costa Gonzales</surname><given-names>LJ</given-names></name><name><surname>Hatton-Ellis</surname><given-names>E</given-names></name><name><surname>Hussein</surname><given-names>A</given-names></name><name><surname>Ignatchenko</surname><given-names>A</given-names></name><name><surname>Insana</surname><given-names>G</given-names></name><name><surname>Ishtiaq</surname><given-names>R</given-names></name><name><surname>Joshi</surname><given-names>V</given-names></name><name><surname>Jyothi</surname><given-names>D</given-names></name><name><surname>Kandasaamy</surname><given-names>S</given-names></name><name><surname>Lock</surname><given-names>A</given-names></name><name><surname>Luciani</surname><given-names>A</given-names></name><name><surname>Lugaric</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Lussi</surname><given-names>Y</given-names></name><name><surname>MacDougall</surname><given-names>A</given-names></name><name><surname>Madeira</surname><given-names>F</given-names></name><name><surname>Mahmoudy</surname><given-names>M</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Moulang</surname><given-names>K</given-names></name><name><surname>Nightingale</surname><given-names>A</given-names></name><name><surname>Pundir</surname><given-names>S</given-names></name><name><surname>Qi</surname><given-names>G</given-names></name><name><surname>Raj</surname><given-names>S</given-names></name><name><surname>Raposo</surname><given-names>P</given-names></name><name><surname>Rice</surname><given-names>DL</given-names></name><name><surname>Saidi</surname><given-names>R</given-names></name><name><surname>Santos</surname><given-names>R</given-names></name><name><surname>Speretta</surname><given-names>E</given-names></name><name><surname>Stephenson</surname><given-names>J</given-names></name><name><surname>Totoo</surname><given-names>P</given-names></name><name><surname>Turner</surname><given-names>E</given-names></name><name><surname>Tyagi</surname><given-names>N</given-names></name><name><surname>Vasudev</surname><given-names>P</given-names></name><name><surname>Warner</surname><given-names>K</given-names></name><name><surname>Watkins</surname><given-names>X</given-names></name><name><surname>Zaru</surname><given-names>R</given-names></name><name><surname>Zellner</surname><given-names>H</given-names></name><name><surname>Bridge</surname><given-names>AJ</given-names></name><name><surname>Aimo</surname><given-names>L</given-names></name><name><surname>Argoud-Puy</surname><given-names>G</given-names></name><name><surname>Auchincloss</surname><given-names>AH</given-names></name><name><surname>Axelsen</surname><given-names>KB</given-names></name><name><surname>Bansal</surname><given-names>P</given-names></name><name><surname>Baratin</surname><given-names>D</given-names></name><name><surname>Batista Neto</surname><given-names>TM</given-names></name><name><surname>Blatter</surname><given-names>MC</given-names></name><name><surname>Bolleman</surname><given-names>JT</given-names></name><name><surname>Boutet</surname><given-names>E</given-names></name><name><surname>Breuza</surname><given-names>L</given-names></name><name><surname>Gil</surname><given-names>BC</given-names></name><name><surname>Casals-Casas</surname><given-names>C</given-names></name><name><surname>Echioukh</surname><given-names>KC</given-names></name><name><surname>Coudert</surname><given-names>E</given-names></name><name><surname>Cuche</surname><given-names>B</given-names></name><name><surname>de Castro</surname><given-names>E</given-names></name><name><surname>Estreicher</surname><given-names>A</given-names></name><name><surname>Famiglietti</surname><given-names>ML</given-names></name><name><surname>Feuermann</surname><given-names>M</given-names></name><name><surname>Gasteiger</surname><given-names>E</given-names></name><name><surname>Gaudet</surname><given-names>P</given-names></name><name><surname>Gehant</surname><given-names>S</given-names></name><name><surname>Gerritsen</surname><given-names>V</given-names></name><name><surname>Gos</surname><given-names>A</given-names></name><name><surname>Gruaz</surname><given-names>N</given-names></name><name><surname>Hulo</surname><given-names>C</given-names></name><name><surname>Hyka-Nouspikel</surname><given-names>N</given-names></name><name><surname>Jungo</surname><given-names>F</given-names></name><name><surname>Kerhornou</surname><given-names>A</given-names></name><name><surname>Le Mercier</surname><given-names>P</given-names></name><name><surname>Lieberherr</surname><given-names>D</given-names></name><name><surname>Masson</surname><given-names>P</given-names></name><name><surname>Morgat</surname><given-names>A</given-names></name><name><surname>Muthukrishnan</surname><given-names>V</given-names></name><name><surname>Paesano</surname><given-names>S</given-names></name><name><surname>Pedruzzi</surname><given-names>I</given-names></name><name><surname>Pilbout</surname><given-names>S</given-names></name><name><surname>Pourcel</surname><given-names>L</given-names></name><name><surname>Poux</surname><given-names>S</given-names></name><name><surname>Pozzato</surname><given-names>M</given-names></name><name><surname>Pruess</surname><given-names>M</given-names></name><name><surname>Redaschi</surname><given-names>N</given-names></name><name><surname>Rivoire</surname><given-names>C</given-names></name><name><surname>Sigrist</surname><given-names>CJA</given-names></name><name><surname>Sonesson</surname><given-names>K</given-names></name><name><surname>Sundaram</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>CH</given-names></name><name><surname>Arighi</surname><given-names>CN</given-names></name><name><surname>Arminski</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Laiho</surname><given-names>K</given-names></name><name><surname>McGarvey</surname><given-names>P</given-names></name><name><surname>Natale</surname><given-names>DA</given-names></name><name><surname>Ross</surname><given-names>K</given-names></name><name><surname>Vinayaka</surname><given-names>CR</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><collab>The UniProt Consortium</collab></person-group><year iso-8601-date="2023">2023</year><article-title>UniProt: the universal protein knowledgebase in 2023</article-title><source>Nucleic Acids Research</source><volume>51</volume><fpage>D523</fpage><lpage>D531</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac1052</pub-id><pub-id pub-id-type="pmid">36408920</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudin</surname><given-names>A</given-names></name><name><surname>Moreno-Romero</surname><given-names>AK</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Selig</surname><given-names>EE</given-names></name><name><surname>Penalva</surname><given-names>LOF</given-names></name><name><surname>Libich</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structural characterization of the rna-binding protein serbp1 reveals intrinsic disorder and atypical rna binding modes</article-title><source>Frontiers in Molecular Biosciences</source><volume>8</volume><elocation-id>744707</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2021.744707</pub-id><pub-id pub-id-type="pmid">34631798</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilan</surname><given-names>V</given-names></name><name><surname>Selevsek</surname><given-names>N</given-names></name><name><surname>Kistemaker</surname><given-names>HAV</given-names></name><name><surname>Abplanalp</surname><given-names>J</given-names></name><name><surname>Feurer</surname><given-names>R</given-names></name><name><surname>Filippov</surname><given-names>DV</given-names></name><name><surname>Hottiger</surname><given-names>MO</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>New quantitative mass spectrometry approaches reveal different adp-ribosylation phases dependent on the levels of oxidative stress</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>16</volume><fpage>949</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1074/mcp.O116.065623</pub-id><pub-id pub-id-type="pmid">28325851</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleckmann</surname><given-names>A</given-names></name><name><surname>Spitzlberger</surname><given-names>N</given-names></name><name><surname>Denninger</surname><given-names>P</given-names></name><name><surname>Ehrnsberger</surname><given-names>HF</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Bruckmann</surname><given-names>A</given-names></name><name><surname>Reich</surname><given-names>S</given-names></name><name><surname>Holzinger</surname><given-names>P</given-names></name><name><surname>Medenbach</surname><given-names>J</given-names></name><name><surname>Grasser</surname><given-names>KD</given-names></name><name><surname>Dresselhaus</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Cytosolic RGG RNA-binding proteins are temperature sensitive flowering time regulators in <italic>Arabidopsis</italic></article-title><source>Biological Chemistry</source><volume>404</volume><fpage>1069</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1515/hsz-2023-0171</pub-id><pub-id pub-id-type="pmid">37674329</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleuzé</surname><given-names>L</given-names></name><name><surname>Triaca</surname><given-names>V</given-names></name><name><surname>Borreca</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>FMRP-driven neuropathology in autistic spectrum disorder and alzheimer’s disease: a losing game</article-title><source>Frontiers in Molecular Biosciences</source><volume>8</volume><elocation-id>699613</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2021.699613</pub-id><pub-id pub-id-type="pmid">34760921</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonfiglio</surname><given-names>JJ</given-names></name><name><surname>Fontana</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Colby</surname><given-names>T</given-names></name><name><surname>Gibbs-Seymour</surname><given-names>I</given-names></name><name><surname>Atanassov</surname><given-names>I</given-names></name><name><surname>Bartlett</surname><given-names>E</given-names></name><name><surname>Zaja</surname><given-names>R</given-names></name><name><surname>Ahel</surname><given-names>I</given-names></name><name><surname>Matic</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Serine adp-ribosylation depends on HPF1</article-title><source>Molecular Cell</source><volume>65</volume><fpage>932</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.01.003</pub-id><pub-id pub-id-type="pmid">28190768</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>KK</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Harris</surname><given-names>B</given-names></name><name><surname>Slaughter</surname><given-names>B</given-names></name><name><surname>Unruh</surname><given-names>J</given-names></name><name><surname>Garrett</surname><given-names>A</given-names></name><name><surname>McDowell</surname><given-names>W</given-names></name><name><surname>Box</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Peak</surname><given-names>A</given-names></name><name><surname>Ramachandran</surname><given-names>S</given-names></name><name><surname>Seidel</surname><given-names>C</given-names></name><name><surname>Gerton</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cohesin proteins promote ribosomal RNA production and protein translation in yeast and human cells</article-title><source>PLOS Genetics</source><volume>8</volume><elocation-id>e1002749</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002749</pub-id><pub-id pub-id-type="pmid">22719263</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boussadia</surname><given-names>O</given-names></name><name><surname>Niepmann</surname><given-names>M</given-names></name><name><surname>Créancier</surname><given-names>L</given-names></name><name><surname>Prats</surname><given-names>A-C</given-names></name><name><surname>Dautry</surname><given-names>F</given-names></name><name><surname>Jacquemin-Sablon</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Unr is required in vivo for efficient initiation of translation from the internal ribosome entry sites of both rhinovirus and poliovirus</article-title><source>Journal of Virology</source><volume>77</volume><fpage>3353</fpage><lpage>3359</lpage><pub-id pub-id-type="doi">10.1128/jvi.77.6.3353-3359.2003</pub-id><pub-id pub-id-type="pmid">12610110</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bramswig</surname><given-names>NC</given-names></name><name><surname>Lüdecke</surname><given-names>HJ</given-names></name><name><surname>Hamdan</surname><given-names>FF</given-names></name><name><surname>Altmüller</surname><given-names>J</given-names></name><name><surname>Beleggia</surname><given-names>F</given-names></name><name><surname>Elcioglu</surname><given-names>NH</given-names></name><name><surname>Freyer</surname><given-names>C</given-names></name><name><surname>Gerkes</surname><given-names>EH</given-names></name><name><surname>Demirkol</surname><given-names>YK</given-names></name><name><surname>Knupp</surname><given-names>KG</given-names></name><name><surname>Kuechler</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lowenstein</surname><given-names>DH</given-names></name><name><surname>Michaud</surname><given-names>JL</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Stegmann</surname><given-names>APA</given-names></name><name><surname>Veenstra-Knol</surname><given-names>HE</given-names></name><name><surname>Wieland</surname><given-names>T</given-names></name><name><surname>Wollnik</surname><given-names>B</given-names></name><name><surname>Engels</surname><given-names>H</given-names></name><name><surname>Strom</surname><given-names>TM</given-names></name><name><surname>Kleefstra</surname><given-names>T</given-names></name><name><surname>Wieczorek</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Heterozygous HNRNPU variants cause early onset epilepsy and severe intellectual disability</article-title><source>Human Genetics</source><volume>136</volume><fpage>821</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1007/s00439-017-1795-6</pub-id><pub-id pub-id-type="pmid">28393272</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>NL</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Melsted</surname><given-names>P</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Near-optimal probabilistic RNA-seq quantification</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/nbt.3519</pub-id><pub-id pub-id-type="pmid">27043002</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Baird</surname><given-names>MR</given-names></name><name><surname>Yip</surname><given-names>MC</given-names></name><name><surname>Murray</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structures of translationally inactive mammalian ribosomes</article-title><source>eLife</source><volume>7</volume><elocation-id>e40486</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.40486</pub-id><pub-id pub-id-type="pmid">30355441</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugier</surname><given-names>A</given-names></name><name><surname>Hafirrassou</surname><given-names>ML</given-names></name><name><surname>Pourcelot</surname><given-names>M</given-names></name><name><surname>Baldaccini</surname><given-names>M</given-names></name><name><surname>Kril</surname><given-names>V</given-names></name><name><surname>Couture</surname><given-names>L</given-names></name><name><surname>Kümmerer</surname><given-names>BM</given-names></name><name><surname>Gallois-Montbrun</surname><given-names>S</given-names></name><name><surname>Bonnet-Madin</surname><given-names>L</given-names></name><name><surname>Vidalain</surname><given-names>P-O</given-names></name><name><surname>Delaugerre</surname><given-names>C</given-names></name><name><surname>Pfeffer</surname><given-names>S</given-names></name><name><surname>Meertens</surname><given-names>L</given-names></name><name><surname>Amara</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>RACK1 associates with RNA-binding proteins vigilin and SERBP1 to facilitate dengue virus replication</article-title><source>Journal of Virology</source><volume>96</volume><elocation-id>e0196221</elocation-id><pub-id pub-id-type="doi">10.1128/jvi.01962-21</pub-id><pub-id pub-id-type="pmid">35266803</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryant</surname><given-names>CD</given-names></name><name><surname>Yazdani</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RNA-binding proteins, neural development and the addictions</article-title><source>Genes, Brain, and Behavior</source><volume>15</volume><fpage>169</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1111/gbb.12273</pub-id><pub-id pub-id-type="pmid">26643147</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calo</surname><given-names>E</given-names></name><name><surname>Flynn</surname><given-names>RA</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Spitale</surname><given-names>RC</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Wysocka</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RNA helicase DDX21 coordinates transcription and ribosomal RNA processing</article-title><source>Nature</source><volume>518</volume><fpage>249</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1038/nature13923</pub-id><pub-id pub-id-type="pmid">25470060</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cave</surname><given-names>JW</given-names></name><name><surname>Willis</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>G-quadruplex regulation of neural gene expression</article-title><source>The FEBS Journal</source><volume>289</volume><fpage>3284</fpage><lpage>3303</lpage><pub-id pub-id-type="doi">10.1111/febs.15900</pub-id><pub-id pub-id-type="pmid">33905176</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JN-M</given-names></name><name><surname>Sánchez-Vidaña</surname><given-names>DI</given-names></name><name><surname>Anoopkumar-Dukie</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Benson Wui-Man</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>RNA-binding protein signaling in adult neurogenesis</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>10</volume><elocation-id>982549</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2022.982549</pub-id><pub-id pub-id-type="pmid">36187492</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HH</given-names></name><name><surname>Yu</surname><given-names>HI</given-names></name><name><surname>Chiang</surname><given-names>WC</given-names></name><name><surname>Lin</surname><given-names>YD</given-names></name><name><surname>Shia</surname><given-names>BC</given-names></name><name><surname>Tarn</surname><given-names>WY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>hnRNP Q regulates Cdc42-mediated neuronal morphogenesis</article-title><source>Molecular and Cellular Biology</source><volume>32</volume><fpage>2224</fpage><lpage>2238</lpage><pub-id pub-id-type="doi">10.1128/MCB.06550-11</pub-id><pub-id pub-id-type="pmid">22493061</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Drug combination studies and their synergy quantification using the Chou-Talalay method</article-title><source>Cancer Research</source><volume>70</volume><fpage>440</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1947</pub-id><pub-id pub-id-type="pmid">20068163</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>KS</given-names></name><name><surname>Won</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Hoe</surname><given-names>KL</given-names></name><name><surname>Kim</surname><given-names>DU</given-names></name><name><surname>Song</surname><given-names>KB</given-names></name><name><surname>Yoo</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Yeast-based screening to identify modulators of G-protein signaling using uncontrolled cell division cycle by overexpression of Stm1</article-title><source>Journal of Biotechnology</source><volume>129</volume><fpage>547</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2007.01.007</pub-id><pub-id pub-id-type="pmid">17346842</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppolecchia</surname><given-names>R</given-names></name><name><surname>Buser</surname><given-names>P</given-names></name><name><surname>Stotz</surname><given-names>A</given-names></name><name><surname>Linder</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>A new yeast translation initiation factor suppresses A mutation in the eIF-4A RNA helicase</article-title><source>The EMBO Journal</source><volume>12</volume><fpage>4005</fpage><lpage>4011</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1993.tb06078.x</pub-id><pub-id pub-id-type="pmid">8404866</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corley</surname><given-names>M</given-names></name><name><surname>Burns</surname><given-names>MC</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>How RNA-binding proteins interact with RNA: molecules and mechanisms</article-title><source>Molecular Cell</source><volume>78</volume><fpage>9</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.03.011</pub-id><pub-id pub-id-type="pmid">32243832</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darling</surname><given-names>AL</given-names></name><name><surname>Shorter</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Combating deleterious phase transitions in neurodegenerative disease</article-title><source>Biochimica et Biophysica Acta. Molecular Cell Research</source><volume>1868</volume><elocation-id>118984</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbamcr.2021.118984</pub-id><pub-id pub-id-type="pmid">33549703</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darnell</surname><given-names>JC</given-names></name><name><surname>Warren</surname><given-names>ST</given-names></name><name><surname>Darnell</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The fragile X mental retardation protein, FMRP, recognizes G-quartets</article-title><source>Mental Retardation and Developmental Disabilities Research Reviews</source><volume>10</volume><fpage>49</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1002/mrdd.20008</pub-id><pub-id pub-id-type="pmid">14994288</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darnell</surname><given-names>JC</given-names></name><name><surname>Klann</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The translation of translational control by FMRP: therapeutic targets for FXS</article-title><source>Nature Neuroscience</source><volume>16</volume><fpage>1530</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1038/nn.3379</pub-id><pub-id pub-id-type="pmid">23584741</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasovich</surname><given-names>M</given-names></name><name><surname>Beckett</surname><given-names>MQ</given-names></name><name><surname>Bailey</surname><given-names>S</given-names></name><name><surname>Ong</surname><given-names>SE</given-names></name><name><surname>Greenberg</surname><given-names>MM</given-names></name><name><surname>Leung</surname><given-names>AKL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Identifying poly(ADP-ribose)-binding proteins with photoaffinity-based proteomics</article-title><source>Journal of the American Chemical Society</source><volume>143</volume><fpage>3037</fpage><lpage>3042</lpage><pub-id pub-id-type="doi">10.1021/jacs.0c12246</pub-id><pub-id pub-id-type="pmid">33596067</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>JK</given-names></name><name><surname>Broadie</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Multifarious functions of the fragile X mental retardation protein</article-title><source>Trends in Genetics</source><volume>33</volume><fpage>703</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2017.07.008</pub-id><pub-id pub-id-type="pmid">28826631</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doncheva</surname><given-names>NT</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Holze</surname><given-names>H</given-names></name><name><surname>Kirsch</surname><given-names>R</given-names></name><name><surname>Nastou</surname><given-names>KC</given-names></name><name><surname>Cuesta-Astroz</surname><given-names>Y</given-names></name><name><surname>Rattei</surname><given-names>T</given-names></name><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>von Mering</surname><given-names>C</given-names></name><name><surname>Jensen</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Cytoscape stringApp 2.0: analysis and visualization of heterogeneous biological networks</article-title><source>Journal of Proteome Research</source><volume>22</volume><fpage>637</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.2c00651</pub-id><pub-id pub-id-type="pmid">36512705</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dormoy-Raclet</surname><given-names>V</given-names></name><name><surname>Markovits</surname><given-names>J</given-names></name><name><surname>Jacquemin-Sablon</surname><given-names>A</given-names></name><name><surname>Jacquemin-Sablon</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Regulation of Unr expression by 5’- and 3’-untranslated regions of its mRNA through modulation of stability and IRES mediated translation</article-title><source>RNA Biology</source><volume>2</volume><fpage>e27</fpage><lpage>e35</lpage><pub-id pub-id-type="doi">10.4161/rna.2.3.2203</pub-id><pub-id pub-id-type="pmid">17114922</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drino</surname><given-names>A</given-names></name><name><surname>Schaefer</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>RNAs, phase separation, and membrane-less organelles: are post-transcriptional modifications modulating organelle dynamics?</article-title><source>BioEssays</source><volume>40</volume><elocation-id>e1800085</elocation-id><pub-id pub-id-type="doi">10.1002/bies.201800085</pub-id><pub-id pub-id-type="pmid">30370622</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>A</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Duan</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Gui</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Qian</surname><given-names>B</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PARylation regulates stress granule dynamics, phase separation, and neurotoxicity of disease-related RNA-binding proteins</article-title><source>Cell Research</source><volume>29</volume><fpage>233</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1038/s41422-019-0141-z</pub-id><pub-id pub-id-type="pmid">30728452</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumas</surname><given-names>L</given-names></name><name><surname>Herviou</surname><given-names>P</given-names></name><name><surname>Dassi</surname><given-names>E</given-names></name><name><surname>Cammas</surname><given-names>A</given-names></name><name><surname>Millevoi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>G-Quadruplexes in RNA biology: recent advances and future directions</article-title><source>Trends in Biochemical Sciences</source><volume>46</volume><fpage>270</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2020.11.001</pub-id><pub-id pub-id-type="pmid">33303320</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duning</surname><given-names>K</given-names></name><name><surname>Buck</surname><given-names>F</given-names></name><name><surname>Barnekow</surname><given-names>A</given-names></name><name><surname>Kremerskothen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>SYNCRIP, a component of dendritically localized mRNPs, binds to the translation regulator BC200 RNA</article-title><source>Journal of Neurochemistry</source><volume>105</volume><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.05138.x</pub-id><pub-id pub-id-type="pmid">18045242</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Marecki</surname><given-names>JC</given-names></name><name><surname>Byrd</surname><given-names>AK</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Raney</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>G-Quadruplex loops regulate PARP-1 enzymatic activation</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>416</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa1172</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>HT</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name><name><surname>Kneynsberg</surname><given-names>A</given-names></name><name><surname>Bodea</surname><given-names>LG</given-names></name><name><surname>Götz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Altered ribosomal function and protein synthesis caused by tau</article-title><source>Acta Neuropathologica Communications</source><volume>9</volume><elocation-id>110</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-021-01208-4</pub-id><pub-id pub-id-type="pmid">34147135</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>H</given-names></name><name><surname>Gough</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>DcGO: database of domain-centric ontologies on functions, phenotypes, diseases and more</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>D536</fpage><lpage>D544</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1080</pub-id><pub-id pub-id-type="pmid">23161684</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Jia</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Liquid-liquid phase separation in biology: specific stoichiometric molecular interactions vs promiscuous interactions mediated by disordered sequences</article-title><source>Biochemistry</source><volume>60</volume><fpage>2397</fpage><lpage>2406</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.1c00376</pub-id><pub-id pub-id-type="pmid">34291921</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonin</surname><given-names>AV</given-names></name><name><surname>Antifeeva</surname><given-names>IA</given-names></name><name><surname>Kuznetsova</surname><given-names>IM</given-names></name><name><surname>Turoverov</surname><given-names>KK</given-names></name><name><surname>Zaslavsky</surname><given-names>BY</given-names></name><name><surname>Kulkarni</surname><given-names>P</given-names></name><name><surname>Uversky</surname><given-names>VN</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Biological soft matter: intrinsically disordered proteins in liquid-liquid phase separation and biomolecular condensates</article-title><source>Essays in Biochemistry</source><volume>66</volume><fpage>831</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1042/EBC20220052</pub-id><pub-id pub-id-type="pmid">36350034</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankish</surname><given-names>A</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><name><surname>Jungreis</surname><given-names>I</given-names></name><name><surname>Lagarde</surname><given-names>J</given-names></name><name><surname>Loveland</surname><given-names>JE</given-names></name><name><surname>Mudge</surname><given-names>JM</given-names></name><name><surname>Sisu</surname><given-names>C</given-names></name><name><surname>Wright</surname><given-names>JC</given-names></name><name><surname>Armstrong</surname><given-names>J</given-names></name><name><surname>Barnes</surname><given-names>I</given-names></name><name><surname>Berry</surname><given-names>A</given-names></name><name><surname>Bignell</surname><given-names>A</given-names></name><name><surname>Boix</surname><given-names>C</given-names></name><name><surname>Carbonell Sala</surname><given-names>S</given-names></name><name><surname>Cunningham</surname><given-names>F</given-names></name><name><surname>Di Domenico</surname><given-names>T</given-names></name><name><surname>Donaldson</surname><given-names>S</given-names></name><name><surname>Fiddes</surname><given-names>IT</given-names></name><name><surname>García Girón</surname><given-names>C</given-names></name><name><surname>Gonzalez</surname><given-names>JM</given-names></name><name><surname>Grego</surname><given-names>T</given-names></name><name><surname>Hardy</surname><given-names>M</given-names></name><name><surname>Hourlier</surname><given-names>T</given-names></name><name><surname>Howe</surname><given-names>KL</given-names></name><name><surname>Hunt</surname><given-names>T</given-names></name><name><surname>Izuogu</surname><given-names>OG</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>FJ</given-names></name><name><surname>Martínez</surname><given-names>L</given-names></name><name><surname>Mohanan</surname><given-names>S</given-names></name><name><surname>Muir</surname><given-names>P</given-names></name><name><surname>Navarro</surname><given-names>FCP</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Pei</surname><given-names>B</given-names></name><name><surname>Pozo</surname><given-names>F</given-names></name><name><surname>Riera</surname><given-names>FC</given-names></name><name><surname>Ruffier</surname><given-names>M</given-names></name><name><surname>Schmitt</surname><given-names>BM</given-names></name><name><surname>Stapleton</surname><given-names>E</given-names></name><name><surname>Suner</surname><given-names>MM</given-names></name><name><surname>Sycheva</surname><given-names>I</given-names></name><name><surname>Uszczynska-Ratajczak</surname><given-names>B</given-names></name><name><surname>Wolf</surname><given-names>MY</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>YT</given-names></name><name><surname>Yates</surname><given-names>A</given-names></name><name><surname>Zerbino</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Choudhary</surname><given-names>JS</given-names></name><name><surname>Gerstein</surname><given-names>M</given-names></name><name><surname>Guigó</surname><given-names>R</given-names></name><name><surname>Hubbard</surname><given-names>TJP</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Paten</surname><given-names>B</given-names></name><name><surname>Tress</surname><given-names>ML</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>GENCODE 2021</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>D916</fpage><lpage>D923</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa1087</pub-id><pub-id pub-id-type="pmid">33270111</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fyke</surname><given-names>W</given-names></name><name><surname>Velinov</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title><italic>FMR1</italic> and autism, an intriguing connection revisited</article-title><source>Genes</source><volume>12</volume><elocation-id>1218</elocation-id><pub-id pub-id-type="doi">10.3390/genes12081218</pub-id><pub-id pub-id-type="pmid">34440392</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>SX</given-names></name><name><surname>Jung</surname><given-names>D</given-names></name><name><surname>Yao</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ShinyGO: a graphical gene-set enrichment tool for animals and plants</article-title><source>Bioinformatics</source><volume>36</volume><fpage>2628</fpage><lpage>2629</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btz931</pub-id><pub-id pub-id-type="pmid">31882993</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gebauer</surname><given-names>F</given-names></name><name><surname>Schwarzl</surname><given-names>T</given-names></name><name><surname>Valcárcel</surname><given-names>J</given-names></name><name><surname>Hentze</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>RNA-binding proteins in human genetic disease</article-title><source>Nature Reviews. Genetics</source><volume>22</volume><fpage>185</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1038/s41576-020-00302-y</pub-id><pub-id pub-id-type="pmid">33235359</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerstberger</surname><given-names>S</given-names></name><name><surname>Hafner</surname><given-names>M</given-names></name><name><surname>Tuschl</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A census of human RNA-binding proteins</article-title><source>Nature Reviews. Genetics</source><volume>15</volume><fpage>829</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1038/nrg3813</pub-id><pub-id pub-id-type="pmid">25365966</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>BA</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Hussey</surname><given-names>KM</given-names></name><name><surname>Shrimp</surname><given-names>JH</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Schwede</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Kraus</surname><given-names>WL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation</article-title><source>Science</source><volume>353</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1126/science.aaf7865</pub-id><pub-id pub-id-type="pmid">27256882</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillentine</surname><given-names>MA</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Hoekzema</surname><given-names>K</given-names></name><name><surname>Rosenfeld</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>CN</given-names></name><name><surname>De Vries</surname><given-names>BBA</given-names></name><name><surname>Vissers</surname><given-names>LELM</given-names></name><name><surname>Nordenskjold</surname><given-names>M</given-names></name><name><surname>Kvarnung</surname><given-names>M</given-names></name><name><surname>Lindstrand</surname><given-names>A</given-names></name><name><surname>Nordgren</surname><given-names>A</given-names></name><name><surname>Gecz</surname><given-names>J</given-names></name><name><surname>Iascone</surname><given-names>M</given-names></name><name><surname>Cereda</surname><given-names>A</given-names></name><name><surname>Scatigno</surname><given-names>A</given-names></name><name><surname>Maitz</surname><given-names>S</given-names></name><name><surname>Zanni</surname><given-names>G</given-names></name><name><surname>Bertini</surname><given-names>E</given-names></name><name><surname>Zweier</surname><given-names>C</given-names></name><name><surname>Schuhmann</surname><given-names>S</given-names></name><name><surname>Wiesener</surname><given-names>A</given-names></name><name><surname>Pepper</surname><given-names>M</given-names></name><name><surname>Panjwani</surname><given-names>H</given-names></name><name><surname>Torti</surname><given-names>E</given-names></name><name><surname>Abid</surname><given-names>F</given-names></name><name><surname>Anselm</surname><given-names>I</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Atwal</surname><given-names>P</given-names></name><name><surname>Bacino</surname><given-names>CA</given-names></name><name><surname>Bhat</surname><given-names>G</given-names></name><name><surname>Cobian</surname><given-names>K</given-names></name><name><surname>Bird</surname><given-names>LM</given-names></name><name><surname>Friedman</surname><given-names>J</given-names></name><name><surname>Wright</surname><given-names>MS</given-names></name><name><surname>Callewaert</surname><given-names>B</given-names></name><name><surname>Petit</surname><given-names>F</given-names></name><name><surname>Mathieu</surname><given-names>S</given-names></name><name><surname>Afenjar</surname><given-names>A</given-names></name><name><surname>Christensen</surname><given-names>CK</given-names></name><name><surname>White</surname><given-names>KM</given-names></name><name><surname>Elpeleg</surname><given-names>O</given-names></name><name><surname>Berger</surname><given-names>I</given-names></name><name><surname>Espineli</surname><given-names>EJ</given-names></name><name><surname>Fagerberg</surname><given-names>C</given-names></name><name><surname>Brasch-Andersen</surname><given-names>C</given-names></name><name><surname>Hansen</surname><given-names>LK</given-names></name><name><surname>Feyma</surname><given-names>T</given-names></name><name><surname>Hughes</surname><given-names>S</given-names></name><name><surname>Thiffault</surname><given-names>I</given-names></name><name><surname>Sullivan</surname><given-names>B</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Keller</surname><given-names>K</given-names></name><name><surname>Keren</surname><given-names>B</given-names></name><name><surname>Mignot</surname><given-names>C</given-names></name><name><surname>Kooy</surname><given-names>F</given-names></name><name><surname>Meuwissen</surname><given-names>M</given-names></name><name><surname>Basinger</surname><given-names>A</given-names></name><name><surname>Kukolich</surname><given-names>M</given-names></name><name><surname>Philips</surname><given-names>M</given-names></name><name><surname>Ortega</surname><given-names>L</given-names></name><name><surname>Drummond-Borg</surname><given-names>M</given-names></name><name><surname>Lauridsen</surname><given-names>M</given-names></name><name><surname>Sorensen</surname><given-names>K</given-names></name><name><surname>Lehman</surname><given-names>A</given-names></name><collab>CAUSES Study</collab><name><surname>Lopez-Rangel</surname><given-names>E</given-names></name><name><surname>Levy</surname><given-names>P</given-names></name><name><surname>Lessel</surname><given-names>D</given-names></name><name><surname>Lotze</surname><given-names>T</given-names></name><name><surname>Madan-Khetarpal</surname><given-names>S</given-names></name><name><surname>Sebastian</surname><given-names>J</given-names></name><name><surname>Vento</surname><given-names>J</given-names></name><name><surname>Vats</surname><given-names>D</given-names></name><name><surname>Benman</surname><given-names>LM</given-names></name><name><surname>Mckee</surname><given-names>S</given-names></name><name><surname>Mirzaa</surname><given-names>GM</given-names></name><name><surname>Muss</surname><given-names>C</given-names></name><name><surname>Pappas</surname><given-names>J</given-names></name><name><surname>Peeters</surname><given-names>H</given-names></name><name><surname>Romano</surname><given-names>C</given-names></name><name><surname>Elia</surname><given-names>M</given-names></name><name><surname>Galesi</surname><given-names>O</given-names></name><name><surname>Simon</surname><given-names>MEH</given-names></name><name><surname>van Gassen</surname><given-names>KLI</given-names></name><name><surname>Simpson</surname><given-names>K</given-names></name><name><surname>Stratton</surname><given-names>R</given-names></name><name><surname>Syed</surname><given-names>S</given-names></name><name><surname>Thevenon</surname><given-names>J</given-names></name><name><surname>Palafoll</surname><given-names>IV</given-names></name><name><surname>Vitobello</surname><given-names>A</given-names></name><name><surname>Bournez</surname><given-names>M</given-names></name><name><surname>Faivre</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>K</given-names></name><collab>SPARK Consortium</collab><name><surname>Earl</surname><given-names>RK</given-names></name><name><surname>Nowakowski</surname><given-names>T</given-names></name><name><surname>Bernier</surname><given-names>RA</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders</article-title><source>Genome Medicine</source><volume>13</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-021-00870-6</pub-id><pub-id pub-id-type="pmid">33874999</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Go</surname><given-names>CD</given-names></name><name><surname>Knight</surname><given-names>JDR</given-names></name><name><surname>Rajasekharan</surname><given-names>A</given-names></name><name><surname>Rathod</surname><given-names>B</given-names></name><name><surname>Hesketh</surname><given-names>GG</given-names></name><name><surname>Abe</surname><given-names>KT</given-names></name><name><surname>Youn</surname><given-names>J-Y</given-names></name><name><surname>Samavarchi-Tehrani</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>LY</given-names></name><name><surname>Popiel</surname><given-names>E</given-names></name><name><surname>Lambert</surname><given-names>J-P</given-names></name><name><surname>Coyaud</surname><given-names>É</given-names></name><name><surname>Cheung</surname><given-names>SWT</given-names></name><name><surname>Rajendran</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>CJ</given-names></name><name><surname>Antonicka</surname><given-names>H</given-names></name><name><surname>Pelletier</surname><given-names>L</given-names></name><name><surname>Palazzo</surname><given-names>AF</given-names></name><name><surname>Shoubridge</surname><given-names>EA</given-names></name><name><surname>Raught</surname><given-names>B</given-names></name><name><surname>Gingras</surname><given-names>A-C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A proximity-dependent biotinylation map of A human cell</article-title><source>Nature</source><volume>595</volume><fpage>120</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03592-2</pub-id><pub-id pub-id-type="pmid">34079125</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>E</given-names></name><name><surname>Shorter</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The molecular language of membraneless organelles</article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><fpage>7115</fpage><lpage>7127</lpage><pub-id pub-id-type="doi">10.1074/jbc.TM118.001192</pub-id><pub-id pub-id-type="pmid">30045872</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>AX</given-names></name><name><surname>Cui</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>LY</given-names></name><name><surname>Yin</surname><given-names>JY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of CSDE1 in translational reprogramming and human diseases</article-title><source>Cell Communication and Signaling</source><volume>18</volume><elocation-id>14</elocation-id><pub-id pub-id-type="doi">10.1186/s12964-019-0496-2</pub-id><pub-id pub-id-type="pmid">31987048</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupte</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Kraus</surname><given-names>WL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes</article-title><source>Genes &amp; Development</source><volume>31</volume><fpage>101</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1101/gad.291518.116</pub-id><pub-id pub-id-type="pmid">28202539</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halstead</surname><given-names>JM</given-names></name><name><surname>Lin</surname><given-names>YQ</given-names></name><name><surname>Durraine</surname><given-names>L</given-names></name><name><surname>Hamilton</surname><given-names>RS</given-names></name><name><surname>Ball</surname><given-names>G</given-names></name><name><surname>Neely</surname><given-names>GG</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name><name><surname>Davis</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Syncrip/hnRNP Q influences synaptic transmission and regulates BMP signaling at the <italic>Drosophila</italic> neuromuscular synapse</article-title><source>Biology Open</source><volume>3</volume><fpage>839</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1242/bio.20149027</pub-id><pub-id pub-id-type="pmid">25171887</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heaton</surname><given-names>JH</given-names></name><name><surname>Dlakic</surname><given-names>WM</given-names></name><name><surname>Dlakic</surname><given-names>M</given-names></name><name><surname>Gelehrter</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the Type-1 plasminogen activator inhibitor mRNA</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>3341</fpage><lpage>3347</lpage><pub-id pub-id-type="doi">10.1074/jbc.M006538200</pub-id><pub-id pub-id-type="pmid">11001948</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriks</surname><given-names>IA</given-names></name><name><surname>Larsen</surname><given-names>SC</given-names></name><name><surname>Nielsen</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An advanced strategy for comprehensive profiling of ADP-ribosylation sites using mass spectrometry-based proteomics</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>18</volume><fpage>1010</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1074/mcp.TIR119.001315</pub-id><pub-id pub-id-type="pmid">30798302</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herdman</surname><given-names>C</given-names></name><name><surname>Mars</surname><given-names>JC</given-names></name><name><surname>Stefanovsky</surname><given-names>VY</given-names></name><name><surname>Tremblay</surname><given-names>MG</given-names></name><name><surname>Sabourin-Felix</surname><given-names>M</given-names></name><name><surname>Lindsay</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>Moss</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A unique enhancer boundary complex on the mouse ribosomal RNA genes persists after loss of Rrn3 or UBF and the inactivation of RNA polymerase I transcription</article-title><source>PLOS Genetics</source><volume>13</volume><elocation-id>e1006899</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006899</pub-id><pub-id pub-id-type="pmid">28715449</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herdy</surname><given-names>B</given-names></name><name><surname>Mayer</surname><given-names>C</given-names></name><name><surname>Varshney</surname><given-names>D</given-names></name><name><surname>Marsico</surname><given-names>G</given-names></name><name><surname>Murat</surname><given-names>P</given-names></name><name><surname>Taylor</surname><given-names>C</given-names></name><name><surname>D’Santos</surname><given-names>C</given-names></name><name><surname>Tannahill</surname><given-names>D</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Analysis of NRAS RNA G-quadruplex binding proteins reveals DDX3X as a novel interactor of cellular G-quadruplex containing transcripts</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>11592</fpage><lpage>11604</lpage><pub-id pub-id-type="doi">10.1093/nar/gky861</pub-id><pub-id pub-id-type="pmid">30256975</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández-Ortega</surname><given-names>K</given-names></name><name><surname>Garcia-Esparcia</surname><given-names>P</given-names></name><name><surname>Gil</surname><given-names>L</given-names></name><name><surname>Lucas</surname><given-names>JJ</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Altered machinery of protein synthesis in alzheimer’s: from the nucleolus to the ribosome</article-title><source>Brain Pathology</source><volume>26</volume><fpage>593</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1111/bpa.12335</pub-id><pub-id pub-id-type="pmid">26512942</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herviou</surname><given-names>P</given-names></name><name><surname>Le Bras</surname><given-names>M</given-names></name><name><surname>Dumas</surname><given-names>L</given-names></name><name><surname>Hieblot</surname><given-names>C</given-names></name><name><surname>Gilhodes</surname><given-names>J</given-names></name><name><surname>Cioci</surname><given-names>G</given-names></name><name><surname>Hugnot</surname><given-names>J-P</given-names></name><name><surname>Ameadan</surname><given-names>A</given-names></name><name><surname>Guillonneau</surname><given-names>F</given-names></name><name><surname>Dassi</surname><given-names>E</given-names></name><name><surname>Cammas</surname><given-names>A</given-names></name><name><surname>Millevoi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>hnRNP H/F drive RNA G-quadruplex-mediated translation linked to genomic instability and therapy resistance in glioblastoma</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2661</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16168-x</pub-id><pub-id pub-id-type="pmid">32461552</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>ZL</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>WH</given-names></name><name><surname>Wang</surname><given-names>XG</given-names></name><name><surname>Tan</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>SB</given-names></name><name><surname>Huang</surname><given-names>ZS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification of g-quadruplex-binding protein from the exploration of rgg motif/g-quadruplex interactions</article-title><source>Journal of the American Chemical Society</source><volume>140</volume><fpage>17945</fpage><lpage>17955</lpage><pub-id pub-id-type="doi">10.1021/jacs.8b09329</pub-id><pub-id pub-id-type="pmid">30517002</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Camacho</surname><given-names>CV</given-names></name><name><surname>Setlem</surname><given-names>R</given-names></name><name><surname>Ryu</surname><given-names>KW</given-names></name><name><surname>Parameswaran</surname><given-names>B</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Kraus</surname><given-names>WL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Functional interplay between histone H2B ADP-ribosylation and phosphorylation controls adipogenesis</article-title><source>Molecular Cell</source><volume>79</volume><fpage>934</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.08.002</pub-id><pub-id pub-id-type="pmid">32822587</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Kraus</surname><given-names>WL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The expanding universe of PARP1-mediated molecular and therapeutic mechanisms</article-title><source>Molecular Cell</source><volume>82</volume><fpage>2315</fpage><lpage>2334</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2022.02.021</pub-id><pub-id pub-id-type="pmid">35271815</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer-Bierhoff</surname><given-names>A</given-names></name><name><surname>Krogh</surname><given-names>N</given-names></name><name><surname>Tessarz</surname><given-names>P</given-names></name><name><surname>Ruppert</surname><given-names>T</given-names></name><name><surname>Nielsen</surname><given-names>H</given-names></name><name><surname>Grummt</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>SIRT7-dependent deacetylation of fibrillarin controls histone H2A Methylation and rRNA synthesis during the cell cycle</article-title><source>Cell Reports</source><volume>25</volume><fpage>2946</fpage><lpage>2954</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.11.051</pub-id><pub-id pub-id-type="pmid">30540930</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastano</surname><given-names>K</given-names></name><name><surname>Mier</surname><given-names>P</given-names></name><name><surname>Dosztányi</surname><given-names>Z</given-names></name><name><surname>Promponas</surname><given-names>VJ</given-names></name><name><surname>Andrade-Navarro</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Functional tuning of intrinsically disordered regions in human proteins by composition bias</article-title><source>Biomolecules</source><volume>12</volume><elocation-id>1486</elocation-id><pub-id pub-id-type="doi">10.3390/biom12101486</pub-id><pub-id pub-id-type="pmid">36291695</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavanagh</surname><given-names>T</given-names></name><name><surname>Halder</surname><given-names>A</given-names></name><name><surname>Drummond</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Tau interactome and RNA binding proteins in neurodegenerative diseases</article-title><source>Molecular Neurodegeneration</source><volume>17</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.1186/s13024-022-00572-6</pub-id><pub-id pub-id-type="pmid">36253823</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keefe</surname><given-names>AD</given-names></name><name><surname>Wilson</surname><given-names>DS</given-names></name><name><surname>Seelig</surname><given-names>B</given-names></name><name><surname>Szostak</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>One-step purification of recombinant proteins using a nanomolar-affinity streptavidin-binding peptide, the SBP-Tag</article-title><source>Protein Expression and Purification</source><volume>23</volume><fpage>440</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1006/prep.2001.1515</pub-id><pub-id pub-id-type="pmid">11722181</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelaini</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Cornelius</surname><given-names>VA</given-names></name><name><surname>Margariti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>RNA-binding proteins hold key roles in function, dysfunction, and disease</article-title><source>Biology</source><volume>10</volume><elocation-id>366</elocation-id><pub-id pub-id-type="doi">10.3390/biology10050366</pub-id><pub-id pub-id-type="pmid">33923168</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khudayberdiev</surname><given-names>S</given-names></name><name><surname>Soutschek</surname><given-names>M</given-names></name><name><surname>Ammann</surname><given-names>I</given-names></name><name><surname>Heinze</surname><given-names>A</given-names></name><name><surname>Rust</surname><given-names>MB</given-names></name><name><surname>Baumeister</surname><given-names>S</given-names></name><name><surname>Schratt</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The cytoplasmic SYNCRIP mRNA interactome of mammalian neurons</article-title><source>RNA Biology</source><volume>18</volume><fpage>1252</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1080/15476286.2020.1830553</pub-id><pub-id pub-id-type="pmid">33030396</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Camacho</surname><given-names>CV</given-names></name><name><surname>Nagari</surname><given-names>A</given-names></name><name><surname>Malladi</surname><given-names>VS</given-names></name><name><surname>Challa</surname><given-names>S</given-names></name><name><surname>Kraus</surname><given-names>WL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth via the rna helicase DDX21</article-title><source>Molecular Cell</source><volume>75</volume><fpage>1270</fpage><lpage>1285</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.06.020</pub-id><pub-id pub-id-type="pmid">31351877</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Challa</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Kraus</surname><given-names>WL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasis</article-title><source>Genes &amp; Development</source><volume>34</volume><fpage>302</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1101/gad.334433.119</pub-id><pub-id pub-id-type="pmid">32029452</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Sharma</surname><given-names>G</given-names></name><name><surname>Ishiguro</surname><given-names>K</given-names></name><name><surname>Hisanaga</surname><given-names>SI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Phospho-tau bar code: analysis of phosphoisotypes of tau and its application to tauopathy</article-title><source>Frontiers in Neuroscience</source><volume>12</volume><elocation-id>44</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2018.00044</pub-id><pub-id pub-id-type="pmid">29467609</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitts</surname><given-names>PA</given-names></name><name><surname>Church</surname><given-names>DM</given-names></name><name><surname>Thibaud-Nissen</surname><given-names>F</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Hem</surname><given-names>V</given-names></name><name><surname>Sapojnikov</surname><given-names>V</given-names></name><name><surname>Smith</surname><given-names>RG</given-names></name><name><surname>Tatusova</surname><given-names>T</given-names></name><name><surname>Xiang</surname><given-names>C</given-names></name><name><surname>Zherikov</surname><given-names>A</given-names></name><name><surname>DiCuccio</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>TD</given-names></name><name><surname>Pruitt</surname><given-names>KD</given-names></name><name><surname>Kimchi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Assembly: a resource for assembled genomes at NCBI</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>D73</fpage><lpage>D80</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1226</pub-id><pub-id pub-id-type="pmid">26578580</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosiol</surname><given-names>N</given-names></name><name><surname>Juranek</surname><given-names>S</given-names></name><name><surname>Brossart</surname><given-names>P</given-names></name><name><surname>Heine</surname><given-names>A</given-names></name><name><surname>Paeschke</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>G-quadruplexes: a promising target for cancer therapy</article-title><source>Molecular Cancer</source><volume>20</volume><elocation-id>40</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-021-01328-4</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Koster</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>R2 genomics analysis and visualization platform</article-title><ext-link ext-link-type="uri" xlink:href="http://r2.amc.nl">http://r2.amc.nl</ext-link><date-in-citation iso-8601-date="2023-03-23">March 23, 2023</date-in-citation></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosti</surname><given-names>A</given-names></name><name><surname>de Araujo</surname><given-names>PR</given-names></name><name><surname>Li</surname><given-names>W-Q</given-names></name><name><surname>Guardia</surname><given-names>GDA</given-names></name><name><surname>Chiou</surname><given-names>J</given-names></name><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Ray</surname><given-names>D</given-names></name><name><surname>Meliso</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y-M</given-names></name><name><surname>Delambre</surname><given-names>T</given-names></name><name><surname>Qiao</surname><given-names>M</given-names></name><name><surname>Burns</surname><given-names>SS</given-names></name><name><surname>Lorbeer</surname><given-names>FK</given-names></name><name><surname>Georgi</surname><given-names>F</given-names></name><name><surname>Flosbach</surname><given-names>M</given-names></name><name><surname>Klinnert</surname><given-names>S</given-names></name><name><surname>Jenseit</surname><given-names>A</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Sandoval</surname><given-names>CR</given-names></name><name><surname>Ha</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Pandey</surname><given-names>R</given-names></name><name><surname>Gruslova</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>YK</given-names></name><name><surname>Brenner</surname><given-names>A</given-names></name><name><surname>Kokovay</surname><given-names>E</given-names></name><name><surname>Hughes</surname><given-names>TR</given-names></name><name><surname>Morris</surname><given-names>QD</given-names></name><name><surname>Galante</surname><given-names>PAF</given-names></name><name><surname>Tiziani</surname><given-names>S</given-names></name><name><surname>Penalva</surname><given-names>LOF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The RNA-binding protein SERBP1 functions as a novel oncogenic factor in glioblastoma by bridging cancer metabolism and epigenetic regulation</article-title><source>Genome Biology</source><volume>21</volume><elocation-id>195</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-020-02115-y</pub-id><pub-id pub-id-type="pmid">32762776</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>SC</given-names></name><name><surname>Hendriks</surname><given-names>IA</given-names></name><name><surname>Lyon</surname><given-names>D</given-names></name><name><surname>Jensen</surname><given-names>LJ</given-names></name><name><surname>Nielsen</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Systems-wide analysis of serine adp-ribosylation reveals widespread occurrence and site-specific overlap with phosphorylation</article-title><source>Cell Reports</source><volume>24</volume><fpage>2493</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.07.083</pub-id><pub-id pub-id-type="pmid">30157440</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Hsieh</surname><given-names>WY</given-names></name><name><surname>Chen</surname><given-names>LY</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Protein arginine methylation of SERBP1 by protein arginine methyltransferase 1 affects cytoplasmic/nuclear distribution</article-title><source>Journal of Cellular Biochemistry</source><volume>113</volume><fpage>2721</fpage><lpage>2728</lpage><pub-id pub-id-type="doi">10.1002/jcb.24151</pub-id><pub-id pub-id-type="pmid">22442049</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y-J</given-names></name><name><surname>Wei</surname><given-names>H-M</given-names></name><name><surname>Chen</surname><given-names>L-Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Localization of SERBP1 in stress granules and nucleoli</article-title><source>The FEBS Journal</source><volume>281</volume><fpage>352</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1111/febs.12606</pub-id><pub-id pub-id-type="pmid">24205981</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Son</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>VN</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The SARS-CoV-2 RNA interactome</article-title><source>Molecular Cell</source><volume>81</volume><fpage>2838</fpage><lpage>2850</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2021.04.022</pub-id><pub-id pub-id-type="pmid">33989516</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelieveld</surname><given-names>SH</given-names></name><name><surname>Reijnders</surname><given-names>MRF</given-names></name><name><surname>Pfundt</surname><given-names>R</given-names></name><name><surname>Yntema</surname><given-names>HG</given-names></name><name><surname>Kamsteeg</surname><given-names>E-J</given-names></name><name><surname>de Vries</surname><given-names>P</given-names></name><name><surname>de Vries</surname><given-names>BBA</given-names></name><name><surname>Willemsen</surname><given-names>MH</given-names></name><name><surname>Kleefstra</surname><given-names>T</given-names></name><name><surname>Löhner</surname><given-names>K</given-names></name><name><surname>Vreeburg</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>SJC</given-names></name><name><surname>van der Burgt</surname><given-names>I</given-names></name><name><surname>Bongers</surname><given-names>EMHF</given-names></name><name><surname>Stegmann</surname><given-names>APA</given-names></name><name><surname>Rump</surname><given-names>P</given-names></name><name><surname>Rinne</surname><given-names>T</given-names></name><name><surname>Nelen</surname><given-names>MR</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name><name><surname>Vissers</surname><given-names>LELM</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Gilissen</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability</article-title><source>Nature Neuroscience</source><volume>19</volume><fpage>1194</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1038/nn.4352</pub-id><pub-id pub-id-type="pmid">27479843</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lester</surname><given-names>E</given-names></name><name><surname>Ooi</surname><given-names>FK</given-names></name><name><surname>Bakkar</surname><given-names>N</given-names></name><name><surname>Ayers</surname><given-names>J</given-names></name><name><surname>Woerman</surname><given-names>AL</given-names></name><name><surname>Wheeler</surname><given-names>J</given-names></name><name><surname>Bowser</surname><given-names>R</given-names></name><name><surname>Carlson</surname><given-names>GA</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components</article-title><source>Neuron</source><volume>109</volume><fpage>1675</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2021.03.026</pub-id><pub-id pub-id-type="pmid">33848474</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>AKL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Poly(ADP-ribose): a dynamic trigger for biomolecular condensate formation</article-title><source>Trends in Cell Biology</source><volume>30</volume><fpage>370</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2020.02.002</pub-id><pub-id pub-id-type="pmid">32302549</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Advances in the phase separation-organized membraneless organelles in cells: a narrative review</article-title><source>Translational Cancer Research</source><volume>10</volume><fpage>4929</fpage><lpage>4946</lpage><pub-id pub-id-type="doi">10.21037/tcr-21-1111</pub-id><pub-id pub-id-type="pmid">35116344</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locker</surname><given-names>N</given-names></name><name><surname>Chamond</surname><given-names>N</given-names></name><name><surname>Sargueil</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A conserved structure within the HIV gag open reading frame that controls translation initiation directly recruits the 40S subunit and eIF3</article-title><source>Nucleic Acids Research</source><volume>39</volume><fpage>2367</fpage><lpage>2377</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq1118</pub-id><pub-id pub-id-type="pmid">21071421</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyu</surname><given-names>K</given-names></name><name><surname>Chow</surname><given-names>EYC</given-names></name><name><surname>Mou</surname><given-names>X</given-names></name><name><surname>Chan</surname><given-names>TF</given-names></name><name><surname>Kwok</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>RNA G-quadruplexes (rG4s): genomics and biological functions</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>5426</fpage><lpage>5450</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab187</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manco</surname><given-names>G</given-names></name><name><surname>Lacerra</surname><given-names>G</given-names></name><name><surname>Porzio</surname><given-names>E</given-names></name><name><surname>Catara</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>ADP-ribosylation post-translational modification: an overview with a focus on rna biology and new pharmacological perspectives</article-title><source>Biomolecules</source><volume>12</volume><elocation-id>443</elocation-id><pub-id pub-id-type="doi">10.3390/biom12030443</pub-id><pub-id pub-id-type="pmid">35327636</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The role of PARP1 in neurodegenerative diseases and aging</article-title><source>The FEBS Journal</source><volume>289</volume><fpage>2013</fpage><lpage>2024</lpage><pub-id pub-id-type="doi">10.1111/febs.15716</pub-id><pub-id pub-id-type="pmid">33460497</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcelino Meliso</surname><given-names>F</given-names></name><name><surname>Hubert</surname><given-names>CG</given-names></name><name><surname>Favoretto Galante</surname><given-names>PA</given-names></name><name><surname>Penalva</surname><given-names>LO</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>RNA processing as an alternative route to attack glioblastoma</article-title><source>Human Genetics</source><volume>136</volume><fpage>1129</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1007/s00439-017-1819-2</pub-id><pub-id pub-id-type="pmid">28608251</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martello</surname><given-names>R</given-names></name><name><surname>Leutert</surname><given-names>M</given-names></name><name><surname>Jungmichel</surname><given-names>S</given-names></name><name><surname>Bilan</surname><given-names>V</given-names></name><name><surname>Larsen</surname><given-names>SC</given-names></name><name><surname>Young</surname><given-names>C</given-names></name><name><surname>Hottiger</surname><given-names>MO</given-names></name><name><surname>Nielsen</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Proteome-wide identification of the endogenous ADP-ribosylome of mammalian cells and tissue</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>12917</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms12917</pub-id><pub-id pub-id-type="pmid">27686526</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martini</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>K</given-names></name><name><surname>Faraway</surname><given-names>R</given-names></name><name><surname>Elze</surname><given-names>L</given-names></name><name><surname>Lockwood</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>McDonald</surname><given-names>NQ</given-names></name><name><surname>Mann</surname><given-names>DJ</given-names></name><name><surname>Armstrong</surname><given-names>A</given-names></name><name><surname>Ule</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A genetically-encoded crosslinker screen identifies SERBP1 as A PKCε substrate influencing translation and cell division</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>6934</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-27189-5</pub-id><pub-id pub-id-type="pmid">34836941</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masai</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>G-quadruplex DNA and RNA: Their roles in regulation of DNA replication and other biological functions</article-title><source>Biochemical and Biophysical Research Communications</source><volume>531</volume><fpage>25</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.05.132</pub-id><pub-id pub-id-type="pmid">32826060</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateju</surname><given-names>D</given-names></name><name><surname>Eichenberger</surname><given-names>B</given-names></name><name><surname>Voigt</surname><given-names>F</given-names></name><name><surname>Eglinger</surname><given-names>J</given-names></name><name><surname>Roth</surname><given-names>G</given-names></name><name><surname>Chao</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-molecule imaging reveals translation of mRNAs localized to stress granules</article-title><source>Cell</source><volume>183</volume><fpage>1801</fpage><lpage>1812</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.010</pub-id><pub-id pub-id-type="pmid">33308477</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McRae</surname><given-names>EKS</given-names></name><name><surname>Dupas</surname><given-names>SJ</given-names></name><name><surname>Booy</surname><given-names>EP</given-names></name><name><surname>Piragasam</surname><given-names>RS</given-names></name><name><surname>Fahlman</surname><given-names>RP</given-names></name><name><surname>McKenna</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An RNA guanine quadruplex regulated pathway to TRAIL-sensitization by DDX21</article-title><source>RNA</source><volume>26</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1261/rna.072199.119</pub-id><pub-id pub-id-type="pmid">31653714</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mekishvili</surname><given-names>M</given-names></name><name><surname>Matveeva</surname><given-names>E</given-names></name><name><surname>Fondufe-Mittendorf</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Methodology to identify poly-ADP-ribose polymerase 1 (PARP1)-mRNA targets by PAR-CLiP</article-title><source>Methods in Molecular Biology</source><volume>1608</volume><fpage>211</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-6993-7_15</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melikishvili</surname><given-names>M</given-names></name><name><surname>Chariker</surname><given-names>JH</given-names></name><name><surname>Rouchka</surname><given-names>EC</given-names></name><name><surname>Fondufe-Mittendorf</surname><given-names>YN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcriptome-wide identification of the RNA-binding landscape of the chromatin-associated protein PARP1 reveals functions in RNA biogenesis</article-title><source>Cell Discovery</source><volume>3</volume><elocation-id>17043</elocation-id><pub-id pub-id-type="doi">10.1038/celldisc.2017.43</pub-id><pub-id pub-id-type="pmid">29387452</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>SA</given-names></name><name><surname>Brown</surname><given-names>EC</given-names></name><name><surname>Coldwell</surname><given-names>MJ</given-names></name><name><surname>Jackson</surname><given-names>RJ</given-names></name><name><surname>Willis</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Protein factor requirements of the Apaf-1 internal ribosome entry segment: roles of polypyrimidine tract binding protein and upstream of N-ras</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>3364</fpage><lpage>3374</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.10.3364-3374.2001</pub-id><pub-id pub-id-type="pmid">11313462</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosler</surname><given-names>T</given-names></name><name><surname>Baymaz</surname><given-names>HI</given-names></name><name><surname>Gräf</surname><given-names>JF</given-names></name><name><surname>Mikicic</surname><given-names>I</given-names></name><name><surname>Blattner</surname><given-names>G</given-names></name><name><surname>Bartlett</surname><given-names>E</given-names></name><name><surname>Ostermaier</surname><given-names>M</given-names></name><name><surname>Piccinno</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Voigt</surname><given-names>A</given-names></name><name><surname>Gatti</surname><given-names>M</given-names></name><name><surname>Pellegrino</surname><given-names>S</given-names></name><name><surname>Altmeyer</surname><given-names>M</given-names></name><name><surname>Luck</surname><given-names>K</given-names></name><name><surname>Ahel</surname><given-names>I</given-names></name><name><surname>Roukos</surname><given-names>V</given-names></name><name><surname>Beli</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>PARP1 proximity proteomics reveals interaction partners at stressed replication forks</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>11600</fpage><lpage>11618</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac948</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murat</surname><given-names>P</given-names></name><name><surname>Marsico</surname><given-names>G</given-names></name><name><surname>Herdy</surname><given-names>B</given-names></name><name><surname>Ghanbarian</surname><given-names>AT</given-names></name><name><surname>Portella</surname><given-names>G</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>RNA G-quadruplexes at upstream open reading frames cause DHX36- and DHX9-dependent translation of human mRNAs</article-title><source>Genome Biology</source><volume>19</volume><elocation-id>229</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-018-1602-2</pub-id><pub-id pub-id-type="pmid">30591072</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muto</surname><given-names>A</given-names></name><name><surname>Sugihara</surname><given-names>Y</given-names></name><name><surname>Shibakawa</surname><given-names>M</given-names></name><name><surname>Oshima</surname><given-names>K</given-names></name><name><surname>Matsuda</surname><given-names>T</given-names></name><name><surname>Nadano</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The mRNA-binding protein Serbp1 as an auxiliary protein associated with mammalian cytoplasmic ribosomes</article-title><source>Cell Biochemistry and Function</source><volume>36</volume><fpage>312</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1002/cbf.3350</pub-id><pub-id pub-id-type="pmid">30039520</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakanishi</surname><given-names>C</given-names></name><name><surname>Seimiya</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>G-quadruplex in cancer biology and drug discovery</article-title><source>Biochemical and Biophysical Research Communications</source><volume>531</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.03.178</pub-id><pub-id pub-id-type="pmid">32312519</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naskar</surname><given-names>A</given-names></name><name><surname>Nayak</surname><given-names>A</given-names></name><name><surname>Salaikumaran</surname><given-names>MR</given-names></name><name><surname>Vishal</surname><given-names>SS</given-names></name><name><surname>Gopal</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Phase separation and pathologic transitions of RNP condensates in neurons: implications for amyotrophic lateral sclerosis, frontotemporal dementia and other neurodegenerative disorders</article-title><source>Frontiers in Molecular Neuroscience</source><volume>16</volume><elocation-id>1242925</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2023.1242925</pub-id><pub-id pub-id-type="pmid">37720552</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nussbacher</surname><given-names>JK</given-names></name><name><surname>Batra</surname><given-names>R</given-names></name><name><surname>Lagier-Tourenne</surname><given-names>C</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RNA-binding proteins in neurodegeneration: Seq and you shall receive</article-title><source>Trends in Neurosciences</source><volume>38</volume><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2015.02.003</pub-id><pub-id pub-id-type="pmid">25765321</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottoz</surname><given-names>DSM</given-names></name><name><surname>Berchowitz</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of disorder in RNA binding affinity and specificity</article-title><source>Open Biology</source><volume>10</volume><elocation-id>200328</elocation-id><pub-id pub-id-type="doi">10.1098/rsob.200328</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passos</surname><given-names>DO</given-names></name><name><surname>Bressan</surname><given-names>GC</given-names></name><name><surname>Nery</surname><given-names>FC</given-names></name><name><surname>Kobarg</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Ki-1/57 interacts with PRMT1 and is a substrate for arginine methylation</article-title><source>The FEBS Journal</source><volume>273</volume><fpage>3946</fpage><lpage>3961</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2006.05399.x</pub-id><pub-id pub-id-type="pmid">16879614</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patra</surname><given-names>S</given-names></name><name><surname>Claude</surname><given-names>JB</given-names></name><name><surname>Naubron</surname><given-names>JV</given-names></name><name><surname>Wenger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Fast interaction dynamics of G-quadruplex and RGG-rich peptides unveiled in zero-mode waveguides</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>12348</fpage><lpage>12357</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1002</pub-id><pub-id pub-id-type="pmid">34791437</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piovesan</surname><given-names>D</given-names></name><name><surname>Del Conte</surname><given-names>A</given-names></name><name><surname>Clementel</surname><given-names>D</given-names></name><name><surname>Monzon</surname><given-names>AM</given-names></name><name><surname>Bevilacqua</surname><given-names>M</given-names></name><name><surname>Aspromonte</surname><given-names>MC</given-names></name><name><surname>Iserte</surname><given-names>JA</given-names></name><name><surname>Orti</surname><given-names>FE</given-names></name><name><surname>Marino-Buslje</surname><given-names>C</given-names></name><name><surname>Tosatto</surname><given-names>SCE</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>MobiDB: 10 years of intrinsically disordered proteins</article-title><source>Nucleic Acids Research</source><volume>51</volume><fpage>D438</fpage><lpage>D444</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac1065</pub-id><pub-id pub-id-type="pmid">36416266</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prashad</surname><given-names>S</given-names></name><name><surname>Gopal</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>RNA-binding proteins in neurological development and disease</article-title><source>RNA Biology</source><volume>18</volume><fpage>972</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1080/15476286.2020.1809186</pub-id><pub-id pub-id-type="pmid">32865115</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puchalski</surname><given-names>RB</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Dalley</surname><given-names>R</given-names></name><name><surname>Nomura</surname><given-names>SR</given-names></name><name><surname>Yoon</surname><given-names>J-G</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Lankerovich</surname><given-names>M</given-names></name><name><surname>Bertagnolli</surname><given-names>D</given-names></name><name><surname>Bickley</surname><given-names>K</given-names></name><name><surname>Boe</surname><given-names>AF</given-names></name><name><surname>Brouner</surname><given-names>K</given-names></name><name><surname>Butler</surname><given-names>S</given-names></name><name><surname>Caldejon</surname><given-names>S</given-names></name><name><surname>Chapin</surname><given-names>M</given-names></name><name><surname>Datta</surname><given-names>S</given-names></name><name><surname>Dee</surname><given-names>N</given-names></name><name><surname>Desta</surname><given-names>T</given-names></name><name><surname>Dolbeare</surname><given-names>T</given-names></name><name><surname>Dotson</surname><given-names>N</given-names></name><name><surname>Ebbert</surname><given-names>A</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name><name><surname>Gee</surname><given-names>G</given-names></name><name><surname>Goldy</surname><given-names>J</given-names></name><name><surname>Gourley</surname><given-names>L</given-names></name><name><surname>Gregor</surname><given-names>BW</given-names></name><name><surname>Gu</surname><given-names>G</given-names></name><name><surname>Hejazinia</surname><given-names>N</given-names></name><name><surname>Hohmann</surname><given-names>J</given-names></name><name><surname>Hothi</surname><given-names>P</given-names></name><name><surname>Howard</surname><given-names>R</given-names></name><name><surname>Joines</surname><given-names>K</given-names></name><name><surname>Kriedberg</surname><given-names>A</given-names></name><name><surname>Kuan</surname><given-names>L</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Lemon</surname><given-names>T</given-names></name><name><surname>Long</surname><given-names>F</given-names></name><name><surname>Mastan</surname><given-names>N</given-names></name><name><surname>Mott</surname><given-names>E</given-names></name><name><surname>Murthy</surname><given-names>C</given-names></name><name><surname>Ngo</surname><given-names>K</given-names></name><name><surname>Olson</surname><given-names>E</given-names></name><name><surname>Reding</surname><given-names>M</given-names></name><name><surname>Riley</surname><given-names>Z</given-names></name><name><surname>Rosen</surname><given-names>D</given-names></name><name><surname>Sandman</surname><given-names>D</given-names></name><name><surname>Shapovalova</surname><given-names>N</given-names></name><name><surname>Slaughterbeck</surname><given-names>CR</given-names></name><name><surname>Sodt</surname><given-names>A</given-names></name><name><surname>Stockdale</surname><given-names>G</given-names></name><name><surname>Szafer</surname><given-names>A</given-names></name><name><surname>Wakeman</surname><given-names>W</given-names></name><name><surname>Wohnoutka</surname><given-names>PE</given-names></name><name><surname>White</surname><given-names>SJ</given-names></name><name><surname>Marsh</surname><given-names>D</given-names></name><name><surname>Rostomily</surname><given-names>RC</given-names></name><name><surname>Ng</surname><given-names>L</given-names></name><name><surname>Dang</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Keogh</surname><given-names>B</given-names></name><name><surname>Gittleman</surname><given-names>HR</given-names></name><name><surname>Barnholtz-Sloan</surname><given-names>JS</given-names></name><name><surname>Cimino</surname><given-names>PJ</given-names></name><name><surname>Uppin</surname><given-names>MS</given-names></name><name><surname>Keene</surname><given-names>CD</given-names></name><name><surname>Farrokhi</surname><given-names>FR</given-names></name><name><surname>Lathia</surname><given-names>JD</given-names></name><name><surname>Berens</surname><given-names>ME</given-names></name><name><surname>Iavarone</surname><given-names>A</given-names></name><name><surname>Bernard</surname><given-names>A</given-names></name><name><surname>Lein</surname><given-names>E</given-names></name><name><surname>Phillips</surname><given-names>JW</given-names></name><name><surname>Rostad</surname><given-names>SW</given-names></name><name><surname>Cobbs</surname><given-names>C</given-names></name><name><surname>Hawrylycz</surname><given-names>MJ</given-names></name><name><surname>Foltz</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An anatomic transcriptional atlas of human glioblastoma</article-title><source>Science</source><volume>360</volume><fpage>660</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1126/science.aaf2666</pub-id><pub-id pub-id-type="pmid">29748285</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>AR</given-names></name><name><surname>Hall</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics</source><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmid">20110278</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Stimulation of translation by human Unr requires cold shock domains 2 and 4, and correlates with poly(A) binding protein interaction</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>22461</elocation-id><pub-id pub-id-type="doi">10.1038/srep22461</pub-id><pub-id pub-id-type="pmid">26936655</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>JD</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The molecular biology of FMRP: new insights into fragile X syndrome</article-title><source>Nature Reviews. Neuroscience</source><volume>22</volume><fpage>209</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1038/s41583-021-00432-0</pub-id><pub-id pub-id-type="pmid">33608673</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roden</surname><given-names>C</given-names></name><name><surname>Gladfelter</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>RNA contributions to the form and function of biomolecular condensates</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>22</volume><fpage>183</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-0264-6</pub-id><pub-id pub-id-type="pmid">32632317</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggiero</surname><given-names>E</given-names></name><name><surname>Richter</surname><given-names>SN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>G-quadruplexes and G-quadruplex ligands: targets and tools in antiviral therapy</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>3270</fpage><lpage>3283</lpage><pub-id pub-id-type="doi">10.1093/nar/gky187</pub-id><pub-id pub-id-type="pmid">29554280</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanya</surname><given-names>DRA</given-names></name><name><surname>Cava</surname><given-names>C</given-names></name><name><surname>Onésime</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Roles of RNA-binding proteins in neurological disorders, COVID-19, and cancer</article-title><source>Human Cell</source><volume>36</volume><fpage>493</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1007/s13577-022-00843-w</pub-id><pub-id pub-id-type="pmid">36528839</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapir</surname><given-names>T</given-names></name><name><surname>Kshirsagar</surname><given-names>A</given-names></name><name><surname>Gorelik</surname><given-names>A</given-names></name><name><surname>Olender</surname><given-names>T</given-names></name><name><surname>Porat</surname><given-names>Z</given-names></name><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>Goldstein</surname><given-names>DB</given-names></name><name><surname>Devinsky</surname><given-names>O</given-names></name><name><surname>Reiner</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Heterogeneous nuclear ribonucleoprotein U (HNRNPU) safeguards the developing mouse cortex</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>4209</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-31752-z</pub-id><pub-id pub-id-type="pmid">35864088</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Henry</surname><given-names>MD</given-names></name><name><surname>Wu</surname><given-names>YN</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data</article-title><source>PNAS</source><volume>111</volume><fpage>E5593</fpage><lpage>E5601</lpage><pub-id pub-id-type="doi">10.1073/pnas.1419161111</pub-id><pub-id pub-id-type="pmid">25480548</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soneson</surname><given-names>C</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Robinson</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences</article-title><source>F1000Research</source><volume>4</volume><elocation-id>1521</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.7563.1</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonnhammer</surname><given-names>EL</given-names></name><name><surname>Eddy</surname><given-names>SR</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Pfam: a comprehensive database of protein domain families based on seed alignments</article-title><source>Proteins</source><volume>28</volume><fpage>405</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0134(199707)28:33.0.CO;2-L</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>C</given-names></name><name><surname>Breitkreutz</surname><given-names>BJ</given-names></name><name><surname>Reguly</surname><given-names>T</given-names></name><name><surname>Boucher</surname><given-names>L</given-names></name><name><surname>Breitkreutz</surname><given-names>A</given-names></name><name><surname>Tyers</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>BioGRID: a general repository for interaction datasets</article-title><source>Nucleic Acids Research</source><volume>34</volume><fpage>D535</fpage><lpage>D539</lpage><pub-id pub-id-type="doi">10.1093/nar/gkj109</pub-id><pub-id pub-id-type="pmid">16381927</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Q</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Liquid-liquid phase separation: orchestrating cell signaling through time and space</article-title><source>Molecular Cell</source><volume>81</volume><fpage>4137</fpage><lpage>4146</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2021.09.010</pub-id><pub-id pub-id-type="pmid">34619090</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Yuan</surname><given-names>B-F</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Photoactive G-quadruplex ligand identifies multiple g-quadruplex-related proteins with extensive sequence tolerance in the cellular environment</article-title><source>Journal of the American Chemical Society</source><volume>143</volume><fpage>1917</fpage><lpage>1923</lpage><pub-id pub-id-type="doi">10.1021/jacs.0c10792</pub-id><pub-id pub-id-type="pmid">33471508</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Supek</surname><given-names>F</given-names></name><name><surname>Bošnjak</surname><given-names>M</given-names></name><name><surname>Škunca</surname><given-names>N</given-names></name><name><surname>Šmuc</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>REVIGO summarizes and visualizes long lists of gene ontology terms</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e21800</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0021800</pub-id><pub-id pub-id-type="pmid">21789182</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutphin</surname><given-names>GL</given-names></name><name><surname>Mahoney</surname><given-names>JM</given-names></name><name><surname>Sheppard</surname><given-names>K</given-names></name><name><surname>Walton</surname><given-names>DO</given-names></name><name><surname>Korstanje</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>WORMHOLE: novel least diverged ortholog prediction through machine learning</article-title><source>PLOS Computational Biology</source><volume>12</volume><elocation-id>e1005182</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005182</pub-id><pub-id pub-id-type="pmid">27812085</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Kirsch</surname><given-names>R</given-names></name><name><surname>Koutrouli</surname><given-names>M</given-names></name><name><surname>Nastou</surname><given-names>K</given-names></name><name><surname>Mehryary</surname><given-names>F</given-names></name><name><surname>Hachilif</surname><given-names>R</given-names></name><name><surname>Gable</surname><given-names>AL</given-names></name><name><surname>Fang</surname><given-names>T</given-names></name><name><surname>Doncheva</surname><given-names>NT</given-names></name><name><surname>Pyysalo</surname><given-names>S</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>LJ</given-names></name><name><surname>von Mering</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest</article-title><source>Nucleic Acids Research</source><volume>51</volume><fpage>D638</fpage><lpage>D646</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac1000</pub-id><pub-id pub-id-type="pmid">36370105</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tafforeau</surname><given-names>L</given-names></name><name><surname>Zorbas</surname><given-names>C</given-names></name><name><surname>Langhendries</surname><given-names>JL</given-names></name><name><surname>Mullineux</surname><given-names>ST</given-names></name><name><surname>Stamatopoulou</surname><given-names>V</given-names></name><name><surname>Mullier</surname><given-names>R</given-names></name><name><surname>Wacheul</surname><given-names>L</given-names></name><name><surname>Lafontaine</surname><given-names>DLJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The complexity of human ribosome biogenesis revealed by systematic nucleolar screening of Pre-rRNA processing factors</article-title><source>Molecular Cell</source><volume>51</volume><fpage>539</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.08.011</pub-id><pub-id pub-id-type="pmid">23973377</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Studies of the expression of human poly(ADP-ribose) polymerase-1 in <italic>Saccharomyces cerevisiae</italic> and identification of PARP-1 substrates by yeast proteome microarray screening</article-title><source>Biochemistry</source><volume>48</volume><fpage>11745</fpage><lpage>11754</lpage><pub-id pub-id-type="doi">10.1021/bi901387k</pub-id><pub-id pub-id-type="pmid">19877712</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thandapani</surname><given-names>P</given-names></name><name><surname>O’Connor</surname><given-names>TR</given-names></name><name><surname>Bailey</surname><given-names>TL</given-names></name><name><surname>Richard</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Defining the RGG/RG motif</article-title><source>Molecular Cell</source><volume>50</volume><fpage>613</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.05.021</pub-id><pub-id pub-id-type="pmid">23746349</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>PD</given-names></name><name><surname>Ebert</surname><given-names>D</given-names></name><name><surname>Muruganujan</surname><given-names>A</given-names></name><name><surname>Mushayahama</surname><given-names>T</given-names></name><name><surname>Albou</surname><given-names>LP</given-names></name><name><surname>Mi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>PANTHER: Making genome-scale phylogenetics accessible to all</article-title><source>Protein Science</source><volume>31</volume><fpage>8</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/pro.4218</pub-id><pub-id pub-id-type="pmid">34717010</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Titlow</surname><given-names>J</given-names></name><name><surname>Robertson</surname><given-names>F</given-names></name><name><surname>Järvelin</surname><given-names>A</given-names></name><name><surname>Ish-Horowicz</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Gratton</surname><given-names>E</given-names></name><name><surname>Davis</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Syncrip/hnRNP Q is required for activity-induced Msp300/Nesprin-1 expression and new synapse formation</article-title><source>The Journal of Cell Biology</source><volume>219</volume><elocation-id>e201903135</elocation-id><pub-id pub-id-type="doi">10.1083/jcb.201903135</pub-id><pub-id pub-id-type="pmid">32040548</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tollervey</surname><given-names>D</given-names></name><name><surname>Lehtonen</surname><given-names>H</given-names></name><name><surname>Jansen</surname><given-names>R</given-names></name><name><surname>Kern</surname><given-names>H</given-names></name><name><surname>Hurt</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Temperature-sensitive mutations demonstrate roles for yeast fibrillarin in pre-rRNA processing, pre-rRNA methylation, and ribosome assembly</article-title><source>Cell</source><volume>72</volume><fpage>443</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90120-f</pub-id><pub-id pub-id-type="pmid">8431947</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tollervey</surname><given-names>D</given-names></name><name><surname>Kiss</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Function and synthesis of small nucleolar RNAs</article-title><source>Current Opinion in Cell Biology</source><volume>9</volume><fpage>337</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/s0955-0674(97)80005-1</pub-id><pub-id pub-id-type="pmid">9159079</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ugrinova</surname><given-names>I</given-names></name><name><surname>Petrova</surname><given-names>M</given-names></name><name><surname>Chalabi-Dchar</surname><given-names>M</given-names></name><name><surname>Bouvet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Multifaceted nucleolin protein and its molecular partners in oncogenesis</article-title><source>Advances in Protein Chemistry and Structural Biology</source><volume>111</volume><fpage>133</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/bs.apcsb.2017.08.001</pub-id><pub-id pub-id-type="pmid">29459030</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uversky</surname><given-names>VN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The roles of intrinsic disorder-based liquid-liquid phase transitions in the “Dr. Jekyll-Mr. Hyde” behavior of proteins involved in amyotrophic lateral sclerosis and frontotemporal lobar degeneration</article-title><source>Autophagy</source><volume>13</volume><fpage>2115</fpage><lpage>2162</lpage><pub-id pub-id-type="doi">10.1080/15548627.2017.1384889</pub-id><pub-id pub-id-type="pmid">28980860</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Leemput</surname><given-names>J</given-names></name><name><surname>Boles</surname><given-names>NC</given-names></name><name><surname>Kiehl</surname><given-names>TR</given-names></name><name><surname>Corneo</surname><given-names>B</given-names></name><name><surname>Lederman</surname><given-names>P</given-names></name><name><surname>Menon</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Martinez</surname><given-names>RA</given-names></name><name><surname>Levi</surname><given-names>BP</given-names></name><name><surname>Thompson</surname><given-names>CL</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Kaykas</surname><given-names>A</given-names></name><name><surname>Temple</surname><given-names>S</given-names></name><name><surname>Fasano</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CORTECON: a temporal transcriptome analysis of in vitro human cerebral cortex development from human embryonic stem cells</article-title><source>Neuron</source><volume>83</volume><fpage>51</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.05.013</pub-id><pub-id pub-id-type="pmid">24991954</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Dyke</surname><given-names>N</given-names></name><name><surname>Baby</surname><given-names>J</given-names></name><name><surname>Van Dyke</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Stm1p, a ribosome-associated protein, is important for protein synthesis in <italic>Saccharomyces cerevisiae</italic> under nutritional stress conditions</article-title><source>Journal of Molecular Biology</source><volume>358</volume><fpage>1023</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2006.03.018</pub-id><pub-id pub-id-type="pmid">16580682</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderweyde</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Varnum</surname><given-names>M</given-names></name><name><surname>Liu-Yesucevitz</surname><given-names>L</given-names></name><name><surname>Citro</surname><given-names>A</given-names></name><name><surname>Ikezu</surname><given-names>T</given-names></name><name><surname>Duff</surname><given-names>K</given-names></name><name><surname>Wolozin</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies</article-title><source>The Journal of Neuroscience</source><volume>32</volume><fpage>8270</fpage><lpage>8283</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1592-12.2012</pub-id><pub-id pub-id-type="pmid">22699908</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varshney</surname><given-names>D</given-names></name><name><surname>Cuesta</surname><given-names>SM</given-names></name><name><surname>Herdy</surname><given-names>B</given-names></name><name><surname>Abdullah</surname><given-names>UB</given-names></name><name><surname>Tannahill</surname><given-names>D</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>RNA G-quadruplex structures control ribosomal protein production</article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>22735</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-01847-6</pub-id><pub-id pub-id-type="pmid">34815422</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velasco</surname><given-names>MX</given-names></name><name><surname>Kosti</surname><given-names>A</given-names></name><name><surname>Penalva</surname><given-names>LOF</given-names></name><name><surname>Hernández</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The diverse roles of RNA-binding proteins in glioma development</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1157</volume><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-19966-1_2</pub-id><pub-id pub-id-type="pmid">31342436</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>D</given-names></name><name><surname>Mohr</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Viral subversion of the host protein synthesis machinery</article-title><source>Nature Reviews. Microbiology</source><volume>9</volume><fpage>860</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2655</pub-id><pub-id pub-id-type="pmid">22002165</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Hoekzema</surname><given-names>K</given-names></name><name><surname>Vecchio</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Sulovari</surname><given-names>A</given-names></name><name><surname>Coe</surname><given-names>BP</given-names></name><name><surname>Gillentine</surname><given-names>MA</given-names></name><name><surname>Wilfert</surname><given-names>AB</given-names></name><name><surname>Perez-Jurado</surname><given-names>LA</given-names></name><name><surname>Kvarnung</surname><given-names>M</given-names></name><name><surname>Sleyp</surname><given-names>Y</given-names></name><name><surname>Earl</surname><given-names>RK</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Geisheker</surname><given-names>MR</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>B</given-names></name><name><surname>Barnett</surname><given-names>C</given-names></name><name><surname>Thompson</surname><given-names>E</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><name><surname>Carroll</surname><given-names>R</given-names></name><name><surname>Friend</surname><given-names>K</given-names></name><name><surname>Catford</surname><given-names>R</given-names></name><name><surname>Palmer</surname><given-names>EE</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Ou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Gerdts</surname><given-names>J</given-names></name><name><surname>Avola</surname><given-names>E</given-names></name><name><surname>Calabrese</surname><given-names>G</given-names></name><name><surname>Elia</surname><given-names>M</given-names></name><name><surname>Greco</surname><given-names>D</given-names></name><name><surname>Lindstrand</surname><given-names>A</given-names></name><name><surname>Nordgren</surname><given-names>A</given-names></name><name><surname>Anderlid</surname><given-names>B-M</given-names></name><name><surname>Vandeweyer</surname><given-names>G</given-names></name><name><surname>Van Dijck</surname><given-names>A</given-names></name><name><surname>Van der Aa</surname><given-names>N</given-names></name><name><surname>McKenna</surname><given-names>B</given-names></name><name><surname>Hancarova</surname><given-names>M</given-names></name><name><surname>Bendova</surname><given-names>S</given-names></name><name><surname>Havlovicova</surname><given-names>M</given-names></name><name><surname>Malerba</surname><given-names>G</given-names></name><name><surname>Bernardina</surname><given-names>BD</given-names></name><name><surname>Muglia</surname><given-names>P</given-names></name><name><surname>van Haeringen</surname><given-names>A</given-names></name><name><surname>Hoffer</surname><given-names>MJV</given-names></name><name><surname>Franke</surname><given-names>B</given-names></name><name><surname>Cappuccio</surname><given-names>G</given-names></name><name><surname>Delatycki</surname><given-names>M</given-names></name><name><surname>Lockhart</surname><given-names>PJ</given-names></name><name><surname>Manning</surname><given-names>MA</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>Brunetti-Pierri</surname><given-names>N</given-names></name><name><surname>Rommelse</surname><given-names>N</given-names></name><name><surname>Amaral</surname><given-names>DG</given-names></name><name><surname>Santen</surname><given-names>GWE</given-names></name><name><surname>Trabetti</surname><given-names>E</given-names></name><name><surname>Sedláček</surname><given-names>Z</given-names></name><name><surname>Michaelson</surname><given-names>JJ</given-names></name><name><surname>Pierce</surname><given-names>K</given-names></name><name><surname>Courchesne</surname><given-names>E</given-names></name><name><surname>Kooy</surname><given-names>RF</given-names></name><name><surname>Nordenskjöld</surname><given-names>M</given-names></name><name><surname>Romano</surname><given-names>C</given-names></name><name><surname>Peeters</surname><given-names>H</given-names></name><name><surname>Bernier</surname><given-names>RA</given-names></name><name><surname>Gecz</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>K</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name><collab>SPARK Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4932</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-18723-y</pub-id><pub-id pub-id-type="pmid">33004838</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webber</surname><given-names>CJ</given-names></name><name><surname>Lei</surname><given-names>SE</given-names></name><name><surname>Wolozin</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The pathophysiology of neurodegenerative disease: disturbing the balance between phase separation and irreversible aggregation</article-title><source>Progress in Molecular Biology and Translational Science</source><volume>174</volume><fpage>187</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/bs.pmbts.2020.04.021</pub-id><pub-id pub-id-type="pmid">32828466</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Functions of PARylation in DNA damage repair pathways</article-title><source>Genomics, Proteomics &amp; Bioinformatics</source><volume>14</volume><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.gpb.2016.05.001</pub-id><pub-id pub-id-type="pmid">27240471</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="software"><person-group person-group-type="author"><collab>Xinglab</collab></person-group><year iso-8601-date="2024">2024</year><data-title>Rmats2sashimiplot</data-title><version designator="5b7bbdb">5b7bbdb</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/Xinglab/rmats2sashimiplot">https://github.com/Xinglab/rmats2sashimiplot</ext-link></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>G-Quadruplexes in neurobiology and virology: functional roles and potential therapeutic approaches</article-title><source>JACS Au</source><volume>1</volume><fpage>2146</fpage><lpage>2161</lpage><pub-id pub-id-type="doi">10.1021/jacsau.1c00451</pub-id><pub-id pub-id-type="pmid">34977886</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youn</surname><given-names>J-Y</given-names></name><name><surname>Dunham</surname><given-names>WH</given-names></name><name><surname>Hong</surname><given-names>SJ</given-names></name><name><surname>Knight</surname><given-names>JDR</given-names></name><name><surname>Bashkurov</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>GI</given-names></name><name><surname>Bagci</surname><given-names>H</given-names></name><name><surname>Rathod</surname><given-names>B</given-names></name><name><surname>MacLeod</surname><given-names>G</given-names></name><name><surname>Eng</surname><given-names>SWM</given-names></name><name><surname>Angers</surname><given-names>S</given-names></name><name><surname>Morris</surname><given-names>Q</given-names></name><name><surname>Fabian</surname><given-names>M</given-names></name><name><surname>Côté</surname><given-names>J-F</given-names></name><name><surname>Gingras</surname><given-names>A-C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>High-density proximity mapping reveals the subcellular organization of mrna-associated granules and bodies</article-title><source>Molecular Cell</source><volume>69</volume><fpage>517</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.12.020</pub-id><pub-id pub-id-type="pmid">29395067</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaja</surname><given-names>R</given-names></name><name><surname>Mikoč</surname><given-names>A</given-names></name><name><surname>Barkauskaite</surname><given-names>E</given-names></name><name><surname>Ahel</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Molecular insights into poly(ADP-ribose) recognition and processing</article-title><source>Biomolecules</source><volume>3</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.3390/biom3010001</pub-id><pub-id pub-id-type="pmid">24970154</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeke</surname><given-names>A</given-names></name><name><surname>Schád</surname><given-names>É</given-names></name><name><surname>Horváth</surname><given-names>T</given-names></name><name><surname>Abukhairan</surname><given-names>R</given-names></name><name><surname>Szabó</surname><given-names>B</given-names></name><name><surname>Tantos</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Deep structural insights into RNA-binding disordered protein regions</article-title><source>Wiley Interdisciplinary Reviews. RNA</source><volume>13</volume><elocation-id>e1714</elocation-id><pub-id pub-id-type="doi">10.1002/wrna.1714</pub-id><pub-id pub-id-type="pmid">35098694</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>X-J</given-names></name><name><surname>Zou</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>T</given-names></name><name><surname>Rao</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Nowsheen</surname><given-names>S</given-names></name><name><surname>Kloeber</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Yin</surname><given-names>P</given-names></name><name><surname>Teng</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Lou</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J-S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A ribosomal gene panel predicting A novel synthetic lethality in non-BRCAness tumors</article-title><source>Signal Transduction and Targeted Therapy</source><volume>8</volume><elocation-id>183</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-023-01401-y</pub-id><pub-id pub-id-type="pmid">37160887</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Pache</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Khodabakhshi</surname><given-names>AH</given-names></name><name><surname>Tanaseichuk</surname><given-names>O</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Chanda</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1523</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id><pub-id pub-id-type="pmid">30944313</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98152.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Donlin-Asp</surname><given-names>Paul</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Edinburgh</institution><country>United Kingdom</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd><kwd>Solid</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This study reports <bold>valuable</bold> insights into the interactome of the RNA-binding protein SERBP1 and possible links through PARylation to diverse processes, including splicing, cell division, and ribosome biogenesis. The diversity of processes SERBP1 may regulate means this work would be of very broad interest to the cell biology community. The proteomics data are <bold>solid</bold>, but the functional connection to downstream processes and the link to Alzheimer's disease, while <bold>compelling</bold>, still require further examination. These latter data currently rely on a very limited set of experiments and patient samples with questionable quality of preservation and methodology.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98152.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Here the authors convincingly identify and characterize the SERBP1 interactome and further define its role in the nucleus, where it is associated with complexes involved in splicing, cell division, chromosome structure, and ribosome biogenesis. Many of the SERBP1-associated proteins are RNA-binding proteins and SERBP1 exerts its impact, at least in part, through these players. SERBP1 is mostly disordered but along with its associated proteins displays a preference for G4 binding and can can bind to PAR and be PARylated. They present data that strongly suggest that complexes in which SERBP1 participates are assembled through G4 or PAR binding. The authors suggest that because SERBP1 lacks traditional functional domains yet is clearly involved in distinct regulatory complexes, SERBP1 likely acts in the early steps of assembly through the recognition of interacting sites present in RNA, DNA, and proteins.</p><p>Strengths:</p><p>The data is very convincing and demonstrated through multiple approaches.</p><p>Weaknesses:</p><p>None. The authors have adequately addressed earlier reviewer concerns.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98152.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this study the authors have used pull-down experiments in a cell line overexpressing tagged SERPINE1 mRNA binding protein 1 (SERBP1) followed by mass spectrometry-based proteomics, to establish its interactome. Extensive analyses are performed to connect the data to published resources. The authors attempt to connect SERBP1 to stress granules and Alzheimer's disease associated tau pathology. Based on the interactome, the authors propose a cross-talk between SERBP1 and PARP1 functions.</p><p>Strengths:</p><p>The main strength of this study lies in the extensive proteomics data analysis, and its effort to connect the data to published studies.</p><p>Weaknesses:</p><p>Support for the proposed model: While the authors propose a feedback regulatory model for SERBP1 and PARP1 function, strong evidence for PARylation modulating SERBP1 functions is lacking. PARP inhibition decreasing the amount of PARylated proteins associated with SERBP1 and likely all other PARylated proteins is expected.</p><p>Evidence from autopsy brain tissue: This study shows unexplained round, punctate staining for SERBP1 in immunohistochemistry (IHC) staining. This may be due to poor preservation of cellular structures in frozen autopsy brain tissue. SERBP1 and pTau co-staining lacks an age matched non-AD control. Most quantifications of human IHC staining and co-localization do not indicate the number of cases and what data points are shown.</p><p>The link to stress granules (SGs): G3BP1 staining indicates cytoplasmic mislocalization and perhaps aggregation pathology, but not necessarily SGs. It is not clear whether physiological transient stress granules are preserved in autopsy brain tissue. The co-localization of abundant cytoplasmic G3BP1 and SERBP1 under normal conditions does not indicate association with SGs. Stress granule proteins assemble phase-separated granules in the cytoplasm under cellular stress, whereas here it is shown that normally cytoplasmic SERBP1 has a nucleocytoplasmic distribution in the presence of H2O2, with no evidence for SG formation.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98152.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Breunig</surname><given-names>Kira</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Lei</surname><given-names>Xuifen</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Montalbano</surname><given-names>Mauro</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Medical Branch at Galveston</institution><addr-line><named-content content-type="city">Galveston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Guardia</surname><given-names>Gabriela DA</given-names></name><role specific-use="author">Author</role><aff><institution>Hospital Sirio-Libanes</institution><addr-line><named-content content-type="city">Sao Paulo</named-content></addr-line><country>Brazil</country></aff></contrib><contrib contrib-type="author"><name><surname>Ostadrahimi</surname><given-names>Shiva</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Alers</surname><given-names>Victoria</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kosti</surname><given-names>Adam</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Chiou</surname><given-names>Jennifer</given-names></name><role specific-use="author">Author</role><aff><institution>UT Austin</institution><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Klein</surname><given-names>Nicole</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Vinarov</surname><given-names>Corina</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lily</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Mujia</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Weidan</given-names></name><role specific-use="author">Author</role><aff><institution>University of Texas Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kraus</surname><given-names>W Lee</given-names></name><role specific-use="author">Author</role><aff><institution>University of Texas Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Libich</surname><given-names>David S</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Tiziani</surname><given-names>Stefano</given-names></name><role specific-use="author">Author</role><aff><institution>UT Austin</institution><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Weintraub</surname><given-names>Susan T</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Galante</surname><given-names>Pedro AF</given-names></name><role specific-use="author">Author</role><aff><institution>Hospital Sirio-Libanes</institution><addr-line><named-content content-type="city">Sao Paulo</named-content></addr-line><country>Brazil</country></aff></contrib><contrib contrib-type="author"><name><surname>Penalva</surname><given-names>Luiz O</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Texas Health Science Center at San Antonio</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer 1 (Public Review):</bold></p><p>Summary:</p><p>Here the authors convincingly identify and characterize the SERBP1 interactome and further define its role in the nucleus, where it is associated with complexes involved in splicing, cell division, chromosome structure, and ribosome biogenesis. Many of the SERBP1-associated proteins are RNA-binding proteins and SERBP1 exerts its impact, at least in part, through these players. SERBP1 is mostly disordered but along with its associated proteins displays a preference for G4 binding and can bind to PAR and be PARylated. They present data that strongly suggest that complexes in which SERBP1 participates are assembled through G4 or PAR binding. The authors suggest that because SERBP1 lacks traditional functional domains yet is clearly involved in distinct regulatory complexes, SERBP1 likely acts in the early steps of assembly through the recognition of interacting sites present in RNA, DNA, and proteins.</p><p>Strengths:</p><p>The data is very convincing and demonstrated through multiple approaches.</p><p>Weaknesses:</p><p>No weaknesses were identified by this reviewer.</p><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>In this study the authors have used pull-down experiments in a cell line overexpressing tagged SERPINE1 mRNA binding protein 1 (SERBP1) followed by mass spectrometry-based proteomics, to establish its interactome. Extensive analyses are performed to connect the data to published resources. The authors attempt to connect SERBP1 to stress granules and Alzheimer's disease-associated tau pathology. Based on the interactome, the authors propose a cross-talk between SERBP1 and PARP1 functions.</p><p>Strengths:</p><p>The main strength of this study lies in the proteomics data analysis, and its effort to connect the data to published studies.</p><p>Weaknesses:</p><p>While the authors propose a feedback regulatory model for SERBP1 and PARP1 functions, strong evidence for PARylation modulating SERBP1 functions is lacking. PARP inhibition decreasing the amount of PARylated proteins associated with SERBP1 and likely all other PARylated proteins is expected. This study is also incomplete in its attempt to establish a connection to Alzheimer's disease related tauopathy. A single AD case is not sufficient, and frozen autopsy tissue shows unexplained punctate staining likely due to poor preservation of cellular structures for immunohistochemistry. There is a lack of essential demographic data, source of the tissue, brain regions shown, and whether there was an IRB protocol for the human brain tissue. The presence of phase-separated transient stress granules in an autopsy brain is unlikely, even if G3BP1 staining is present. Normally, stress granule proteins move to the cytoplasm under cellular stress, whereas SERBP1 becomes nuclear. The co-localization of abundant cytoplasmic G3BP1 and SERBP1 under normal conditions does not indicate an association with stress granules.</p><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary:</p><p>A survey of SERBP1-associated functions and their impact on the transcriptome upon gene depletion, as well as the identification of chemical inhibitors upon gene over-expression.</p><p>Strengths:</p><p>(1) Provides a valuable resource for the community, supported by statistical analyses.</p><p>(2) Offers a survey of different processes with correlation data, serving as a good starting point for the community to follow up.</p><p>Weaknesses:</p><p>(1) The authors provided numerous correlations on diverse topics, from cell division to RNA splicing and PARP1 association, but did not follow up their findings with experiments, offering little mechanistic insight into the actual role of SERBP1. The model in Figure 5D is entirely speculative and lacks data support in the manuscript.</p></disp-quote><p>Our article includes several pieces of evidence that support SERBP1’s role in splicing, translation, cell division and association with PARP1. We respectfully disagree that the model in Figure 5D is speculative. The goal of our study was to generate initial evidence of SERBP1 involvement in different biological processes based on its interactome. The characterization of molecular mechanisms in all these scenarios requires a substantial amount work and will the topic of follow up manuscripts.</p><disp-quote content-type="editor-comment"><p>(2) Following up with experiments to demonstrate that their findings are real (e.g., those related to splicing defects and the PARylation/PAR-binding association) would be beneficial. For example, whether the association between PARP1 and SERBP1 is sensitive to PAR-degrading enzymes is unclear.</p></disp-quote><p>We included experiments showing the interaction between endogenous SERBP1 and PARP1. Additionally, we demonstrated that SERBP1 interaction with PARP1 was disrupted when cells are treated with PARP inhibitors.</p><disp-quote content-type="editor-comment"><p>(3) They did not clearly articulate how experiments were performed. For instance, the drug screen and even the initial experiment involving the pull-down were poorly described. Many in the community may not be familiar with vectors such as pSBP or pUltra without looking up details.</p></disp-quote><p>We provided additional details about the vectors and expanded the description of experiments in results and figure legends.</p><disp-quote content-type="editor-comment"><p>(4) The co-staining of SERBP1 with pTau, PARP1, and G3BP1 in the brain is interesting, but it would be beneficial to follow up with immunoprecipitation in normal and patient samples to confirm the increased physical association.</p></disp-quote><p>Thank you for this suggestion. We performed instead a Proximity Ligation Assay (PLA) on human tissue. Data was included in Fig. 7B and C. PLA between pTau and SERBP1 confirmed interaction in AD cortices as well as SERBP1 with PARP1.</p><disp-quote content-type="editor-comment"><p>(5) The combination index of 0.7-0.9 for PJ34 + siSERBP1 is weak. Could this be due to the non-specific nature of the drug against other PARPs? Have the authors looked into this possibility?</p></disp-quote><p>The combination index could be considered weak in the case of U251 cells but not in the case of U343 cells. PJ34 has been shown to be mainly a PARP-1 inhibitor. Different PJ34 concentrations and different drugs will be examined in future studies. It is worth mentioning that in a genetic screening, SERBP1 has been shown to increase sensitivity to different PARP inhibitors (PMID: 37160887). This information is included in the manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>This is a really well-done piece of research that is written very well. The data are very convincing and the conclusions are well supported. Some wording in Figures 2B and D is pixelated and hard to read. All the figure legends could benefit from being expanded but this is especially true for Figures 2, 3, 7, and 8. There is a ton of data being presented and a very limited description of what was done and what is being concluded. Some of the content may not be fully comprehended by some readers with limited descriptions.</p></disp-quote><p>We revised all figures to assure images are clear and their resolution is high. We expanded all figure legends to provide a better explanation of the experimental design.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>The &quot;merged&quot; pdf file is the same as the &quot;article&quot;.</p></disp-quote><p>Individual files were uploaded this time.</p><disp-quote content-type="editor-comment"><p>The abstract should spell out acronyms, such as the name of the protein Serpine1 mRNA-binding protein 1 (SERBP1).</p></disp-quote><p>This was not included since the abstract has a word limit.</p><disp-quote content-type="editor-comment"><p>&quot;SERBP1 (Serpine1 mRNA-binding protein 1) is a unique member of this group of RBPs&quot;. In what way is it unique?</p></disp-quote><p>The text was modified to better explain SERBP1’s singularities.</p><disp-quote content-type="editor-comment"><p>&quot;RBPs containing IDRs and RGG motifs are particularly relevant in the nervous system. Their misfolding contributes to the formation of pathological protein aggregates in Alzheimer's disease (AD), Frontotemporal Lobar Dementia (FTLD), Amyotrophic Lateral Sclerosis (ALS), and Parkinson's disease (PD)&quot; -&gt; while TDP-43 and FUS in ALS/FTD may fit this description, it is not true for tau and amyloid-beta (AD) and alpha-synuclein (PD).</p></disp-quote><p>&quot;SERBP1 is a unique RBPs containing IDRs and RGG motifs yet lacks other readily recognizable, canonical or structured RNA binding motifs. Moreover, SERBP1 has been observed by our study and others as common Tau interactor in Alzheimer’s Disease (AD) brains. RBPs containing IDRs (e.g. TDP-43, FUS, hnRNPs, TIA1) have been shown self-aggregate and co-aggregate with pathogenic amyloids (Tau, Aβ-amyloid and α-Synuclein) in AD, Frontotemporal Lobar Dementia (FTLD), Amyotrophic Lateral Sclerosis (ALS), and Parkinson's disease (PD) and this suggest that, like other IDRs RBPs, SERBP1 contributes to RNA dysmetabolism in neurodegenerative diseases”.</p><disp-quote content-type="editor-comment"><p>While the authors propose a feedback regulatory model for SERBP1 and PARP1 functions, strong evidence for PARylation modulating SERBP1 functions is lacking. The fact that PARP inhibition decreases the amount of PARylated proteins associated with SERBP1 and likely all other PARylated proteins is expected and cannot count as evidence.</p></disp-quote><p>We included data showing that treatment with PJ34 (PARP inhibitor) decreases SERBP1 interaction with PARP1 and G3BP1. We are currently conducting a more extensive analysis to identify SERBP1 PAR binding domain and the impact of PARP inhibition on its interactions and functions. These experiments will be included in a new manuscript.</p><disp-quote content-type="editor-comment"><p>A single AD case is not sufficient.</p></disp-quote><p>Sorry for the poor clarity. We included in the study 6 cases from age-matched controls and 6 cases of AD. We summarize all cases demographics, and the experimental application assigned to each case in Table 1. Moreover, we included a paragraph regarding Human tissue harvesting.</p><disp-quote content-type="editor-comment"><p>Most western blot data are not quantified from multiple replicates, as required.</p></disp-quote><p>Quantifications are now provided.</p><disp-quote content-type="editor-comment"><p>FTLD - frontotemporal lobar degeneration (not dementia).</p></disp-quote><p>This was corrected.</p><disp-quote content-type="editor-comment"><p>Frozen autopsy tissue is problematic due to poor preservation. The staining presented here shows unexplained punctate staining likely due to poor preservation of cellular structures for immunohistochemistry.</p></disp-quote><p>We included a paragraph regarding human tissue harvesting. We have successfully used frozen tissues in our previous studies, observing a well preserved neuronal and tissue structure (PMIDs: 32855391, 31532069 and 30367664)</p><disp-quote content-type="editor-comment"><p>The presence of phase-separated stress granules in tissue is controversial since these are transient structures.</p><p>Normally, stress granule proteins move to the cytoplasm under cellular stress, whereas SERBP1 becomes nuclear. The co-localization of abundant (and partially overexposed) cytoplasmic G3BP1 and SERBP1 under normal conditions is not evidence for association with stress granules. Does induction of stress granule formation lead to colocalization in stress granules? The H2O2 experiment suggests otherwise.</p></disp-quote><p>RBPs implicated in stress response move to stress granules when cells are exposed to stress. SERBP1 has been shown to shuttle to stress granules and nucleus in stress conditions (PMID: 24205981). Our results are in agreement.</p><p>Using co-IF, we observed some overlap between G3BP1 and SERBP1 in AD tissues. As shown in Fig. S6A and B, 50% of stress granules overlap with SERBP1 signal. On the contrary, it is hard to assess their relationship in aged-matched control brains where stress granules form and accumulate with a lower rate than in AD. SERBP1 is not very abundant in normal brains. It is known that RNA-Binding Proteins aggregation and/or dysfunctional LLPS dysregulate stress granules formation and accumulation in AD and other proteinopathies (PMIDs 30853299, 27256390 and 31911437). However, it is too early to determine the role of SERBP1 and its contribution to stress granules formation and accumulation. We will examine this topic in future studies.</p><disp-quote content-type="editor-comment"><p>There is a lack of essential demographics data (age, clinical diagnosis, path diagnosis, co-pathologies, Braak stage, etc.), source of the tissue (what brain bank?), brain regions shown, and whether there was informed consent for the collection and use of human brain tissue.</p></disp-quote><p>We included the information requested in materials and methods section.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>The authors need to better explain their experimental rationale and approach in the main text, not just in the supplementary materials.</p></disp-quote><p>We have extensively revised the text to provide a better description of experiments in the results section and figure legends.</p></body></sub-article></article>